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Introduction The Bone and Joint Monitor Project was developed to
quantify the global burden of musculoskeletal conditions and develop
strategies for their prevention. Experts within the Monitor Project have
worked previously with officers at the World Health Organization
(WHO) to estimate morbidity and mortality associated with rheumatic
conditions. The present collaboration seeks means of providing addi-
tional and more current burden data.
Objective To develop recommendations for performing epidemiologi-
cal studies in sample populations with musculoskeletal conditions and
problems, accounting for determinants and consequences to the indi-
vidual and society.
Methods Recommendations have been developed identifying the most
relevant domains for measuring and monitoring the various muscu-
loskeletal conditions by review of epidemiological data on occurrence,
determinants and outcomes, and by expert opinion. Instruments that
measure these domains were reviewed.
Results The domains recommended follow the principles of the WHO
International Classification of Functioning, Disability and Health [1,2],
and consider: health condition; body function and structure; activity lim-
itation; participation restriction; personal and environmental contextual
factors; and, in addition, the resource utilisation and social conse-
quences. The musculoskeletal conditions and problems considered
were osteoarthitis, inflammatory arthritis, osteoporosis, spinal prob-
lems, musculoskeletal trauma and injuries, and musculoskeletal pain
with restricted activity. The selection of indicators for each domain con-
sidered the feasibility of their use in a health interview survey (HIS), a
health examination survey (HES), a register or a clinical study. Consen-
sus on case definition was reached depending on the study methodol-
ogy. For example, osteoporosis defined by bone densitometry cannot
be ascertained in an HIS, whereas the outcome of osteoporosis (i.e.
fragility fracture) can be. Osteoarthitis can be identified as joint pain in
an HIS but the preferred definition is pain with X-ray changes and can
only be ascertained in an HES. Previously validated generic and
disease-specific instruments have been identified that include indica-
tors for all or most of the recommended domains for the consequences
of the different conditions and problems. The indicators of the domains
for resource utilisation and social consequences and feasibility for col-
lection will vary in different socioeconomic and geographic areas.
Guidance on sampling methods is also being developed.
Conclusions The comparability of data collected across the globe will
improve by the application of agreed upon indicators that consider key
domains for the different musculoskeletal conditions and problems in
epidemiological studies conducted in different populations.
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Osteoarthritis is the most common disabling condition of man in the
Western world. Biologically, osteoarthritis implies the (symptomatic)
degeneration of the whole joint with many structures involved such as
subchondral bone and the periarticular soft tissues. Still, the degenera-
tion of the articular cartilage appears to be the focus of the structural
changes taking place during the osteoarthritic disease process.
Cartilage degeneration implies mostly a failure of the extracellular
matrix of the articular cartilage. The matrix represents the functional
component responsible for the biomechanical integrity of the tissue.
Thus, many studies over decades in osteoarthritis and cartilage
research have focused on the understanding of degenerative or
degradative processes taking place within the matrix. This has led to
significant continuous advances in our understanding of the biochem-
istry and pathobiochemistry of molecules and their assembly within the
cartilage matrix.
The cells of the tissue, which do not exert per se structural functions
within the tissue, were considered largely responsible for the proper
matrix turnover. They were thought to react to external mediators and
biomechanical stimuli or assaults and to be more or less able to com-
pensate for continuous (bio)mechanical tissue destruction. More
recently, however, besides matrix (patho)biochemistry, the cellular phe-
notype during the disease process has come more and more into the
focus of interest. This was induced on the one hand by upcoming (mol-
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ecular) technology, but also by increasing evidence that also the cells
degenerate per se. Osteoarthritic chondrocytes are not only no longer
able to compensate for matrix degeneration, but themselves are (co)ini-
tiators and (co)promoters of the disease process.
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Genetics of osteoarthritis
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T Forster, K Chapman
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Epidemiological studies have demonstrated a major genetic compo-
nent to osteoarthritis (OA), with heritability estimates of over 50% for
most joint sites. These studies have also highlighted differences in the
degree of OA heritability between joint sites and between the sexes,
implying a high level of heterogeneity.
We published a genome-wide scan in 1999. We had focused on fami-
lies containing siblings with severe large-joint OA ascertained by joint-
replacement surgery. Our data showed that OA genetic susceptibility
did exhibit joint specificity and that this susceptibility had a greater role
in female disease. During the past 5 years we have been investigating
our linkage regions and we have so far identified FRZB (chromosome
2q32.1), COL9A1 (6q12-q13), BMP5 (6p12.1) and IL4R (16p12.1-
p11.2) as encoding for OA susceptibility. Common variants at these
genes affect either the structural properties of the protein (FRZB and
IL4R) or the transcription of the gene (BMP5 and COL9A1). The vari-
ants are particularly relevant to the development of hip OA in females.
What is particularly interesting about our recent discoveries is that the
proteins encoded for by IL4R, BMP5 and FRZB are involved in chon-
drocyte cell signalling and signal transduction pathways. It appears
probable, therefore, that OA genetic risk for the hip is principally
accounted for by aberrant cell signalling. This was not anticipated.
In this presentation I will focus on our latest genetic findings. I will also
discuss the results from other studies. A number of OA genome-wide
scans have been performed, some on large joints and others investigat-
ing hand disease. Many loci appear unique to one particular study, with
only some loci being positive in multiple studies. The reasons for this
will be discussed.
A concern often expressed at orthopaedic and rheumatology meetings
is that genetic linkages and associations are not consistently repro-
duced. These are reasonable criticisms but it needs to be remembered
that the genetic component of a complex trait such as OA will not be
mediated by fully penetrant risk alleles. Instead, any one allele will con-
tribute only a fraction of the overall risk and this allele will, by chance,
have varying frequencies in different cohorts. It is unreasonable, there-
fore, to expect a linkage or an association in one cohort to be repli-
cated in all cohorts.
Acknowledgements  Our research was funded by Research into
Ageing, The Arthritis Research Campaign, The Nuffield Foundation and
The Wellcome Trust.
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Inbred animals are useful for studies of the identification of genes asso-
ciated with rheumatoid arthritis (RA) since they are a more efficient tool
for identification genes controlling complex diseases. There are several
arthritis models, each of which may reflect various variants of the het-
erogeneity of RA in humans. Examples are collagen-induced arthritis
and pristane-induced arthritis, which both fulfil the clinical diagnostic
criteria for RA.
Type II collagen (CII) is immunogenic and contains peptides that can
be bound to major histocompatibility complex (MHC) class II and pre-
sented to T cells, whereas pristane is not immunogenic by itself. Both
diseases are genetically complex and the susceptibility is, as RA,
dependent on many polymorphic genes operating in concert. So far
two genes in this concert have been identified; the MHC class II Ab
gene in the mouse [1] and the Ncf1 gene in the rat [2]. The Ncf1
protein is a part of the NADPH oxidase complex involved in generation
of the inducible oxidative burst. The discovery of the Ncf1 polymor-
phism led to a new proposed pathway in which oxygen radicals modify
antigen presentation and the resulting activation of autoreactive T cells.
This hypothesis has now been further documented by the identification
of an Ncf1 mutation in the mouse that reproduces the effects earlier
observed in the rat. Mice with the deficient Ncf1 allele, and expressing
the MHC class II allele Aq, binding CII peptides, could be shown to be
dramatically more susceptible to collagen-induced arthritis, and also
developed a chronic form of arthritis. Interestingly, the immune
response to CII was enhanced by the Ncf1 deficiency linking the Ncf1
pathway to the adaptive immune response.
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Although the etiology of rheumatoid arthritis (RA) is still unknown, it is
generally believed that a combination of multiple polymorphic genetic
factors and environmental contributions lead to the pathogenic auto-
immune reactions characterized by destructive polyarthritis and various
extra-articular inflammatory involvements. A genetic approach to iden-
tify RA-associated genes from the whole genome is proposed to be
one of the promising methodologies to elucidate the etiology of RA.
Although multiple genome-wide linkage studies and many association
studies to test an individual gene that is functionally relevant to RA
have been performed to identify RA-associated nonhuman leukocyte
antigen genes, no region or gene has been conclusively shown to be
one of the RA-susceptible loci or genes. Therefore, a linkage disequilib-
rium approach using single nucleotide polymorphisms (SNPs) as
genetic markers to identify disease-associated genes was considered
a promising alternative method for RA, as well as other common dis-
eases with complex genetic predispositions.
Our RIKEN SNP Research Center has established a high-throughput
SNP-genotyping system and has been investigating multiple common
diseases using a whole-genome gene-based linkage disequilibrium
mapping approach. In 2003, we reported that functional variants of the
PADI4 gene were associated with RA. PADI4 is an enzyme that con-
verts arginine residue in proteins to citrulline. The citrullinated proteins
are targets of the most specific autoantibodies in RA. We have identi-
fied this gene in a whole-genome, hypothesis-free approach. Therefore,
this made our methodology strongly reliable in that the RA-associated
gene identified by our hypothesis-free approach was functionally
strongly relevant to the pathogenesis of RA.
Recently we also found that SLC22A4 and RUNX1 are associated
with RA. SLC22A4 is an organic cation transporter with unknown
physiologic function, and RUNX1 is a hematologic transcriptional regu-
lator that has been shown to be responsible for acute myelogenic
leukemia. It is suggested that the association of RUNX1 with RA is due
to its regulation of expression of SLC22A4. Because the physiologic
function of SLC22A4 is still unclear, further investigation is needed into
how SLC22A4 affects RA susceptibility. Although the association of
RUNX1 with RA was identified as a regulatory factor of SLC22A4, it is
possible that RUNX1 is a key molecule in autoimmunity, as it has been
reported to be associated with systemic lupus erythematosus and pso-
riasis, two other autoimmune diseases.
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The molecular pathogenesis of rheumatoid arthritis (RA) is still poorly
understood and its clinical course can vary widely. We apply a systems
biology approach to gain insight into the complex pathogenesis and
disease heterogeneity. Genomics studies revealed considerable het-
erogeneity in global gene expression signatures between synovial
tissue specimens from different patients with RA. Based on the molec-
ular signatures, at least two distinct subsets of RA tissues could be
identified. One class revealed abundant expression of gene clusters
indicative of an ongoing activation of the adaptive immune response,
whereas the other class resembled the expression pattern of
osteoarthritic tissues, which are characterized by a low inflammatory
gene expression signature and increased tissue remodeling. The mole-
cular heterogeneity is featured not only at the whole synovial tissue
level, but also at the level of fibroblast-like synoviocytes (FLS) cultured
from those tissues. One of the most impressive features of our gene
expression profiling studies is the clear correlation of the FLS pheno-
type with that of paired synovial tissue from which the cells were
derived. One class of FLS is tightly related to the presence of lympho-
cytes in the lesions, whereas the other class of FLS suggests that syn-
oviocyte-mediated invasion appears to be less dependent on infiltrating
immune cells. These data support the notion that heterogeneity
observed between synovial tissues is reflected in the FLS as a stable
trait. Clearly, the list of genes that are differentially expressed between
the tissue and FLS subgroups facilitates our understanding of the
pathophysiology of the molecular forms of disease. Moreover, the dif-
ferences in the gene expression profiles reflect important aspects of
biological variation within the clinically diagnosed disease that provide
a molecular basis for the well recognized but as yet poorly understood
heterogeneity in RA and may help to (sub)classify rheumatic diseases.
Acknowledgements The authors are grateful to Dr Pat Brown and Dr
David Botstein, in whose laboratories part of the work described in this
report was performed. Supported in part by the Howard Hughes
Medical Institute, a grant from the National Cancer Institute, a grant
from the Netherlands Organization for Scientific Research, and the
Dutch Arthritis Foundation.
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Rheumatoid arthritis (RA) is a joint-affecting disease and is character-
ized with overgrowth of articular synovial cells, so-called ‘pannus’. To
understand the pathomechanism of RA, we attempted to characterize
the rheumatoid synovial cell and found a novel protein, ‘Synoviolin (syn-
ovial cell + protein)’. Structural analysis indicated that Synoviolin is an
endoplasmic reticulum (ER)-resident E3 ubiquitin ligase, which is
important for ‘ER-associated degradation (ERAD)’. Its overexpression
causes arthropathy, resembling RA in mice. Moreover, the heterozygote
of Synoviolin (+/–) is remarkably resistant to collagen-induced arthritis.
These ‘gain of function’ and ‘loss of function’ analyses clearly indicate
the important role of Synoviolin in arthropathy.
Therefore, we present a new pathogenic mechanism for RA that is
related with ERAD, an essential system for ER homeostasis by eliminat-
ing unfolded proteins from the organelle. Recent studies have shown
that the accumulation of unfolded proteins mediated by impaired ERAD
system results in ER stress-induced apoptosis of cells and causes
various degenerative human diseases. Besides, the ERAD system is
tightly linked with cell growth, apoptosis and differentiation. This evi-
dence led us to a new hypothesis that ‘hyper function of ERAD system’
may cause synovial cell overgrowth through its anti-apoptotic effect in
RA. Thus, we propose that inhibition of Synoviolin is one of the promis-
ing strategies for RA treatment by targeting synovial cells.
Session II — Role of leptin and eicosanoids in
arthritic diseases
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Leptin, the product of the Ob gene, is a polypeptide hormone that
plays an important role in the regulation of body weight by inhibiting
food intake and stimulating energy expenditure. Moreover, leptin
exhibits a variety of other effects including the regulation of endocrine
function, reproduction and hematopoiesis. Consistently, leptin-deficient
mice are not only obese, but display major hormonal disturbances,
including hypercorticosteronemia, diabetes, and infertility. In addition, it
has been known for many years that leptin-deficient (ob/ob) and leptin
receptor-deficient (db/db) mice have an altered immune response.
More recent studies have shown that T cells and B cells express the
long signaling leptin receptor isoform (ObRb) and that leptin exerts
direct effects on T lymphocytes, including the stimulation of cell prolif-
eration, the promotion of Th1 responses, and the protection of thymo-
cytes from corticosteroid-induced apoptosis. Consistently, ob/ob mice
are protected from inflammation mediated by T cells and B cells in
some models such as experimental colitis, experimental autoimmune
encephalomyelitis, and concanavalin A-induced hepatitis. Conversely,
the administration of recombinant leptin increased the severity of exper-
imental autoimmune encephalomyelitis. Using a model of antigen-
induced arthritis, we demonstrated that ob/ob and db/db mice have a
milder form of arthritis and that cellular and humoral immune responses
to the injected antigen are decreased as compared with wild-type
mice. Furthermore, ex vivo stimulated lymph node cells from ob/ob and
db/db mice produced less interferon gamma and more IL-10 than cells
obtained from control mice.
Leptin production is regulated by various proinflammatory cytokines
during the acute-phase response, and leptin stimulates the production
of both proinflammatory and antiinflammatory cytokines in vitro. ob/ob
mice exhibit increased susceptibility to lipopolysaccharide-induced and
tumor necrosis factor alpha-induced lethality, suggesting that leptin is
also involved in regulating the innate immune response. We recently
examined the role of leptin in zymosan-induced arthritis (ZIA), where
joint inflammation is dependent on innate immunity. Our results demon-
strate that, as opposed to antigen-induced arthritis, ZIA is not impaired
in ob/ob and db/db mice. On the contrary, these mice exhibit a delayed
resolution of the inflammatory process, with increased circulating levels
of IL-6 and serum amyloid A, and a tendency to develop more severe
joint damage. Leptin deficiency thus appears to interfere with adequate
control of the inflammatory response in ZIA.
Although data obtained in different models of inflammatory diseases
suggest that leptin plays a role in immune response, the analysis of
direct effects of leptin on lymphocytes in vivo is precluded by the
Available online http://arthritis-research.com/supplements/6/S3S4
important hormonal and metabolic alterations, which are linked to leptin
deficiency. To our knowledge, it has never been thoroughly investi-
gated to which extent immune defects in ob/ob or db/db animals are
linked to leptin deficiency or, respectively, leptin receptor deficiency
per se, as opposed to confounding factors such as hypercorticos-
teronemia. To examine the importance of direct effects of leptin on lym-
phopoiesis and immune response, we generated bone marrow
chimeras by transplantation of db/db bone marrow cells into lethally
irradiated normal recipient mice, which provide a normal environment
for the grafted cells. Donor db/db mice display a marked atrophy of the
thymus as compared with db/+ controls. In bone marrow chimeras, the
size and cellularity of the thymus were not different between mice
grafted with db/db or db/+ bone marrow 12 weeks after the graft, sug-
gesting that the thymic atrophy observed in db/db donors is not due to
direct effects of leptin on lymphocytes. Moreover, RT-PCR analyses
suggest that CD4/CD8 double positive thymocytes do not express
ObRb. Further studies are in progress in order to examine which cell
types respond to leptin in the thymus and whether impaired leptin sig-
naling in lymphocytes affects immune responses after antigen chal-
lenge in db/db bone marrow chimeras.
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Leptin is a small, 16-kDa protein produced and secreted primarily by
adipocytes found in white adipose tissue. Initially discovered as a
central regulator of appetite and energy expenditure, leptin may also be
involved in the regulation of metabolic activity in the growth plate and
bone. Since obese individuals have an increased incidence of
osteoarthritis (OA), we evaluated the contribution of leptin to cartilage
changes associated with this degenerative disease.
Leptin levels in synovial fluid samples obtained from OA patients under-
going joint replacement were measured by ELISA assay. In addition,
histologic sections of tibial plateau cartilage and osteophytes obtained
from OA patients were graded using the Mankin score, and were
immunostained using antibodies to leptin, transforming growth factor
beta 1 (TGF-β1), and insulin-like growth factor 1 (IGF-1). For experi-
mental studies, various doses of leptin (10, 30,100, and 300 µg) were
injected into the knee joints of rats. Tibial plateaus were collected and
processed for proteoglycan synthesis by radiolabeled sulfate incorpo-
ration, and for expression of leptin and growth factors by RT-PCR and
immunohistochemical analysis.
Our results indicated that leptin was observed in synovial fluid from the
human OA-affected knee (n = 14 men, 8.16 ± 5.5 µg/l; and n = 6
women, 12.95 ± 8.92 µg/l). These leptin concentrations were corre-
lated with the body mass index (r = 0.572, P < 0.01). Interestingly, a
marked expression of leptin was observed in OA cartilage, especially in
fibrillated cartilage with clusters and in osteophytes, while few chon-
drocytes produced leptin in normal cartilage. Furthermore, the pattern
and level of leptin expression were related to the grade of cartilage
destruction, and paralleled those of growth factors (IGF-1 and TGF-
β1). When injected into rat knee joints, leptin stimulated chondrocytes
anabolic functions and induced the synthesis of IGF-1 and TGF-β1 in
cartilage at both mRNA and protein levels.
Taken together, these findings provide a new peripheral function to
leptin as a key regulator of chondrocyte metabolism, and indicate that
leptin may play an important role in the pathophysiology of OA.
Acknowledgement This study was supported by grants from the
Contrat de Programme de Recherche Clinique, CHU Nancy, France.
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Leptin is an adipocyte-derived hormone that is found in the peripheral
circulation in correlation with total body fat mass. While leptin is best
known for its ability to regulate energy homeostasis, it is a pleotropic
hormone whose receptor is widely distributed in various tissues includ-
ing cells of the immune system. We have previously reported that
leukotriene (LT) synthesis in macrophages from leptin-deficient mice is
attenuated and that the provision of exogenous leptin restores this
defect. To explore the possibility that leptin regulates eicosanoid syn-
thesis in cells from normal animals, we cultured rat alveolar and murine
peritoneal macrophages overnight with media alone or with increasing
doses of leptin. Following stimulation with calcium ionophore (A23187)
or zymosan, we observed that leptin enhanced prostaglandin E2 and LT
synthesis in a dose-dependent manner. Since arachidonic acid (AA) is
the metabolic precursor of the eicosanoids, we next asked whether
leptin regulates AA release and phospholipase A2 (PLA2) activity. Rat
alveolar macrophages (AMs) were prelabeled overnight with [3H]AA
and cultured with increasing doses of leptin on the following day.
Leptin enhanced A23187-stimulated [3H]AA release in a dose-depen-
dent manner that peaked at 5 ng/ml (300% above control). Using rat
AMs pretreated overnight with leptin, we observed that leptin
enhanced both calcium-dependent and calcium-independent PLA2
activity. To determine the time required for leptin to enhance AA
release, AMs were prelabeled overnight with [3H]AA, cultured with
leptin (5 ng/ml) on the following day, and cell culture medium was col-
lected following stimulation with A23187. Leptin enhanced AA release
at 30 min, and 1, 2, 4, and 16 hours following A23187 stimulation. To
explore the mechanism by which short-term leptin pretreatment
enhances AA release, we assessed cPLA2α phosphorylation in rat AM
lysates following leptin pretreatment. Western blot analysis of immuno-
precipitated cPLA2α revealed that leptin pretreatment of rat AMs
increased cPLA2α phosphorylation (ser505) in a dose-dependent
manner that peaked at 15 min (sevenfold increase with 10 ng/ml)
before returning to baseline levels at 60 min. To determine the mecha-
nism by which long-term leptin pretreatment enhances macrophage AA
release and LT synthesis, we assessed the expression of 5-lipoxyge-
nase, 5-lipoxygenase activating protein, and cPLA2α in murine peri-
toneal macrophages and of cPLA2γ in rat AMs using western blot
analysis. Overnight pretreatment with leptin increased the expression of
5-lipoxygenase (200%) in murine peritoneal macrophages and of
cPLA2γ (180%) in rat AMs. Our data suggest that the increased inci-
dence of inflammatory diseases, such as asthma and osteoarthritis,
associated with obesity may be related to the ability of leptin to
increase AA release and eicosanoid synthesis.
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P Bausero, C Salvat, V Meynier de Salinelles, A Pigenet, 
M Raymondjean, F Berenbaum
UMR 7079 CNRS, University Paris 6 Pierre & Marie Curie, Paris,
France
Arthritis Res Ther 2004, 6(Suppl 3):10 (DOI 10.1186/ar1344)
Healthy cartilage is maintained in a state of dynamic equilibrium by
matrix synthesis and matrix degradation by the chondrocytes. Any dys-
regulation with increased degradation and/or inadequate synthesis
leads to hte loss of tissue structure and function, as in rheumatoid
arthritis and osteoarthritis. The proinflammatory cytokine IL-1 plays a
major role in this phenomenon. IL-1 acts on chondrocytes in part by
stimulating the release of prostaglandin E2 (PGE2) at the sites of
inflammation. Recently, a human membrane-associated prostaglandin
E2 synthase-1 (mPGES-1) was cloned. This enzyme catalyzes the con-
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version of prostaglandin H2 to PGE2 in a highly specific manner. We
previously demonstrated that mPGES-1 mRNA is induced by IL-1 in
chondrocytes in a dose-dependent and time-dependent manner.
In order to study the transcriptional regulation of mPGES-1 in primary
rabbit articular chondrocytes, we have cloned its promoter upstream of
the CAT ORF (vector pCAT3-basic; Promega, Charbonnières-les-
Bains, France). We show by transient transfection experiments that the
mPGES-1 promoter is stimulated by IL-1. A close examination of puta-
tive binding sites has revealed the presence of two CCAAT/Enhancer
Binding Protein (C/EBP) binding sequences (TTNNGNAAT) located
between –548 to –558 base pairs and –610 to –619 base pairs. Co-
transfections of expression vectors encoding the two different isoforms
of C/EBP (β and δ) strongly stimulate the promoter activity. To further
study the role of C/EBP in mPGES-1 expression, we performed gel
shift experiments on wild-type and mutated oligonucleotides derived
from the mPGES-1 sequence. These experiments confirm the specific
binding of C/EBP on the mPGES-1 promoter. Taken together, our
results suggest that C/EBP factors indeed bind and regulate the
mPGES promoter in articular chondrocytes.
11
ALXR, a common GPCR gateway for
antiinflammatory and/or proinflammatory cell
activation: relevance of selective kinase and
phospholipase signaling by uteroglobin, lipoxin A4
and serum amyloid A in ALXR-mediated
chemotaxis
G Antico1, S Sodin-Semrl2, J Varga2, L Miele1, S Fiore2
1Biopharmaceutical Sciences, University of Illinois, COM, Chicago,
Illinois, USA; 2Section of Rheumatology, University of Illinois, COM,
Chicago, Illinois, USA
Arthritis Res Ther 2004, 6(Suppl 3):11 (DOI 10.1186/ar1345)
The lipoxin A4 receptor (ALXR) is expressed in fibroblast-like synovio-
cytes and is targeted by both antiinflammatory and proinflammatory
endogenous ligands. Recently, annexin-1 (lipocortin) has been identi-
fied to be an ALXR ligand. Uteroglobin (Ug) is secretoglobin that
shares with annexin-1 properties such as potent inhibition of phospholi-
pase A2 (PLA2) as well as sequence similarities in the ‘antiflammin’
consensus region. Potential receptor interactions of Ug with ALXR
were therefore investigated and PLA2 activity assays were performed in
CHO and HL-60 cell lines stably overexpressing ALXR. Serum amyloid
A (SAA), an ALXR ligand displaying proinflammatory activities, was
compared with two antiinflammatory ligands, Ug and lipoxin A4 (LXA4).
While Ug and LXA4 did not alter baseline PLA2 activity (Ug) or pro-
voked a pulsed peak of activity (LXA4), SAA did induce a delayed and
prolonged activation of PLA2. SAA-induced PLA2 activation was
sharply inhibited in the presence of Ug. Ug inhibition of SAA-depen-
dent phospholipase activity occurred at submillimolar Ca2+ concentra-
tions, suggesting an effect on cytosolic PLA2 (rather than secretory
PLA2, a known target inhibited by Ug and annexin-1 but requiring
millimolar Ca2+). Studies of Erk, p38 and AKT kinase phosphorylation
confirmed that SAA and Ug interact with ALXR to oppositely regulate
GPCR-coupled downstream signaling events. Overall the analysis of
phospholipase D activity, kinase phosphorylation and cAMP levels also
suggested that proinflammatory and antiinflammatory ligands of ALXR
engage differently coupled pathways, leading to activation of these
processes (SAA) or to their inhibition (LXA4 and Ug). These signaling
events are functionally matched by the ability of SAA to stimulate NF-
κB activity, IL-8 release and cell chemotaxis, and that of LXA4 and Ug
to strongly inhibit them. Expression of Ug and SAA mRNAs was also
detected in human fibroblast-like synoviocytes, suggesting that ALXR
may play a pivotal role in the pathophysiology of arthritis. In addition,
annexin-1 and Ug inhibition of PLA2 offers enticing new venues to
control inflammatory arthritides by limiting, for example, cascade signal-
ing amplification via synthesis of proinflammatory eicosanoids, along
with a redirection of ALXR signaling toward antiinflammatory feedback
mechanisms.
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Background The lipid mediators of inflammation include platelet-acti-
vating factor (PAF) and several classes of metabolites of arachidonic
acid derived from the cyclooxygenase (prostaglandins and thrombox-
anes) and lipoxygenase pathways, such as leukotrienes (LTs) and lipox-
ins. Of these lipid mediators, LTs and PAF are potent agonists of
leukocytes and endothelial cells and show important proinflammatory
properties. Several elegant studies have recently provided strong
support for a role of one of these mediators, LTB4, in animal models of
rheumatoid arthritis [1–3]. Interestingly, LTB4, LTC4/LTD4 and PAF are
concomitantly generated at the blood–endothelium interface when neu-
trophils bind to activated endothelial cells at inflammatory sites in vivo
and are exposed to a chemoattractant. The hypothesis explored in this
project is that the three classes of lipid mediators collectively and syn-
ergistically act to promote and facilitate neutrophil extravasation and
accumulation at inflammatory sites. The hypothesis also implicates that,
given the high level of redundancy in the abilities of the three lipid medi-
ators to activate neutrophils and endothelial cells, the blockade of one
of these mediators can only have a modest and incomplete inhibitory
effect on neutrophil extravasation.
Objective The objective of these studies is therefore to compare the
role of each individual mediator and the collective effect of the three
mediators in regulating neutrophil trafficking. Another objective is to
assess whether or not the combined use of antagonists to the three
classes of mediators could result in a stronger inhibitory effect on neu-
trophil trafficking.
Methods The studies are performed using potent and selective LTB4,
LTD4 and PAF antagonists in both in vitro and in vivo models. The sep-
arate and collective role of the three classes of lipid mediators will be
investigated in the migration of human neutrophils through a monolayer
of human endothelial cells grown on a gel of extracellular matrix pro-
teins. The studies also involve the use of models of dermal inflammation
in rats and rabbits and the mouse air pouch model.
Results The results show that, in the various models tested, neutrophil
migration elicited by proinflammatory agents such as IL-1, tumor necro-
sis factor alpha and lipopolysaccharide is generally decreased by LTB4
or PAF antagonists, and that the combination of both antagonists
results in a greater inhibitory effect, supporting the concept that several
lipid mediators generated locally (at the blood–endothelium interface
and/or at inflammatory sites) regulate neutrophil trafficking. Additional
experiments involving antagonists to the three classes of lipid media-
tors, as well as LTB4 and PAF receptor knockout mice, are in progress.
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The mammalian Toll-like receptors (TLRs) activate cells of the innate
immune system when stimulated by diverse ligands of microbial origin.
In some instances, these ligands are directly engaged by the TLRs;
however, this is not necessarily true in all cases. TLR2 recognizes mul-
tiple, structurally disparate microbial ligands, consistent with a require-
ment for co-receptors in ligand binding. Using N-ethyl-N-nitrosourea,
we generated the recessive immunodeficiency phenotype oblivious, in
which macrophages show diminished awareness of the S-enantiomer
of the di-acylated bacterial lipopeptide MALP-2 and lipoteichoic acid,
together with spontaneous ocular colonization by Gram-positive organ-
isms and hypersusceptibility to Staphylococcus aureus infection.
Oblivious macrophages readily detect the tri-acylated bacterial
lipopeptide PAM3CSK4 as well as zymosan, revealing that some TLR2
ligands are activated via an Oblivious-independent pathway. The gene
responsible for the oblivious phenotype has been positionally cloned.
In its ability to carry the lipoteichoic acid and MALP-2 signal to the
transmembrane signaling receptors TLR2 and TLR6, Oblivious serves
a function analogous to CD14, which concentrates the lipopolysaccha-
rdide signal for transduction by TLR4. Besides microbial molecules,
oblivious also serves as a receptor for endogenous molecules and may
mediate (some) of the inflammatory events involved in the development
of atherosclerosis.
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Nod1 and Nod2 are two cytosolic proteins thought to play a role in
innate immunity. Both detect the presence of microbes through recog-
nition of peptidoglycan fragments but also may initiate apoptosis. The
nod2 gene has been strongly associated with several autoimmune dis-
eases and particularly Crohn’s disease; in contrast, nod1 polymor-
phisms have not been linked to any genetic disorders. Here we provide
multiple lines of evidence showing that Nod1 participates in apoptosis.
Nod1-deficient breast cancer cells (MCF-7) were more resistant to
tumor necrosis factor-induced cytotoxicity, and this was accompanied
by a reduction in caspase signaling. Further, γTriDAP, a naturally occur-
ring tripeptide product from peptidoglycan and a ligand for Nod1,
induced cell death consistent with apoptosis in wild-type MCF-7 cells
but not in Nod1-deficient cells. γTriDAP triggered processing of PARP
and many caspases, including caspase 6, caspase 7, caspase 8 and
caspase 9. Only caspase 9 inhibitor totally abrogated γTriDAP cytotoxi-
city. RIP2/RICK, a downstream protein kinase of Nod1, appears to be
an essential component of the Nod1 proapoptotic pathway since
expression of a dominant negative form of RIP2 abolished γTriDAP-
induced cell death. This is a newly defined activity for Nod1 and sug-
gests that Nod1-induced apoptosis may be responsible for cell injury in
a variety of disease states.
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The success of tumor necrosis factor (TNF) antagonists in the therapy
of inflammatory arthritides has established the central role of this
cytokine in the pathogenesis of these disorders. TNF is notable in that
it is predominantly controlled at the post-transcriptional level in
macrophages. TNF biosynthesis is highly regulated by the AU-rich
element (AURE) found in its 3′ untranslated region. This AURE regu-
lates both the stability and rate of translation of TNF mRNA. In the
macrophage, the ERK, JNK, and p38 SAPK signaling pathways con-
verge on the AURE in regulating the nuclear export, stability and trans-
lation of TNF mRNA. Second, the C3H zinc finger protein,
tristetraprolin (TTP), appears to play a major role in the post-transcrip-
tional regulation of TNF by binding the AURE. Recent studies have
identified that TTP is a target of the p38 SAPK/MAPKAP K2 kinase
(MK2) pathway. Phosphorylation of TTP by MK2 has been reported in
vitro and in vivo; data suggest that MK2 activation inactivates the func-
tion of TTP as a destabilizing protein.
Intriguingly, TTP binding to the AURE does not appear to be regulated
by this phosphorylation. Rather, the function of TTP seems to be modu-
lated through interactions with specific proteins that alter its subcellular
localization. This creates a model where TTP provides specificity in
binding cytokine-type AURE but the consequences of this interaction
are determined by protein–protein interactions. Second, we have iden-
tified that TTP does not bind all AURE, but rather exhibits specificity for
nUAUUUAUn sequences. Third, we have identified that TTP regulates
its own mRNA stability. Fourth, we have demonstrated that TTP local-
izes to the polysomes in the context of macrophage activation by
lipopolysaccharide. Fifth, we have demonstrated that TTP is expressed
in many different hematopoietic cells and appears to function as an
AURE binding protein. Thus, although the role of TTP in TNF biology is
best understood in the macrophage, it appears that some, if not all, of
these concepts may be relevant to other cells involved in the immune
and inflammatory response.
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Pain, a critical component of host defense, is one of the hallmarks of
the inflammatory response. We therefore hypothesized that pain might
be exacerbated by proinflammatory chemokines. To test this hypothe-
sis, CCR1 was co-transfected into HEK293 cells together with the
Vanilloid Receptor 1 (TRPV1), a cation channel required for certain
types of thermal hyperalgesia. Capsaicin induced calcium influx by
TRPV1. When CCR1:TRPV1/HEK293 cells were pretreated with
CCL3, the sensitivity of TRPV1-mediated calcium flux was increased
about fivefold. Pertusis toxin inhibited CCL3-elicited sensitization of
TRPV1, indicating the involvement of G-protein signaling. RT-PCR
analysis data showed that a spectrum of chemokine and cytokine
receptors are expressed in rat dorsal root ganglia (DRG). Immunohisto-
chemical staining of the DRG showed that CCR1 coexpressed with
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TRPV1 on over 85% of small diameter neurons. CCR1 on neuronal
cells was functional, as demonstrated by CCL3-induced calcium flux
and protein kinase C activation. Pretreatment with CCL3 enhanced the
response of DRG neurons to capsaicin, and this sensitization was
inhibited by pertussis toxin, U73122, or staurosporine. Futhermore,
injection of CCL3 into mice spine cords enhances the sensitivity of the
mice tails toward the hot water, indicative of chemokine-induced sensi-
tization effects in vivo. The fact that a proinflammatory chemokine, by
interacting with its receptor on small-diameter neurons, sensitizes
TRPV1 reveals a novel mechanism of receptor cross-sensitization that
may contribute to hyperalgesia during inflammation.
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Systemic lupus erythematosus is a complex multigenic inherited
disease with susceptibility determined by a combination of genetic,
environmental and stochastic factors. Although not yet defined, recent
technical advances have provided the means to dissect the component
genetic contributions of polygenic traits. We have applied such
approaches to mouse models of spontaneous systemic lupus erythe-
matosus, and in this presentation I will summarize our genome-wide
mapping studies that identified loci predisposing to several major
lupus-related traits. Through the generation and study of interval con-
genic lines, precise mapping, and screening of candidate genes, identi-
fication of the specific genes and mechanisms associated with some of
the major loci is currently being pursued.
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While the symptoms associated with rheumatoid arthritis (RA) are well
described, the factors that are crucially involved in induction and/or
progression of RA are poorly defined. Nonetheless, it is generally
accepted that cells belonging to the adaptive immune system (i.e. B
cells and T cells) are intimately engaged in the processes responsible
for RA induction and/or progression. As these cells require triggering
of their antigen receptors before they can exert their functions, it is
likely that antigen recognition is important in the pathological
processes driving RA. Unfortunately, no antigens casually related to the
induction/perpetuation of RA are known. Nonetheless, studies
addressing the question of how immunity against autoantigens is regu-
lated, combined with studies aiming at defining the molecular identity
of antigens involved in disease, will be important to gain a better under-
standing of the pathways involved in the induction/progression of RA.
Recently, we have found that CD4+CD25+ regulatory T cells play a
pivotal role in the control of arthritis in mice. More importantly, treat-
ment of established arthritis by adoptive transfer of these cells stopped
further progression of disease. These data indicate the feasibility to
inhibit ongoing disease by specific manipulation of the immune system.
The data described also indicate that the class of immune response
against autoantigens could profoundly influence the susceptibility for,
and/or outcome of, autoimmune responses. However, until now, there
has been only limited evidence for autoantigen-specific regulatory
responses in humans. Here we analyzed the natural immune response
against Human Cartilage gp39 (HC-Gp39), a candidate autoantigen in
RA. Peripheral blood mononuclear cells from healthy individuals
reacted against HC Gp39 with the production of IL-10, but not inter-
feron gamma. Ex vivo assays indicated that the natural occurring HC
Gp39-directed immune response in bulk is capable of suppressing
cytotoxic T-cell and recall responses, indicating that, rather than being
unresponsive, the HC Gp39-directed immune response in healthy indi-
viduals is biased towards a regulatory phenotype. Moreover, CD4+ T-
cell lines directed against HC Gp39 expressed CD25, GITR, CTLA-4
and Foxp3 molecules and were capable of suppressing other immune
responses. Cell–cell contact was required for this suppression. In con-
trast, the quality of the HC Gp39-directed immune response in patients
with RA exhibits polarization toward a proinflammatory Th1 phenotype.
Together these findings indicate that the presence of HC Gp39-spe-
cific immune responses in healthy individuals may have a profound
inhibitory effect on inflammatory responses in areas were HC Gp39 is
present, and imply that the balance of autoreactive proinflammatory and
antiinflammatory HC Gp39-directed immune responsiveness is dis-
rupted in RA patients.
Plenary lecture – The use of tissue engineering
for joint structure repair: a future?
Current tissue engineering approaches to cartilage
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Chondral defects, generated as a result of trauma and injury or degen-
erative joint diseases, such as osteoarthritis, represent some of the
most challenging orthopedic conditions in terms of natural tissue
healing and repair. Damages to the articular cartilage fail to elicit signifi-
cant reparative activity, due to the acellularity of the tissue. Clonal pro-
liferation of articular chondrocytes is often seen, and results in the
production of mechanically inferior fibrocartilage. Extensive degenera-
tion of the articular surface eventually necessitates total joint arthro-
plasty. There is, therefore, a timely need for the development of
biological approaches to cartilage repair. The emerging research disci-
pline of tissue engineering aims to develop functional tissue substitutes
by combining experimental approaches in biology and engineering, and
represents a particularly attractive technology for the treatment of
skeletal diseases, most of which involve tissue degeneration or failure
to heal. Functionally, it is instructional to approach cartilage regenera-
tion in the context of developmental chondrogenesis; that is, the forma-
tion of cartilage from a progenitor mesenchymal cell population during
embryonic development. In particular, adult tissue-derived mesenchy-
mal stem cells (MSCs), which display multilineage differentiation poten-
tial, are currently considered a highly promising source of progenitor
cells for tissue engineering. Chondrogenesis in the developing verte-
brate limb consists of a highly coordinated and orchestrated series of
events involving the commitment and differentiation of mesenchymal
cells to mature chondrocytes. This process is regulated by the sequen-
tial and coordinated expression of genes that encode for specific cell
adhesion molecules, growth factors, and extracellular matrix molecules
that carry out morphogenetic and signaling activities. Recently,
members of the Wnt family of signaling molecules have been function-
ally implicated in limb development. The Wnts comprise a large family
of cysteine-rich glycoproteins that perform a number of inductive and
regulatory functions in both normal development and oncogenic trans-
formations. The expression of various Wnts has been identified in the
developing limb, and our recent studies showed that Wnts play an
important role in mesenchymal chondrogenesis. Interestingly, our
recent work with human MSCs indicates the functional involvement of
Wnts and the cell adhesion molecular, N-cadherin, as well as members
of the transforming growth factor beta superfamily in MSC chondroge-
nesis, suggesting that regenerative chondrogenesis and developmental
chondrogenesis are likely to share common regulatory pathways. By
combining MSCs, biodegradable polymeric scaffolds, and the applica-
tion of growth and differentiation factors, we are currently developing
cartilage constructs in vitro that are potentially applicable for cartilage
repair in vivo. Specifically, we recently fabricated a nanofibrous scaf-
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fold using a synthetic biodegradable polymer, poly(ε-caprolactone),
and demonstrated its ability to support in vitro chondrogenesis of
MSCs. The electrospun porous scaffold consisted of uniform, randomly
oriented nanofibers (700 nm diameter); MSCs seeded into the scaffold
and cultured in the presence of transforming growth factor beta 1 dif-
ferentiated to chondrocytes, indicated by gene expression and histo-
logical profiles, at a level similar to that observed in high-density pellet
cultures. The physical nature and improved mechanical properties of
such scaffolds, particularly in comparison with cell pellets, suggest that
these constructs may serve as a practical carrier for MSC transplanta-
tion in cell-based tissue engineering approaches to cartilage repair,
supported by our preliminary animal model study. The future success of
cartilage tissue engineering is dependent on a number of requirements,
including expansion of progenitor cells, optimization of biomaterial scaf-
fold design, and molecular enhancement of cell differentiation and
growth using biologics and gene therapeutic means. We believe that
the understanding of developmental chondrogenesis serves as a ratio-
nal and powerful paradigm for cartilage tissue engineering.
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Several studies have provided powerful proof of concept for the notion
that single cytokine targeting can manifest effective immune suppres-
sion even in the context of complex networks of cytokine activities. We
have studied the biology and functional expression of the innate
response cytokine IL-15 and, more recently, members of the IL-1/IL-1
receptor superfamily in inflammatory synovitis. These cytokines are
characterised by early upregulation during inflammatory responses and
characteristic functional synergy and cross-regulation in the intact
immune response. IL-15 is an IL-2-like cytokine of 15 kDa that pos-
sesses broad proinflammatory activities via its heterotrimeric receptor
(IL-15Rα/IL-15/2Rβ/common γ), including promoting T-cell maturation,
activation, and cytokine production, natural killer cell maturation and
effector function, neutrophil activation, dendritic cell activation,
endothelial cell rescue from apoptosis, macrophage activation and B-
cell activation and isotype switching. IL-15 is expressed at mRNA and
protein levels in several inflammatory arthritides including rheumatoid
arthritis. When targeted in rodent models of inflammation using either
soluble IL-15Rα or modified IL-15 mutant fusion proteins, amelioration
of onset and of existing arthritis is observed. A recent phase I study in
which a fully human IgG1 monoclonal antibody (HuMax-IL15; Genmab,
Copenhagen, Denmark) was administered to 30 patients with active
rheumatoid arthritis indicated that IL-15 blockade was well tolerated up
to 8 weeks, with early indications of efficacy detected. We have now
observed close interactions between IL-15 and IL-1 receptor superfam-
ily signalling in promoting T-cell activation. Specifically, IL-15 syner-
gises with the TLR2 ligand BLP to promote memory T-cell activation
(co-stimulatory) and also via a cell membrane-dependent pathway to
promote adjacent macrophage activation and tumour necrosis factor
release. We have also observed that a further member of the IL-1
receptor superfamily, namely ST2, is expressed in synovial fibroblasts.
Membrane-bound ST2 negatively regulates type I IL-1 receptor and
TLR4 signalling by sequestrating the adaptors MyD88 and Mal. Intrigu-
ingly, soluble ST2 suppresses development of collagen-induced arthri-
tis in DBA/1 mice if given prophylactically, and also established
collagen-induced arthritis if administered after disease onset. Together
these data suggest that complex interactions between the common γ-
receptor chain and IL-1 receptor superfamily signalling cytokines are of
importance in developing synovial inflammatory responses and that elu-
cidation of these pathways offers therapeutic utility.
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Background Osteoarthritic (OA) chondrocytes are able to re-express
numerous genes normally activated in the growth plate, and more par-
ticularly in the hypertrophic zone. Among several genes, we are inter-
ested in studying galectin-3 (gal-3) since we have recently
demonstrated that its expression was increased in OA cartilage [1].
gal-3 is a mammalian lectin, which interacts with β-galactoside
residues and is involved in numerous functions such as adhesion, splic-
ing activity, cell cycle regulation, as well as a receptor for advanced gly-
cation end products (AGE receptor). These functions are related to the
gal-3 cellular localization. Indeed, this protein may be found in the
plasma membrane, in cytoplasm and in the nucleus.
Objective In the present study, we investigated the role(s) of gal-3
using both the mono-iodoacetate-induced OA model and in vitro exper-
iments.
Methods OA was induced by a single injection of iodoacetate (5
mg/ml, 2 µl) into each knee joint of 4-month-old mice (WT) or gal-3 null
mice (KO). Mice were sacrified 7, 14 and 21 days after the single injec-
tion. Histologic evaluation was performed on sagittal sections of mouse
knee joint. The severity of the OA lesions was graded on a scale of
0–14 in a blinded fashion, by two independent observers, using the
histologic/histochemical scale of Mankin. Intracellular and extracellular
roles of gal-3 were investigated in both human chondrocytes and in
chondrogenic ATDC5 cells, a mouse cell line derived from the 129
strain.
Results Intra-articular injection of mono-iodoacetate, which induced
osteoarthritis, upregulated the expression of gal-3 in WT mice 7 days
post injection, reaching a statistical significance 14 days post injection
(P  < 0.05). The histologic grading score indicated that KO mice
(control group) had a poorer quality of cartilage compared with WT
mice (control group). Moreover, the induction of OA in KO mice
showed a marked decreased of bone area, noticeable 7 days post
injection (P < 0.05).
According to the results obtained, it seemed that gal-3 was important
for the cartilage homeostasis. Colnot and colleagues have suggested
that gal-3 could be implicated in chondrocyte survival [2]. Therefore,
we treated OA chondrocytes with sodium nitroprusside (SNP), which
is known to generate chondrocyte cell death. Our results showed that
gal-3 was much further decreased than was Bcl2 in experiments per-
formed under the same conditions [3]. Moreover, SNP decreased the
gal-3 phosphorylation, which is a key process in the capacity of gal-3
to prevent cell death. Finally, ATDC5 cells transfected with a gal-3-
expressing vector were more resistant to SNP-induced cell death com-
pared with those transfected with the empty vector. On the other hand,
Ohshima and colleagues found gal-3 in synovial fluid, particularly
during inflammation [4]. Therefore, we investigated the potential role of
exogenous gal-3 in chondrocyte cultures. Surprisingly, we found that
exogenous gal-3 induced chondrocyte death.
One of the most fascinating phenomena is the regulation of gal-3
secretion. Indeed, several cells produced gal-3 but not all are able to
secrete a great amount of it, chondrocytes belonging to the latter cate-
gory. Conversely, gal-3 is secreted in a much greater quantity by inflam-
matory cells that could affect — at least locally (i.e. at the pannus level)
— chondrocyte survival.
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Musculoskeletal disorders such as rheumatoid arthritis (RA) are a
common cause of pain and disability. Over the past decade, advances
in understanding RA pathogenesis, based on studies of human cells
and animal models of disease, have led to the identification of new
targets for therapeutic intervention. Nevertheless, despite the clinical
success of anticytokine biologicals, further initiatives in understanding
RA pathogenesis to aid further drug discovery are highly desirable.
An early event in RA is an alteration in synovial blood vessel density.
The hyperplasia of the synovium necessitates a compensatory increase
in the number of blood vessels to nourish and oxygenate the tissue. A
key response to increased requirement for nutrients and/or reduced
oxygen is to form new blood vessels (angiogenesis). In RA, the synovial
blood vessel number has been found to correlate with hyperplasia,
mononuclear cell infiltration and indices of joint tenderness. Endothelial
cells lining blood vessels within RA synovium have been shown to
express cell-cycle antigens. A variety of angiogenic mediators, includ-
ing cytokines and growth factors, have been identified in rheumatoid
joints. We and other workers have shown that expression of the angio-
genic factor vascular endothelial growth factor (VEGF) is increased in
RA. Importantly, circulating levels of VEGF are elevated in patients with
established RA and are reduced by anti-tumour necrosis factor alpha
antibody treatment, suggesting that part of the beneficial effect of anti-
tumour necrosis factor alpha in RA may be reduced angiogenesis.
However, new blood vessel formation may not keep pace with synovial
proliferation leading to regions of hypoperfusion. Intra-articular oxygen
tension is significantly lower in RA patients when compared with con-
trols, and hypoxia-inducible transcription factors such as HIF-1α and
HIF-2α are significantly upregulated. Of relevance in the context of RA,
VEGF is significantly upregulated by hypoxia, which would promote
further blood vessel formation. As well as being a key angiogenic
factor, VEGF also promotes vascular endothelial cell survival, by
increasing expression of anti-apoptotic proteins such as Bcl-2, and
members of the inhibitor of apoptosis family (namely cIAP-1, XIAP and
survivin), which directly bind to and inhibit caspases. Our data suggest
that induction of these apoptosis inhibitors is mediated via the NF-κB
pathway.
We are currently further investigating pathways activated by VEGF, as
well as dissecting out the response of synovial cells to hypoxia, both in
terms of induction of angiogenic molecules such as VEGF and upregu-
lation of inflammatory cytokines such as tumour necrosis factor alpha.
There have been a number of studies showing that angiogenesis block-
ade is effective in animal models of arthritis. Since VEGF is elevated
early during the course of RA, and since RA is most active in the initial
stages of disease, early treatment might reduce subsequent joint
erosion and damage. RA may be a potential target for anti-angiogenic
therapy, and targeting VEGF may prove to be especially beneficial.
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The mitogen activated protein (MAP) kinases represent another attrac-
tive target for rheumatoid arthritis (RA) because they can regulate cell
proliferation, apoptosis, cytokine expression, and metalloproteinase
production. They represent a complex, inter-related signal transduction
mechanism that integrates extracellular stresses and induces an appro-
priate cellular response. The three major MAP kinase families, c-Jun-N-
terminal kinase (JNK), extracellular regulating kinase (ERK) and p38
kinase, differ in their substrate specificity and subsequent responses to
stress depending on the cell type and the environmental influences.
The MAP kinases regulate various genes via both transcriptional and
post-transcriptional mechanisms. The upstream MAP kinase kinases
(MAPKK) serve as regulators of MAP kinase activity by phosphorylating
specific threonine and tyrosine residues. MAPKKs are, in turn, regu-
lated, by MAPKK kinases (MAPKKK or MAP3K).
The p38 MAP kinase is of particular interest and several inhibitors have
progressed into clinical trials. There are at least four isoforms of p38
(α, β, γ and δ), although the α form is probably the most important in
macrophages for cytokine regulation. Many of the cytokine regulatory
effects appear to be mediated through the downstream p38 substrate
MAPKAP-2. Some evidence suggests that tumor necrosis factor pro-
duction, in particular, is regulated by this kinase. Preclinical models
demonstrate that p38 inhibitors are effective in a number of animal
models of arthritis, including murine collagen-induced arthritis. Of note,
p38 inhibitors also suppress joint destruction in these models, perhaps
due to a combination of indirect effects on cytokine expression and a
direct effect on metalloproteinase production.
In vitro studies previously identified the MAPKKs MKK3 and MKK6 as
the primary regulators of p38 phosphorylation and activation. To inves-
tigate a potential role for MKK3 and MKK6 in RA, we evaluated their
expression and regulation in RA synovium and cultured fibroblast-like
synoviocytes (FLS). Immunohistochemistry demonstrated that MKK3
and MKK6 are expressed in RA and osteoarthritis (OA) synovium.
Digital image analysis showed no significant differences between OA
and RA with regard to expression or distribution. However, phosphory-
lated MKK3/MKK6 expression was significantly higher in RA synovium
and was localized to the sublining mononuclear cells and the intimal
lining. Western blot analysis of synovial tissue lysates confirm the
increased expression of phosphorylated MKK3/MKK6 in RA. Western
blot analysis demonstrated constitutive expression of MKK3 and MKK6
in RA and OA FLS. Phospho-MKK3 levels were low in medium-treated
FLS, but were rapidly increased by IL-1 and tumor necrosis factor
alpha, although phospho-MKK6 levels only modestly increased. p38
co-immunoprecipitated with MKK3 and MKK6 from cytokine-stimulated
FLS, and the complex phosphorylated ATF2 in an in vitro kinase assay.
Studies using dominant negative constructs in cultured synoviocytes
suggest that both are required for full activation of p38. These data are
the first documentation of MKK3 and MKK6 activation in human inflam-
matory disease. By forming a complex with p38 in synovial tissue and
FLS, these kinases can potentially be targeted to regulate the produc-
tion of proinflammatory cytokine production in inflamed synovium.
Available online http://arthritis-research.com/supplements/6/S3S10
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An early feature of inflammatory arthritis is an increase in the number,
size and activity of osteoclasts leading to the destruction of periarticu-
lar and subchondral bone and mineralized cartilage [1]. Osteoclastic
resorption is regulated by a number of processes, including the prolifer-
ation, differentiation and recruitment of osteoclast precursors, the
migration and activation of mature osteoclasts, and programmed cell
death. Regulatory mechanisms involve soluble mediators, cell–cell and
cell–matrix interactions. The latter involve integrins — heterodimeric
receptors that link the cytoskeleton to the extracellular matrix and
mediate outside-in and inside-out signaling. Mature osteoclasts
express three integrins (αvβ3,  αvβ1 and α2β1), with the αvβ3 vit-
ronectin receptor predominating.
We used a single cell assay to demonstrate that macrophage-colony
stimulating factor (M-CSF) and transforming growth factor beta are
chemotaxins for mammalian osteoclasts. Interestingly, the RGD-
containing disintegrin echistatin, which binds αvβ3 integrin, inhibited
M-CSF-induced chemotaxis at concentrations as low as 0.1 nM [2];
whereas it did not inhibit migration induced by transforming growth
factor beta [3].
We have recently examined the effects of Vitaxin®, a humanized mono-
clonal antibody that blocks human and rabbit αvβ3 integrins [4].
Vitaxin® caused a concentration-dependent decrease in the number of
rabbit osteoclasts attached to plastic. Moreover, Vitaxin® inhibited
resorption by rabbit osteoclasts cultured on slices of bovine bone
(Vitaxin® at 0.7 nM reduced resorption by ~50%). Vitaxin® also sup-
pressed bone resorption by in vitro-derived human osteoclasts, with a
maximum of 63% inhibition observed at concentrations greater than 2
nM. Vitaxin® does not react with rodent αvβ3 integrin; therefore, we
used a blocking anti-rat αvβ3 integrin to assess effects on rat osteo-
clast motility. This antibody induced rapid retraction of M-CSF-treated
rat osteoclasts but, unlike echistatin, did not inhibit chemotaxis induced
by M-CSF.
Evidence from our laboratories and others, using disintegrins, antibod-
ies, RGD-containing peptides and small molecules that bind the αvβ3
integrin, point to its potential as a target for the development of antire-
sorptive therapies. The role of αvβ3 integrins in angiogenesis may
make such therapeutics especially useful for the treatment of rheuma-
toid arthritis and metastatic bone disease. Differences in responses to
various agents and to genetic ablation of αvβ3 integrins point to multi-
ple underlying mechanisms and underscore the need for further investi-
gations.
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Background Over the past several decades, the osteoarthritis (OA)
field has relied on radiographs in clinical trials, in order to assess longi-
tudinal structural changes in weight-bearing joints such as the knee.
Because alternative imaging modalities such as magnetic resonance
imaging are beginning to mature, it is timely to compare and contrast
the utility of these imaging methods for the purpose of conducting
future structure-modifying OA drug clinical trials
Objective Insights from a large, multicenter knee OA study will be
shared in the context of considering the next generation of longitudinal
imaging methods to study OA.
Methods Patients in the study all had radiographic and symptomatic
knee OA. A total of 2400 patients were randomized to the study, with
an 85% study completion rate. The radiographic data for the study
were collected at baseline, month 12 and month 24, using a highly
standardized radiographic method directed at the medial compartment
of the signal knee. Fluoroscopic confirmation of proper knee position
was achieved at each study visit.
Results A 2-year, 2400-patient study of knee OA has been completed
and is being analyzed. Insights will be shared at the GARN Conference.
Session VI — The use of imaging and
biomarkers in the assessment and follow-up
of arthritis
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The recent introduction of effective structure-modifying therapies for
rheumatoid arthritis (RA) has changed the way that rheumatologists
manage patients with RA, and this has created new demands on imaging
and biochemical markers both in clinical practice and in clinical research.
Among other things, it has shifted therapeutic strategy towards early,
aggressive treatment before the onset of erosive joint damage in order to
prevent irreversible functional disability. Additionally, it has made it unethi-
cal to withhold active therapy and therefore to perform true placebo-con-
trolled clinical trials. This has necessitated using active comparator study
designs instead, which require more patients, more clinical sites and
longer studies to test the efficacy of putative new therapies. This adds
time and cost to drug development, which slows progress and potentially
raises the cost of new therapies that do get approved. Enriching study
populations with rapidly progressing patients may offset some of this
effect, but this necessitates the availability of prognostic markers that can
accurately identify which patients are most likely to develop erosive
damage and functional disability. This can be challenging in early RA, as
30% or more of the patients in early RA cohorts do not progress. Early
prognosticators are also needed by clinical practitioners to determine
which patients need aggressive treatment before the narrow window of
opportunity for containing erosive disease closes.
Magnetic resonance imaging (MRI) provides greater sensitivity for bone
erosions than radiography does, especially in early RA, when radiogra-
phy is relatively uninformative. This, along with its ability to detect pre-
erosive features, such as synovitis and bone edema, allows MRI to
identify patients with the aggressive phenotype of RA very early in the
course of their disease. Supplementing MRI with specialized molecular
markers, such as CTX-I, CTX-II, glucosyl-galactosyl pyridinoline, COMP
and others, may provide additional predictive power. These MRI and
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molecular markers can also be used to monitor disease progression
and treatment response in clinical trials with greater statistical power
than radiography can offer.
Accordingly, as the introduction of structure-modifying therapy into
mainstream clinical practice drives the demand for sensitivity and preci-
sion in predicting and monitoring erosive damage in early RA beyond
the technical limits of conventional radiography, MRI and specialized
molecular markers become increasingly attractive alternatives for evalu-
ating therapeutic efficacy in clinical trials as well as in clinical practice.
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Understanding of joint cartilage development and the pathophysiology
of osteoarthritis (OA) has previously been limited by the lack of a nonin-
vasive method for assessing joint cartilage in vivo. There has been
increasing interest in the use of magnetic resonance imaging (MRI) in
the measurement of articular cartilage volume as a possible outcome
measure in arthritis. Recent work has shown that the cartilage volume,
as measured by MRI, can be measured in a valid and reproducible way,
with a coefficient of variation of ~2%. The knee cartilage volume corre-
lates inversely with the radiographic grade of OA. Studies have shown
that significant loss in knee cartilage has already occurred by the time
radiographic change occurs at the knee. Subjects with OA lose
approximately 5% of their knee cartilage per annum, while normal,
healthy males and females lose between 1% and 3% per annum. There
is evidence from longitudinal data that loss of knee cartilage volume is
associated with a worsening of knee symptoms and that those in the
top tertile of rate of cartilage loss have a sevenfold increased risk of
progressing to a knee replacement within 4 years. Other joint struc-
tures can be measured using MRI. Interesting data have emerged from
examining knee bone marrow oedema and cartilage defects: bone
marrow oedema has been shown to be associated with pain and pro-
gression of knee OA in the adjacent tibiofemoral compartment. Recent
data suggest that knee cartilage defects predict healthy subjects at risk
of losing knee cartilage and increase the risk of progressing to a knee
replacement in those with knee OA. The emerging data suggest that
MRI assessment of joints in normal subjects and those with OA has the
potential to significantly increase our understanding of the patho-
genetic mechanisms involved in the development of OA, and thus to
identify strategies to prevent and treat this disease.
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The aim of this study was to expand our previous work assessing carti-
lage volume changes on knee osteoarthritic (OA) patients over time by
quantitative magnetic resonance imaging (MRI).
A subset of 110 patients, chosen from a large clinical trial evaluating
the impact of a bisphosphonate on OA knee, was studied. The overall
patient population (n = 1232) represented a standard study with the
mean age of 60.5 years, 61% female, and an average body mass index
of 30.3 kg/m2. Patients with KL Grade IV radiographs were excluded.
MRIs of the knee were performed at baseline, 12 months and
24 months. The images were arranged randomly and quantified by
readers blinded to the time sequence. Total cartilage volumes and car-
tilage from the medial and lateral compartments were analyzed. Data
are presented for the population that had all three sets of MRIs
(n = 107 patients). Data on cartilage volume changes with time are pre-
sented as pooled data.
The mean losses of knee OA cartilage volume in percentage from
baseline, computed at all follow-up time points, were all statistically sig-
nificantly different from zero and are similar to those previously
obtained from a pilot study of 32 patients [1]. Three populations
described as fast progressors (n = 11 patients; –13.2% of total carti-
lage), intermediate progressors (n = 48; –7.2%) and slow progressors
(n = 48; –2.3%) were identified based on loss distribution at
24 months.
Table 1
Total Medial  Lateral 
Time point cartilage* compartment* compartment*
12 months –3.7 ± 0.3% –5.4 ± 0.4% –2.2 ± 0.3%
24 months –5.6 ± 0.4% –8.1 ± 0.6% –3.4 ± 0.4%
Data presented as mean ± standard error of the mean, n = 107. * P < 0.0001 for
all measurements using a paired t test.
These data support our previous observations in a smaller cohort of
patients, showing MRI to be a precise and sensitive measure, able to
reliably detect significant changes in human knee OA cartilage volume
over time; as early as 12 months. Moreover, the percentage loss of car-
tilage volume further validates, by its statistical power, the results of our
pilot study.
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The use of imaging allows an accurate definition of the pathogenesis of
patients with inflammatory arthritis. It can identify certain predictive
prognostic factors, such as erosions or the level of synovitis. By using
three-dimensional imaging up to 10-fold greater sensitivity for the
assessment of erosions is achieved. Using such methods it is possible
to produce a more homogeneous population for entry into studies. The
results of this are an improvement in outcome data with a consistency
of response.
By directly imaging the site of pathology it is possible to increase both
the sensitivity and validity of a study; for example, the level of synovitis
can be used as a direct measure of outcome. Measuring erosions
using ultrasound or magnetic resonance imaging can increase the sen-
sitivity of studies that have as their endpoint structural damage. By
increasing the power of studies it is possible to use smaller numbers of
patients. These can be used at the phase I/II level of drug development
to establish the probable efficacy/usefulness.
Available online http://arthritis-research.com/supplements/6/S3S12
In rheumatic conditions where effective therapies have been demon-
strated there is no a major problem with placebo use. This is a particu-
lar problem with studies of conventional drugs that require large patient
numbers because of the insensitivity of the X-ray end points. Further-
more, it is only possible to show tests between active therapy and
placebo rather than between two active therapies. The increased sensi-
tivity and accuracy of the new imaging methods allow comparison
between active comparators with the power to show differences with
relatively small numbers. This has benefits for patients who are not
exposed to placebo, for investigators who can compare current best
therapies and new therapies, and for organisers of clinical studies with
results produced much more rapidly.
There are number of biological markers that can be used for the
assessment and follow-up of arthritis patients. The acute phase C-reac-
tive protein is a very sensitive measure of inflammation and an excellent
predictor of radiological damage. In biologic studies there is evidence
of its predictive value very early in the follow-up process. There are a
number of markers in serum and urine that can be used as surrogates
of bone and cartilage damage. Their main use is when the normal pre-
dictors of damage are absent when early phase studies preclude the
use of long-term follow-up.
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Osteoarthritis (OA), the most prevalent joint disease, is characterized
by abnormal and degraded cartilage, inflamed and/or thickened syn-
ovial tissue, and alterations of bone metabolism (sclerosis, cysts, osteo-
phytes). The extracellular matrix of joint tissues is composed primarily of
collagens including type I (bone and synovium), type II (cartilage) and
type III (synovium) associated with proteoglycans (e.g. aggrecan in car-
tilage) and other glycoproteins. Potential biological markers for OA
include matrix components (and/or their breakdown products), cyto-
kines, and proteases [1].
Although bone turnover markers may reflect the focal abnormalities of
subchondral bone metabolism in OA, circulating and urinary levels are
more likely to reflect the overall skeletal turnover, which may be influ-
enced by a variety of conditions including age, menopausal status,
osteoporosis and other bone diseases. Major efforts have recently
been made to develop more specific markers, especially those reflect-
ing cartilage type II collagen synthesis (PIINP and PIICP) and destruc-
tion and synovial activity that plays a pivotal role in the pathogenesis of
OA. Antibodies recognizing different type II collagen fragments have
been developed and include those directed against the neo-epitopes
generated by the collagenases, and against C-telopeptide breakdown
fragments (CTX-II). We have characterized a pyridinoline derivative,
glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD), which is found in large
amounts in human synovium and in very low levels in the cartilage and
other soft tissues. Urinary Glc-Gal-PYD excretion has been found to be
increased in knee OA and hip OA, and the levels show stronger correla-
tions with symptoms of OA than do markers for bone and cartilage [2].
Recent prospective studies have shown that baseline levels of some
cartilage markers are associated with a more rapid joint damage. In a
study of 52 patients with knee OA, we found that low serum levels of
PIIANP or high urinary CTX-II excretion were associated with faster
joint destruction as evaluated over a 1-year period, either by plain radi-
ographs or by arthroscopy [3]. Combining these two biological markers
to obtain an index of uncoupling of type II collagen synthesis and break-
down was more effective in predicting cartilage destruction than mea-
surements of a single marker. The predictive value of CTX-II has been
confirmed in a larger study of volunteers followed prospectively for
more than 6 years, where progression was assessed by joint space
narrowing at the knees and hips [4]. In the ECHODIAH cohort, includ-
ing 333 patients with hip OA followed prospectively for 3 years, we
found that among a panel of 10 different biochemical markers of bone,
cartilage and synovium activity, increased levels of urinary CTX-II and
hyaluronic acid were strongly predictive of radiological progression
independent of disease activity and radiological parameters [5]. One of
the main issues that currently impair efficient development of structure
OA modifying therapies is the low sensitivity of the plain X-ray, requir-
ing long-term studies to show a significant difference between
placebo-treated and active-drug-treated patients. In the COBRA study
of patients with early rheumatoid arthritis, we found that the combined
therapy (sulphasalazine + methotrexate + prednisone) produced a sig-
nificant decrease in urinary CTX-II that can be observed within
3 months of therapy. The magnitude of the changes of CTX-II at
3 months were predictive — independent of changes in disease activity
— of the changes in radiological scores after 5 years, indicating that the
higher the decrease of CTX-II at 3 months, the lower will be the pro-
gression of joint damage at 5 years [6]. Such data are currently missing
in OA, mainly because of the absence of treatments that have defini-
tively been shown to reduce progression.
Recent work on biological markers for OA has made valuable progress;
in particular, with the development of specific markers for the produc-
tion and breakdown of type II collagen and of synovial membrane activ-
ity. Although, they are unlikely to be clinically useful for the identification
of patients with OA, an increasing body of evidence suggests that
combination of some biological markers will be useful adjuncts to radi-
ography and magnetic resonance imaging to predict progression of
OA. The rapid responsiveness of biological markers should prove valu-
able in the clinical development of drugs for preventing joint destruc-
tion and in monitoring their treatment effects in patients with OA.
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Proteinases play an important role in the pathogenesis of joint destruc-
tion, and matrix metalloproteinases (MMP) are believed to play a crucial
role as they have the ability to degrade various compounds of the extra-
cellular matrix of the joints, including collagen. The work described in
this presentation focuses on the question of which MMPs and in what
forms are they present in synovial fluid (SF) and the circulation of
patients with joint pathology. Also, the applicability of the MMP mea-
surements as markers of disease activity or joint damage progression is
investigated. High levels of proMMP-3, proMMP-8 and proMMP-9 were
found in SF and in the circulation of the rheumatoid arthritis (RA)
patients as compared with the control population or osteoarthritis
patients. Also MMP activity in MMP/α2-macroglobulin (α2M) complexes
was shown to be higher in RA patients. Moreover, it was shown that
proMMP-8 and proMMP-9 (collagenase 2 and gelatinase B) levels are
related to the levels of collagen degradation products (hydroxyproline)
in SF. Although there is only a trend towards correlation between
proMMP-8 and hydroxyproline in SF, levels of proMMP-3 were not cor-
related with hydroxyproline levels. Comparison between systemic levels
of inflammation (C-reactive protein) and MMP levels showed the oppo-
site situation. Only proMMP-3 levels were correlated with C-reactive
protein, and not proMMP-8 or proMMP-9 levels. These observations
suggested that the aforementioned enzymes can be seen as candidate
markers for the pathophysiological processes of joint inflammation and
degradation. Moreover, MMP activity in MMP/α2M complexes was con-
sidered a possible marker of the proteolytic system since increased
levels of MMP activity were found in SF and in the serum of RA
patients as compared with osteoarthritis patients. To investigate the
predictive role of MMP levels in the circulation, we measured MMPs in
patients in an Early Arthritis Clinic. The results show that proMMP-3
levels at the onset of the disease were predictive of cartilage loss at the
end of the second year of the follow-up period. Moreover, proMMP-3
predicted joint damage progression independently from other known
parameters such as sheared epitope or rheumatoid factor. Collage-
nase-2 (MMP-8) was not predictive of joint damage, and neither were
high levels of proMMP-9. Based on these findings, we conclude that
whereas MMP-8 and MMP-9 levels reflect the current status of the
protheolytic system, MMP-3 levels at the onset of RA show the poten-
tial of the system to be destructive. It is extensively documented that
protein levels of tissue inhibitor of metalloproteinase (TIMP)-1 in SF
and in the circulation of RA patients are insufficient to counteract the
increased production of MMPs. However, little is known about the acti-
vation of proMMPs in vivo. It was previously indicated that activated,
but not TIMP-inhibited, MMPs can be neutralized by α2M. We hypothe-
sized that in pathological situations involving joint inflammation and
destruction the high production of proMMPs leads to increased levels
of activated MMPs, and because of the MMP/TIMP imbalance high
levels of MMP/α2M complexes may be found in these conditions. Thus,
high levels of MMP/α2M complexes would support the idea of a
MMP/TIMP imbalance. To test this hypothesis, a method to measure
MMP activity in MMP/α2M complexes using small fluorogenic sub-
strates, such as TNO211-F, was developed. Indeed, high levels of
MMP in complexes with α2M are found in SF and in the circulation of
patients with joint pathology. The presence of increased levels of
α2M/MMP complexes shows that TIMP levels are insufficient to inhibit
all activated MMPs; thus, the MMP/TIMP imbalance theory is sup-
ported by these findings. In conclusion, the results to be discussed
show that high proMMP production leads to increased levels of acti-
vated MMP in SF and the systemic circulation of RA patients. Upon
activation MMPs form complexes with α2M in SF and in the systemic
circulation of RA patients, which is at least partly responsible for neu-
tralization of MMPs. MMP-1, MMP-3, MMP-8 and MMP-9 are likely to
be involved the pathogenesis of RA as shown by the MMP profile in SF
and the serum of RA patients. proMMP-3 levels at the onset of RA are
predictive of the progression of joint damage. The MMP/TIMP imbal-
ance is present in various joint pathologies. MMP/α2M complexes are
reduced in the systemic circulation of RA patients upon treatment with
disease-modifying anti-rheumatic drugs.
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Antibody-initiated organ injury: apoptosis,
inflammation and fibrosis in neonatal lupus
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Few diseases exemplify the integration of research from bench to
bedside as well as neonatal lupus (NL). Although congenital heart
block (CHB) and neonatal rash are strongly associated with maternal
anti-Ro antibodies, the former occurs earlier and is permanent, and the
latter is transient. Defining the pathogenicity of maternal antibodies in
both manifestations must account for accessibility of the intracellular
target antigen(s). In vitro studies suggest that one pathologic cascade
leading to scarring of the conduction system may be initiated via apop-
tosis of the cardiocytes, resulting in translocation of Ro/La antigens
and subsequent surface binding by maternal autoantibodies [1]. These
opsonized cardiocytes are phagocytosed by macrophages, which
secrete factors not only supporting an inflammatory response (secre-
tion of tumor necrosis factor alpha [TNF-α]), but a fibrotic response
(secretion of transforming growth factor beta [TGF-β]). The latter
results in the transdifferentiation of fibroblasts into myofibroblasts, a
scarring phenotype. In vivo studies support the molecular scenario
identified in the co-culturing experiments. Based on immunohistochem-
istry of four fetal hearts identified in utero with CHB or isolated
myocarditis, apoptosis was most extensive in fetuses dying early and
was most pronounced in regions containing conduction tissue [2].
Deposition of IgG was observed in the CHB/myocarditis fetuses and
colocalized to the apoptotic cells. Giant cells and macrophages (fre-
quently seen proximal to IgG) were present in septal and thickened
fibrous subendocardial regions, most apparent in the youngest fetuses.
Septal tissue also revealed extensive areas of fibrosis and microcalcifi-
cation in which a predominant smooth muscle actin-positive infiltrate
(myofibroblast scarring phenotype) was observed [2]. TGF-β was
expressed in septal regions and was present extracellularly in the
fibrous matrix and intracellularly in macrophage infiltrates [3]. The
detection of nuclear SMAD2 and PAI-1 provided strong evidence for
TGF-β activation. Assessment of fetal genetic factors revealed that the
TGF-β polymorphism Leu10 (associated with increased fibrosis) was
significantly higher in CHB children (genotypic frequency, 60%; allelic
frequency, 78%) than unaffected offspring (genotypic frequency, 29%,
P = 0.016; allelic frequency, 56%, P = 0.011) [3]. With regard to NL
rash, the immunohistology of biopsies taken from the lesional skin of
three affected children revealed prominent TNF-α staining (cell-associ-
ated and extracellular) in the epidermal region and dermal–epidermal
junction as well as the deeper fibroblast zone and adnexa [4]. The
–308A allele (associated with higher production of TNF-α), HLA
DRQB1*02, and HLA DRB1*03 were each present in the majority of
children with rash (64%, 68%, and 64%, respectively). The frequency
of all three 6p alleles together in one individual was significantly greater
in the children with rash compared with children exposed to maternal
anti-SSA/Ro antibodies who had either CHB or no manifestation of NL
(59% versus 30%, P = 0.02) [4]. In summary, although maternal anti-
bodies are common to both manifestations of NL, the genetic fetal
Available online http://arthritis-research.com/supplements/6/S3S14
factor in rash appears to be maternally derived [4] and that in CHB
paternally derived [3]. TNF-α may be one of several factors that amplify
susceptibility, particularly in NL rash; however, the genetic studies,
backed by the histological data, more convincingly link TGF-β to the
pathogenesis of CHB. This profibrosing cytokine and its secretion/acti-
vation circuitry may provide a novel direction for evaluating fetal factors
in the development of a robust animal model of CHB as well as thera-
peutic strategies in humans.
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Many patients with systemic lupus erythematosus experience cognitive
decline as their disease progresses. The pathogenic mechanisms
include thrombosis, vasculitis, and drug toxicity. We have demon-
strated that a subset of anti-DNA antibodies cross-reacts with N-
methyl-D-aspartate NMDA receptors and can cause excitotoxic cell
death. In mice with high serum titers of these antibodies, there is no
evidence of brain damage until there is a breach in the blood–brain
barrier. With a break in the blood–brain barrier induced by administra-
tion of lipopolysaccharide, the antibodies bind preferentially to hip-
pocampal neurons that express N-methyl-D-aspartate receptors at high
density. The antibodies mediate a noninflammatory apoptotic cell
death. By 1 week following lipopolysaccharide administration, there is a
30% loss of hippocampal neurons. At 1 month there is no further loss
of neurons, suggesting that the blood–brain barrier closes and the anti-
bodies have no further access to brain tissue.
Mice experiencing hippocampal damage from antibody show
decreased  N-acetyaspartate in the hippocampus by magnetic reso-
nance spectroscopy. An abnormal metabolism is detectable only in the
hippocampus, confirming the selectivity of the damage. These mice
also display impaired performance on tasks of memory function that are
dependent on the integrity of the hippocampus. Thus, these studies
provide a new model for cognitive impairment in systemic lupus and
suggest that antibodies may mediate, through noninflammatory mecha-
nisms, changes in cognitive function.
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Anti-DNA topoisomerase I autoantibodies bind
directly to the cell surface of fibroblasts in patients
with systemic sclerosis
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Objective Fibroblasts play a crucial role in the development of systemic
sclerosis (SSc), and antifibroblast antibodies (AFAs) capable of induc-
ing a proinflammatory phenotype in fibroblasts have been detected in
SSc sera. In the present study, we examined the prevalence of AFAs in
SSc and other diseases, and the possible correlation between AFAs
and known antinuclear antibody specificities in SSc patients.
Methods Sera from 99 patients with SSc, from 123 patients with other
autoimmune and nonautoimmune diseases, and from 30 age-matched
and gender-matched healthy controls were examined. The AFA preva-
lence was assessed by flow cytometry and further characterized by
indirect immunofluorescence, ELISA and immunoblotting. Anti-topoiso-
merase I (anti-topo I) from SSc sera was purified by affinity chromatog-
raphy on topoisomerase I.
Results AFAs were more common in SSc patients (26%) than in any
other diseases studied. The presence of AFAs was significantly associ-
ated with pulmonary involvement and death. SSc AFA-positive sera
bound to all human and rodent fibroblasts tested but not to human
primary endothelial or smooth muscle cells. All SSc AFAs strongly
reacted with topoisomerase I by ELISA and immunoblotting. The
binding intensity of SSc AFAs correlated strongly with reactivity against
topoisomerase I on immunoblots of fibroblast extracts, and with the
immunofluorescent pattern typical of anti-topo I on permeabilized cells.
Total IgGs and affinity-purified anti-topo I from AFA-positive SSc sera
were found to react with the surface of unpermeabilized fibroblasts by
flow cytometry and by immunofluorescence and confocal microscopy.
Conclusion This is the first report establishing that AFAs in SSc are
strongly correlated with anti-topo I and, furthermore, that anti-topo I
itself displays AFA activity by reacting with determinants at the fibro-
blast surface.
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Mechanisms of autoimmunity in mice lacking the
mer membrane tyrosine kinase
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There has been increased recent interest in the role of macrophages
(Mp) and dendritic cells in systemic lupus erythematosus pathogene-
sis. The mer receptor tyrosine kinase, expressed on Mp and dendritic
cells, mediates the binding of the former but not the latter to apoptotic
cells. mer also is important in determining the cytokine profile that
ensues after phagocytosis. Mice lacking mer develop antinuclear anti-
bodies and rheumatoid factor. These autoantibodies appear to arise
mostly from the splenic marginal zone. Stimulated spleen cells and
peritoneal Mp from mer-deficient mice have increased expression of
tumor necrosis factor alpha and IκΒα, along with increased sponta-
neous expression of CD30L. The proinflammatory cytokine profile of
mer-deficient mice may contribute to the immunogenicity of apoptotic
debris.  In vitro ligation of mer from normal Mp leads to diminished
tumor necrosis factor alpha expression and increased IL-10 and IL-4.
mer, which controls both phagocytosis and cytokine synthesis after
exposure to apoptotic cells, may be an attractive target for therapeutic
intervention in inflammatory and autoimmune disorders.
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Natural antibodies and autoantibodies bind to
injured tissues, activate complement and cause
organ damage
GC Tsokos, S Fleming
Walter Reed Army Institute of Research, Silver Spring, Maryland, USA
Arthritis Res Ther 2004, 6(Suppl 3):35 (DOI 10.1186/ar1370)
Complement traditionally represents the first line of defense against
infections. More recently, complement was shown to play a role in
shaping the repertoire of the immune response. However, it is well
established that uncontrolled and excessive complement activation sig-
nificantly contributes to diverse pathologies ranging from inflammation,
autoimmune tissue injury and injury that follows ischemia, hypoperfu-
sion and reperfusion. In addressing the role of complement in tissue
injury, two central questions arise: how is complement activated in
each type of injury and to what extent is complement activation respon-
sible for tissue injury? To obtain insight into these questions, we have
adopted a mesenteric ischemia/reperfusion (IR) model of tissue injury
because the local intestinal damage is associated with complement
activation and recruitment and activation of neutrophils. Because
immunoglobulin-deficient, RAG-1–/– mice are protected from IR injury
and because some Cr2–/– mice have limited numbers of B1 B cells, we
asked whether Cr2–/– mice have an altered response to IR injury.
Cr2–/– mice are protected from IR injury that is completely restored
after injection of normal IgG and IgM. In addition, antibodies with speci-
ficities against negatively charged phospholipids and DNA attach to
injured tissue and activate complement, resulting in damage. We
propose that certain autoantibodies, produced by B1 cells and consti-
tuting part of the natural antibody repertoire, bind to cryptic antigens
expressed by injured cells and tissues, activate complement and effect
tissue damage.
Session VIII — Is bone quality a factor for
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Menopause and hormone replacement therapy:
effects on the immune system, arthritis and bone
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Arthritis Res Ther 2004, 6(Suppl 3):36 (DOI 10.1186/ar1371)
Menopause is, among other things, associated with increased risk of
bone loss and development of rheumatoid arthritis (RA). Numerous
postmenopausal women in the Western world have replaced the
endogenous estrogen by treatment with hormone replacement therapy
(HRT) (i.e. estrogen + progestin) or estrogen replacement therapy
(ERT) (i.e. estrogen alone). Until recently HRT was also regarded as
preventive of cardiovascular disease, and possibly even dementia.
However, recent findings in large placebo-controlled studies of long-
term HRT and ERT in healthy postmenopausal women demonstrated
an increased risk of coronary events, stroke, breast cancer and pul-
monary embolism among the HRT-treated women. Consequently,
today HRT is only recommended for 3–6 months in women with severe
menopausal symptoms.
Is there any evidence that HRT has beneficial effects on established
RA? We recently completed a 2-year controlled, randomized and
prospective trial comparing calcium/vitamin D3 + HRT and
calcium/vitamin D3 alone in patients with long-lasting RA. The outcome
clearly showed that the HRT-treated patients responded with a signifi-
cant decrease in Disease Activity Score 28 and laboratory signs of
inflammation (sedimentation rate and hemoglobin), an increase in bone
mineral density and less progression of radiographic joint destruction
compared with controls [1]. Unfortunately, we do not know how HRT
affects the increased risk for vascular disease in RA.
How could we develop a ‘safe’ HRT with preserved bone protective
and anti-arthritic properties? It is an absolute necessity to increase our
understanding of how estrogen exerts its effects in different biological
compartments. We therefore conducted several studies in estrogen
receptor (ER) knockout mice lacking one or both of ER-α and ER-β. In
summary, these experiments show that ER-α is the dominant receptor
for estrogen-mediated effects on immune organ development, T and B
lymphopoiesis and inflammation, and that ER-β seems to play a regula-
tory role [2,3].
Another approach was to analyze the immune-modulating, antiinflam-
matory and anti-arthritic properties of a selective estrogen receptor
modulator, raloxifene [4], and the synthetic compound 4-estren-
3α,17β-diol (estren) [5]. Data from recent, as yet unpublished, experi-
ments will be presented and discussed.
In conclusion, although certain side-effects of conventional HRT have
been identified, there is good hope of finding HRT that reproduces only
the beneficial effects of estrogen on bone and arthritis.
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Glucocorticoid-induced osteoporosis is the most common cause of
secondary osteoporosis, and the degree of bone loss is related to the
dose of glucocorticoids and the duration of the exposure. However,
prolonged exposure to modest doses of glucocorticoids increases the
risk of fractures and there is differential individual sensitivity to these
steroids. Following treatment with glucocorticoids, there is an initial
rapid loss of bone probably due to increased bone resorption and then
a slower progressive loss probably secondary to decreased bone
remodeling. Glucocorticoids decrease gastrointestinal calcium absorp-
tion and enhance bone resorption by increasing osteoclastogenesis
since they stimulate the expression of receptor activator of NF-κB
ligand and colony stimulating factor-1, and decrease the levels of
osteoprotegerin, a soluble decoy receptor for receptor activator of
NF-κB ligand. Glucocorticoids may prolong the life of mature osteo-
clasts under selected conditions. Eventually, glucocorticoids decrease
bone remodeling by depleting the population of osteoblasts. This
occurs by a decrease in osteoblastogenesis, and an increase in the
apoptosis of mature osteoblasts and osteocytes. Glucocorticoids delay
the maturation of immature stromal cells toward osteoblasts and inhibit
the function of mature osteoblasts. Instead, glucocorticoids enhance
adipogenesis, and this probably occurs at the expense of osteoblastic
differentiation. The effect is secondary to the induction of CAAT
enhancer binding protein beta and CAAT enhancer binding protein
delta, and of peroxisome proliferator-activated receptor gamma, which
inhibits osteoblastic differentiation. These effects suggest that gluco-
corticoids play a role in the trade of osteoblasts and adipocytes. This is
confirmed further by the fact that Notch is induced by glucocorticoids
and Notch inhibits osteoblastogenesis and enhances adipogenesis.
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Clinically, the early effects of glucocorticoids on bone resorption can
be reversed by the administration of bisphosphonates, whereas the
inhibitory effects on bone formation might be reversed by parathyroid
hormone. In conclusion, glucocorticoids have profound effects on
skeletal cells that lead to the development of osteoporosis.
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Adverse effects of rheumatoid arthritis on bone
remodeling
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Rheumatoid arthritis (RA) represents an excellent model for gaining
insights into the adverse effects of inflammatory arthritis on local articu-
lar as well as generalized systemic bone remodeling. Bone loss mani-
fested by focal erosions at the margins of diarthrodial joints represents
the radiographic hallmark of RA. These lesions are produced by resorp-
tion of cortical bone at the bone–pannus junction. Inflammatory pannus
can also extend into the marrow space, with accompanying subcortical
and trabecular bone destruction. In animal models of inflammatory
arthritis, erosion of subchondral bone contributes significantly to carti-
lage loss, as the scaffolding bone is destroyed by the inflammatory
process. Preservation of subchondral bone integrity would be pre-
dicted to have a cartilage sparing effect even in the presence of contin-
ued intra-articular joint inflammation. Recent studies employing
magnetic resonance imaging have shown that marginal joint erosions
occur very early in the course of RA and progress throughout the
disease [1,2]. The propensity of the inflamed pannus tissue in RA to
induce bone resorption is probably related to its capacity to produce a
variety of factors with potent osteoclast differentiation and activation
activity. Particular attention has focused on receptor activator of NF-κB
ligand (RANKL), a member of the tumor necrosis factor ligand family,
because of the requirement of this factor for osteoclastogenesis.
RANKL is expressed by synovial fibroblasts and activated T cells in RA
synovial tissues [3]. In three different animal models of inflammatory
arthritis, treatment with osteoprotegerin (the soluble receptor that
inhibits RANKL activity) results in marked suppression of focal bone
erosions [4–6]. In addition, mice possessing the null mutation for
RANKL are protected from focal bone destruction in the serum transfer
model of inflammatory arthritis [7]. These observations lend support to
the concept that enhanced osteoclast-mediated bone resorption at the
pannus–bone interface and in subchondral and trabecular bone play a
critical role in the pathogenesis of focal articular bone erosions.
An additional observation in patients with active RA is the absence of
bone repair radiographically. This finding suggests that the processes
that regulate coupling of bone resorption and formation under physio-
logic conditions have been disrupted, and that the enhanced focal
bone resorption associated with the synovial inflammatory lesion is not
matched by a compensatory increase in bone formation. Of particular
interest will be the determination of the effects of therapies that inhibit
joint erosions on these focal bone remodeling events at the
bone–pannus interface and in the subchondral bone.
In addition to the disordered focal bone remodeling associated with the
synovitis, patients with RA also exhibit evidence of generalized axial
and appendicular osteopenia at sites that are distant from inflamed
joints [8]. The reduction in bone mass has been confirmed using multi-
ple different techniques, and patients with RA have an increased risk of
hip and vertebral fractures [9]. Assessment of biochemical markers of
bone turnover indicates that there is a generalized increase in bone
resorption, and that there is a correlation between disease activity and
the rate of systemic bone resorption. Patients with greater disease
activity exhibit enhanced rates of bone loss. It is likely that the distur-
bance in systemic bone remodeling is mediated by proinflammatory
cytokines with osteoclastogenic activity that are released into the circu-
lation from the inflamed joints. These factors probably then act systemi-
cally to produce a generalized increase in osteoclast-mediated bone
resorption. Bisphosphonates have been shown to reverse systemic
bone loss in patients with RA, but studies thus far have not shown that
these treatment regimens reduce the progression of focal bone ero-
sions [10]. It is likely, however, that new approaches for more effec-
tively inhibiting osteoclast-mediated bone resorption will become avail-
able; for example, agents that specifically inhibit osteoclast formation or
activity by targeting mediators such as RANKL. Whether preservation
of the skeletal architecture, independent of, or in addition to suppres-
sion of joint and systemic inflammation, will impact on the progression
of functional disability needs to be investigated in appropriately
designed clinical trials.
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Subchondral bone architecture and quality in
osteoarthritis
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Osteoarthritis (OA) is traditionally seen as a disease of articular carti-
lage. However, changes in the bone that have long formed part of the
radiological diagnosis — subchondral sclerosis, cysts and osteophyto-
sis — are increasingly recognised as being an integral part of the
disease. It is curious that cysts, regions of bone loss, are found in sites
that are loaded, whereas osteophytes grow at the joint margins in sites
that might be expected to be relatively lightly loaded. This is contrary to
normal expectations of mechanical regulation of bone formation and
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resorption. Evidence from animal models of idiopathic OA suggests
that bone changes may precede cartilage deterioration, which would
indicate that they are part of the primary disease process. Patients with
OA changes evident on hip radiographs were found to have a higher
than average bone mineral density not only in the hip, but also in the
distal radius, vertebrae and calcaneus.
These gross changes in the bone are reflected in the composition,
structure and organisation of the trabecular bone and in the subchon-
dral bone plate. There is massive proliferation of cancellous bone, by
up to 60% by volume, throughout the femoral head and neck. Corre-
sponding to this, histomorphometry has shown an increase in trabecu-
lar thickness, with a concomitant reduction in trabecular number, and
an increase in osteoid width and eroded surfaces. A reduction in miner-
alisation is found in subchondral trabecular bone, perhaps reflecting a
more rapidly formed woven bone-like tissue seen using scanning elec-
tron microscopy. This is reflected in a lower material density. Scanning
electron microscopy also showed instances of abnormal bone forma-
tion in the trabecular spaces and a much greater number of Howship’s
lacunae indicating enhanced osteoclastic activity. A thickening of the
subchondral bone plate has been reported in humans and cynomolgus
macaques with OA, which also suggests an imbalance between bone
formation and resorption. Changes are not limited to the affected joint.
The iliac crest in women with hand OA has been found to have more
bone, but with a mineralization profile shifting to higher densities, sug-
gesting reduced bone turnover.
The proliferation of subchondral bone results in an increase in apparent,
or tissue, modulus. Although the apparent modulus increases, the reduc-
tion in mineral content results in a reduction in the modulus of the bone
matrix itself. Indentation studies showed a reduced hardness, and by
implication modulus, in the subchondral bone matrix. Using thermal analy-
sis and X-ray diffraction, we found no differences in crystallite size, unit
cell dimensions or decomposition properties indicating, however, that the
nature of the mineral itself, a carbonated apatite, was not altered.
Studies have implicated the receptor activator of NF-κB/receptor acti-
vator of NF-κB ligand/osteoprotegerin regulatory pathway by showing
increased levels of mRNA for receptor activator of NF-κB and a
decrease in the ratio of receptor activator of NF-κB ligand to osteopro-
tegerin. This ratio then failed to correlate with bone remodelling indices,
unlike in the normal controls, suggesting a disruption of the regulation
of bone remodelling. In addition, it has been suggested that the co-reg-
ulation of the mechanical properties of bone and cartilage does not
function as normal. We have also shown that the femoral head contains
twice the amount of fat per unit volume of cancellous bone tissue
(including bone marrow) as osteoporotic bone and has elevated levels
of (n-6) fatty acids, especially arachidonic acid.
Considerable changes in bone composition, architecture, quality and
regulation are hallmarks of OA. It is still not clear whether these
changes follow, precede or accompany the widely studied changes in
articular cartilage. Subchondral bone does not appear to play a biome-
chanical role in the initiation of the disease. The widespread changes in
bone, the frequent presence of multiple joint involvement and the link
with obesity has lead to the suggestion of a systemic musculoskeletal
disorder, in contrast to the traditional cartilage-first hypothesis.
Session IX — Pain in arthritis: the inside story
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It has been documented that nonsteroidal antiinflammatory drugs
(NSAIDs) exhibit pharmacological actions at both the peripheral and
central levels. However, the actual participation of the mechanisms of
action elicited at different anatomical sites after systemic NSAID admin-
istration is not clear. To gain further knowledge on this issue, the aim of
the present work is to study the pharmacodynamics and pharmacokinet-
ics of diclofenac, a NSAID prototype, using an integrative approach.
We have previously documented that local diclofenac administration at
the site of injury induces antinociception in the formalin test, as well as
in the pain-induced functional impairment model in the rat. This effect is
reduced by nitric oxide (NO) and cyclic GMP synthesis inhibitors, as
well as by potassium channel blockers [1,2]. We therefore assayed the
effect of oral (systemic) diclofenac in the formalin test after pretreat-
ment with either NG-nitro-L-arginine Methyl ester (L-NAME), a NO syn-
thesis blocker, or glibenclamide, a potassium channel blocker, given by
two routes of administration: locally at the site of injury and intrathe-
cally. L-NAME and glibenclamide given by these two routes significantly
reduced oral diclofenac antinociception. These results suggest that,
after systemic administration, effective diclofenac concentrations are
achieved at the site of injury as well as at the spinal cord, and that in
these two sites of action there is a participation of the L-arginine–
NO–cyclic GMP–potassium channel pathway.
In a second series of experiments, diclofenac was administered locally
at the site of injury (peripheral location), intrathecally, and simultane-
ously at the site of injury, intrathecally. Isobolographic analysis showed
that there is an additive interaction between the effects at the periph-
eral and spinal levels. It is then likely that, after systemic administration,
the observed antinociceptive effect is the result of the sum of periph-
eral and central mechanisms. Thus, effective diclofenac concentrations
at central sites achieved after systemic administration probably are
considerably lower that those required to observe an antinociceptive
effect after direct injection, due to the interaction of mechanisms
elicited at different anatomical locations. Therefore, from a pharmacoki-
netic point of view, the various central and peripheral sites of action
can be considered as the affected compartment.
In a third experimental series, the pharmacokinetics and antinociceptive
effect of diclofenac was assayed in the pain-induced functional impair-
ment model in the rat, which allows a simultaneous determination of
antinociception and blood drug concentration [3]. It appeared that
there was no direct relationship between diclofenac in blood and
antinociception. Antinociception, however, was significantly related to
affect compartment concentrations estimated by pharmacokinetic–phar-
macodynamic modeling, consistently with the earlier described pharma-
codynamic results. Computer simulations using the derived
pharmacokinetic–pharmacodynamic model showed that an oral formula-
tion of diclofenac yielding a very fast absorption, and hence a high blood
concentration peak, can optimize drug transfer to the affected compart-
ment, resulting in a fast-onset, long-lasting antinociceptive response.
Our results show that the study of NSAID pharmacodynamics and
pharmacokinetics using an integrative approach is useful for the char-
acterization of the mechanisms of action involved after systemic drug
administration, yielding information that allows the optimization of
dosing regimens.
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During inflammation in a joint, patients experience hyperalgesia and
sometimes resting pain. Hyperalgesia includes stronger pain upon
Available online http://arthritis-research.com/supplements/6/S3S18
noxious stimulation (e.g. strong pressure or twisting the joint) and the
experience of pain when stimuli are applied that are not felt painful
under normal conditions (palpation, movements in the working range).
Resting pain is felt without intentional stimulation. Neuronal mecha-
nisms involved in arthritic pain are the peripheral sensitization (sensiti-
zation of primary afferent fibres supplying the joint) and central
sensitization (sensitization of spinal cord neurons). The peripheral sen-
sitization includes the sensitization of so-called polymodal nociceptors
(high threshold receptors that are excited under normal conditions by
noxious mechanical stimuli) and of silent nociceptors (neurons that are
not excited even by noxious mechanical stimuli). When these nocicep-
tors are sensitized in the process of inflammation they are rendered
more excitable and then they even respond to normally non-painful
stimuli. In addition, the enhanced input from sensitized nociceptors
induces hyperexcitability of second-order neurons in the spinal cord.
This central sensitization is an increased gain in the spinal nociceptive
processing, and sensitized spinal cord neurons show stronger
responses to stimulation of inflamed tissue but also to stimulation of
adjacent and even remote healthy tissue. Thus the whole pain pathway
is sensitized and this explains why, in the inflamed tissue, pain is
evoked by stimuli that do not elicit pain under normal conditions [1].
Numerous mediators and ion channels are involved in the activation
and sensitization of nociceptive neurons [1]. Importantly, some media-
tors that are involved in the pathophysiology of inflammation are also
involved in the generation of peripheral and central sensitization (e.g.
prostaglandins). Cyclooxygenases and prostaglandins in the periphery
and in the spinal cord have been important topics in pain research [2].
During development of an acute inflammation in the knee joint,
prostaglandin E2 release in the spinal cord is significantly enhanced.
This is in part due to an upregulation of cyclooxygenase-2 in the spinal
cord that is already seen within 3 hours of inflammation [3]. The appli-
cation of prostaglandin E2 to the spinal cord produces hyperexcitability
of spinal cord neurons similar to peripheral inflammation. When
indomethacin is applied to the spinal cord before and during the devel-
opment of joint inflammation, the development of central sensitization is
significantly attenuated [4]. These findings show the importance of
spinal prostaglandins in the generation of inflammation-evoked spinal
hyperexcitability. However, the spinal administration of indomethacin to
the spinal cord after establishment of inflammation did not reduce
responses of spinal cord neurons to mechanical stimulation of the
inflamed joint, raising the question of how important spinal
prostaglandins are in the maintenance of spinal hyperexcitability [4].
Prostaglandin E2 acts through EP1, EP2, EP3 and EP4 receptors. The
generation of spinal hyperexcitability by spinal prostaglandin E2 can be
mimicked by spinal application of agonists at the EP1, EP2 and EP4
receptors. When the joint is inflamed and hyperexcitability is estab-
lished, EP2 and EP4 receptor agonists fail to change responses of
spinal cord neurons to mechanical stimulation of the joint. Interestingly,
however, the spinal application of an agonist at the EP3 alpha receptor
even reduced responses although it had no effect under normal condi-
tions [5]. Thus considerable plasticity of EP receptor activation seems
to determine the precise role of spinal prostaglandins in different
phases of inflammation.
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A recently described family of receptors, called the Toll-like receptors
(TLRs), may help explain what triggers the production of inflammatory
mediators such as tumour necrosis factor and chemokines in diseases
such as rheumatoid arthritis. TLRs recognize microbial products and
trigger signalling pathways, which culminate in enhanced expression of
immune and inflammatory genes. They are emerging as key players in
the pathogenesis of infectious and inflammatory diseases. TLRs are
defined by the presence of leucine-rich repeats and a signalling
domain, which contains the Toll/IL-1 receptor (TIR) domain. An impor-
tant finding is that the cystolic domain of the receptor for the cytokine
IL-1 is similar to TLRs and that they signal in a similar way. Ten TLRs
exist in humans and the best characterized are TLR4, which senses
lipopolysaccharide from Gram-negative bacteria, and TLR3, which
senses viral RNA. Signalling by each TLR is initiated by the receptor
TIR domain and recruits via homotypic adapter proteins that contain
TIR domains. Five such adapters have been discovered to date includ-
ing MyD88, Mal (also known as TIRAP), Trif, Tram, and SARM. Signals
activated include the transcription factor NF-κB and mitogen-activated
protein kinases, which lead to induction of gene expression. Differ-
ences are emerging between TLRs in terms of which adapter is
recruited by which TLR. This may lead to specificities in TLR signalling,
with pathways being triggered that are specific for the elimination of
the invading microbe.
Manipulation of proteins with TIR domains presents a number of oppor-
tunities for enhancing host defence or disease resistance, or strategies
to limit inflammation. In the context of chronic inflammatory diseases,
roles for TLRs in the pathogenesis of inflammation are emerging in con-
ditions such as rheumatoid arthritis and systemic lupus erythematosus.
Examples include the expression and action of TLRs in synoviocytes
and a role for TLR9 in the production of rheumatoid factor from autore-
active B cells. Since TLRs are likely to be key drivers of TNF produc-
tion, limiting their actions may have clinical benefit in inflammatory
diseases. Additionally, since signals like NF-κB and p38 mitogen-acti-
vated protein kinase are activated by TLRs, inhibiting these processes
will limit the effect of TLRs. Recent evidence, that certain receptor
signals activated by TLRs may have an inflammatory rather than an
immune role, raises the possibility of limiting the proinflammatory
effects of TLRs without affecting roles in host defence. Furthermore,
certain members of the TLR family (SIGIRR and ST2) may in fact be
inhibitory receptors, and several negative signals generated during TLR
action have been identified. As information on TLRs accumulates, more
opportunities will present themselves for drug development.
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Systemic lupus erythematosus (SLE) is a B-cell-dependent autoim-
mune disease characterized by autoantibodies specific for nuclear anti-
gens such as dsDNA and histones. Apoptotic blebs released from
dying cells are thought to represent a major source of autoantigen. The
cellular and molecular basis for SLE is not known but a major risk factor
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is deficiency in products of natural immunity. For example, individuals
deficient in serum complement proteins C1q or C4 almost always
develop lupus. This presents a paradox as the complement system is
known to mediate pathogenesis in SLE. In addition to its known role in
inflammation, the complement system participates in humoral antibody
responses via enhancement of B-lymphocyte activation, germinal
center survival and maintenance of long-term effector responses.
Two nonmutually exclusive hypotheses for a protective role of comple-
ment are termed the clearance hypothesis and the B-cell tolerance
hypothesis. The former proposes that complement (and natural immu-
nity) protects by clearance of apoptotic blebs and sequesters them
from the adaptive immune system. The tolerance hypothesis proposes
that complement and natural immunity act in concert to localize lupus-
antigens to sites within the primary and secondary lymphoid compart-
ments where developing B cells undergo negative selection. To
examine directly a role for complement C4 in protection from self-reac-
tive B cells, we have bred the deficient mice with mice bearing
rearranged immunoglobulin heavy chain and light chain anti-chromatin
transgenes (Tg) (termed 564) specific for chromatin. On a normal C4-
sufficient background, the self-reactive Tg B cells are blocked at the
immature or transitional stage of development. By contrast, in the
absence of C4, the self-reactive B cells continue to develop and enter
the mature compartment. Moreover, they appear to secrete self-reac-
tive antibody of both IgM and IgG isotypes. These results identify a
functional role for C4 in regulation of self-reactive B cells and support
the B-cell tolerance hypothesis.
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The innate immune system is now known to play an important role in
modification of adaptive immunity. In addition, innate immunity is cen-
trally important to the development of collagen-induced arthritis (CIA), a
widely studied model for the human disease rheumatoid arthritis. Com-
plement is a key component of the innate immune system, and comple-
ment activation in inflamed joints has been previously shown to both
characterize active disease in patients with rheumatoid arthritis as well
as to be essential to the development of CIA in mice and other similar
animal models. There is little understanding, however, of the specific
mechanisms by which complement influences cellular and humoral
autoimmunity in CIA, or how complement activation fragments intersect
with other innate or adaptive immune mechanisms in the disease
process. We have recently found that the alternative complement
pathway component factor B is centrally involved in disease pathogen-
esis in the CIA model. Following transfer of anti-type II collagen mono-
clonal antibodies into factor B-deficient mice, only modest inflammation
results as compared with wild-type mice. In addition, expression of
complement receptor 2 (CR2/CD21) and complement receptor 1
(CR1/CD35), molecules that are expressed on B lymphocytes and T
lymphocytes as well as follicular dendritic cells and are known links for
innate and adaptive immunity, is required to develop CIA. Specifically,
elimination of CR2/CR1 expression by gene targeting results in a
marked decrease in the generation of arthritis following immunization
with type II collagen in DBA1/j mice. Of interest, despite substantial
protection from disease in receptor-deficient mice, only modest
changes occur in IgG anti-type II collagen antibody subclass and
isotype responses. Understanding the mechanisms by which the alter-
native pathway as well as complement receptors modulate inflamma-
tory arthritis should provide important insights into the relationships
between innate and adaptive immunity.
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Systemic lupus erythematosus (SLE) is a prototype systemic autoim-
mune disease characterized by flares of high morbidity for which we
have no predictors. We used oligonucleotide microarrays to analyze
the genes expressed by blood mononuclear cells from active SLE
patients, arthritis patients and healthy controls. Here we show that
active SLE can be distinguished by a remarkably homogeneous gene
expression pattern with overexpression of granulopoiesis-related and
interferon (IFN)-induced genes. Using the most stringent statistical
analysis (Bonferroni correction), 15 genes were found highly upregu-
lated in SLE patients, 14 of which are either well-known or newly identi-
fied targets of IFN. The other gene is the defensin DEFA-3, a major
product of immature granulocytes. A more liberal correction to the pair-
wise tests (Benjamini and Hochberg correction) yielded 16 additional
genes, 12 of which are known to be IFN-regulated and four to be gran-
ulocyte specific. High-dose intravenous infusion of glucocorticoids, one
of the standard treatments of disease flares, shuts down the IFN signa-
ture, further supporting the critical role of this cytokine in SLE. Further-
more, we have identified a set of 10 genes whose expression
correlated with disease activity according to the SLE Disease Activity
Index. The most striking correlation (P < 0.001, r = 0.55) was found
with the formyl peptide receptor-like 1 protein that mediates chemotac-
tic activities of defensins. Therefore, while the IFN signature confirms
the central role of this cytokine in SLE, the microarray analysis of blood
cells reveals that immature granulocytes may be involved in SLE patho-
genesis.
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Toll-like receptors (TLRs) are a family of immune defense proteins that
appear to have evolved to detect molecules that are common to broad
classes of pathogens, but are not present in our own cells. Specific
TLRs can be activated with synthetic ligands to induce protective or
therapeutic innate and adaptive immune responses. CpG-oligo-
deoxynucleotides (ODN) are TLR9 ligands that have proven particularly
active for immunotherapy of cancer and infectious and allergic dis-
eases in animal models. Several CpG-ODN are now in phase I/II
human clinical trials for these indications, and have shown early evi-
dence of efficacy, with excellent safety and tolerability. Patients in
cancer clinical trials have been tolerating weekly injections of CpG-
ODN for longer than 6 months. Objective disease responses have
been documented in five different tumor types. A few subjects have
developed positive anti-dsDNA ELISAs, but antinuclear antibodies gen-
erally have been negative and the synthetic TLR9 agonists in human
trials have not induced autoimmune disease. Although stimulation of
the TLR9 pathway does not appear to be sufficient for induction of
autoimmune disease, this pathway does appear to be required for the
full development of systemic autoimmunity in some mouse models,
which suggests a therapeutic role for TLR9 antagonists. These results
provide new insights into the mechanism of action for the anti-
rheumatic disease activity of the anti-malarials. This class of com-
pounds had been hypothesized to act by interfering with antigen
processing and presentation, but these biologic activities only occur at
concentrations that are approximately two orders of magnitude above
the concentrations attained in treated patients. Surprisingly, the most
potent biologic activity of the anti-malarials now appears to be their
inhibition of TLR9 stimulation by immunostimulatory CpG motifs. Thus,
TLR9 should be considered as a validated drug target, and the classic
antimalarials as relatively weak TLR9 antagonists.
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IL-1β, as the prototypic inflammatory cytokine, induces or activates a
number of different transcription factors, including NF-κB, CCAAT/
enhancer binding protein beta (C/EBPβ), C/EBPδ and certain Ets
factors, which are involved in upregulating the expression of genes such
as cyclooxygenase-2, matrix metalloproteinase (MMP)-13, and inducible
nitric oxide synthase in chondrocytes and other cell types. IL-1β sup-
presses the expression of genes associated with the differentiated
chondrocyte phenotype, including type II collagen (COL2A1) and
aggrecan. We reported previously that IL-1β-induced Egr-1 inhibits
COL2A1 promoter activity by binding to the –131/+125 bp core pro-
moter and preventing the interactions among CREB binding protein,
Sp1 and TATA-binding proteins [1]. This early response permits further
transcriptional repression by IL-1β-induced factors that bind to
upstream promoter sequences. The Ets factor ESE-1, which is epithe-
lial-specific under physiological conditions, is expressed in rheumatoid
arthritis and, to a variable extent, osteoarthritis synovial tissues. ESE-1
mRNA is induced by treatment of chondrocytes, synovial fibroblasts,
osteoblasts, and monocyte-macrophages with IL-1β, tumor necrosis
factor alpha, or lipopolysaccharide. After stimulation with IL-1β, ESE-1
mRNA appears within 30 min, peaks between 4 and 8 hours, and
declines after 16 hours. This induction relies on the translocation of the
NF-κB family members, p50 and p65 to the nucleus and transactivation
of the ESE-1 promoter via a high-affinity NF-κB binding site [2]. Follow-
ing induction, ESE-1 can directly activate IL-1-induced promoters by
binding to two or more functional Ets sites [3].
To determine the mechanisms by which IL-1-induced transcription factors
regulate COL2A1 gene expression, we used as a model the human chon-
drocyte cell line C-28/I2, in transient transfections with pGL2-COL2A1
constructs and as a source of nuclear factors for gel shift analysis. Our
results indicate that ESE-1 acts as a direct repressor of COL2A1 pro-
moter activity by binding to at least two of several Ets sites upstream of
–131 bp and blocking protein–protein interactions between the SOX
protein complex and the coactivator CREB binding protein/p300, thereby
disrupting the basal transcriptional machinery. Egr-1, by displacement of
Sp1, and NF-κB, as well as C/EBPβ and C/EBPδ [4], may also partici-
pate by direct or indirect mechanisms. These activities are consistent with
early cytokine-activated events that are usually associated with gene acti-
vation but produce a negative response in the context of the COL2A1
promoter. The differential activation of upstream signaling events that
result in induction of these transcription factors could explain the synergy
and redundancy in cytokine responses. While ESE-1, by itself, is a potent
negative regulator of COL2A1 promoter activity, IL-1β also stimulates the
production of prostaglandin E2 [5] and bone morphogenic protein-2 [6],
both of which stimulate COL2A1 expression and may blunt the effects of
the negative regulators. Thus, in the context of osteoarthritis cartilage, the
initial events that activate chondrocyte synthetic activity probably result in
activation of the normally inactive COL2A1 promoter, which would then
be susceptible to transcriptional repression depending upon the balance
of positive and negative regulators. Since IL-1β-induced transcription
factors also upregulate genes associated with catabolic and inflammatory
responses, including cyclooxygenase-2, MMP-13, and inducible nitric
oxide synthase, and similar signaling pathways may be induced by
adverse mechanical stress, the dissection of the molecular mechanisms
involved may lead to the development of targeted therapies for blocking
destruction of the cartilage matrix and promoting its repair.
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Oncostatin M (OSM) is a member of the IL-6 family that we previously
showed could synergise with IL-1 to induce cartilage proteoglycan and
collagen degradation in a cartilage explant culture system [1]; these
observations now extend to IL-6 in the presence of its soluble receptor. A
significant finding was the synergistic induction of the collagenase, matrix
metalloproteinase (MMP)-1, which occurs via interplay between the
janus-activated kinase/signal transducer and activator of transcription,
activator protein 1 and mitogen-activated protein kinase pathways. Other
collagenases such as MMP-8 and MMP-13 are also upregulated along
with MMP-14 and MMP-3. This latter enzyme can activate the collage-
nases and an important feature of OSM may be its ability to activate
enzymes that initiate the activation cascades that lead to the production
of active collagenases. These studies have important implications for
inflammatory joint disease since OSM (and indeed IL-6) have been pro-
posed to be protective in rheumatoid arthritis. We also demonstrated that
OSM can also exacerbate the effects of other important proinflammatory
mediators such as tumour necrosis factor alpha (TNF-α) and IL-17.
We have continued molecular and cellular studies to discover the
mechanism of action that leads to synergy. Using Affymetrix microar-
rays we have shown that a specific cohort of genes are upregulated by
these cytokine mixtures that include MMPs, a disintegrin and metallo-
proteinases, activators, cell surface proteins and cytokines. Analysis
using two-dimensional gel electrophoresis and proteomic analysis has
confirmed that many of the corresponding proteins are made by chon-
drocytes after stimulation. Purification of specific proteins from condi-
tioned culture medium has been undertaken to try and determine the
specific collagenase responsible for collagen turnover.
In order to assess the effects of these cytokine combinations in vivo,
we have assessed the effects of intra-articular gene transfer of OSM in
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combination with either IL-1 or TNF-α on murine knee joints using
recombinant adenovirus. Engineered adenoviruses were administered
for only 7 days, after which time joints were fixed, decalcified and sec-
tioned. Histological analyses indicated marked synovial hyperplasia and
inflammatory cell infiltration for IL-1, TNF-α and OSM treated joints but
not in controls (joints treated with an ‘empty’ adenovirus). The inflam-
mation was more pronounced for both the OSM + IL-1 and OSM +
TNF-α combinations with evidence of extensive cartilage and bone
destruction. Significant loss of both proteoglycan and collagen was
also seen for these combinations, and immunohistochemistry revealed
an increased expression of MMPs with decreased tissue inhibitors of
metalloproteinases in both articular cartilage and synovium. The effects
of these combinations were significantly greater than those seen with
any of the cytokines alone. Cytokine combinations also upregulated
receptor activator of NF-κB/receptor activator of NF-κB ligand
(RANK/RANKL) and increased the number of TRAP-positive cells. A sig-
nificant increase in osteoclast formation and activation and bone damage
was accompanied by marked upregulation of RANK/RANKL in inflamma-
tory cells within the synovial tissue. Taken together, these data confirm
that, in vivo, OSM can significantly exacerbate the effects of both IL-1
and TNF-α, resulting in inflammation and tissue destruction characteristic
of that seen in rheumatoid arthritis. In vitro data showed that the damage
to cartilage in the cartilage model system can be blocked by both trans-
forming growth factor beta and insulin like growth factor-1.
These studies provide further evidence to implicate the upregulation of
collagenases as a key factor in the destruction of collagen that occurs
in joint pathology, and suggests that OSM is a potent mediator when
found in the joint with other proinflammatory cytokines.
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Extracellular matrix (ECM) degradation plays an important part in many
musculoskeletal pathologies including arthritis and bone tumour. Matrix
metalloproteases (MMPs) degrade the ECM and are thus important in the
development of these pathologies. Furthermore, recent evidence suggest
the existence of interactions between endothelin-1 (ET-1) and MMPs.
This study aimed at determining the effect of ET-1, Big ET-1 (the imme-
diate precursor of ET-1) and IL-1β (a proinflammatory cytokine that
induces MMP synthesis) on MMPs in order to determine the mecha-
nism of action of these factors in chondrosarcoma and osteosarcoma
cells. We have also studied the effects of the NF-κB inhibitor and the
inhibitor of furine convertase that is involved in Big ET-1 maturation.
Here we characterized the MMPs, ET-1 and ET-1 receptors in
SW1353 and MG63 cells by western blot, zymography, northern blot,
immunohistochemistry, RT-PCR, and in situ hybridization.
First, we showed that ET-1 and its two receptors (ETA and ETB) are
constitutively expressed in osteosarcoma and chondrosarcoma cells.
Then, we demonstrated that both ET-1 and Big ET-1 markedly induce
synthesis and enzymatic activity of MMP-2 and that enzymatic activity is
significantly increased when compared with MMP-9. Furthermore, inhi-
bition of NF-κB activation (by pyrrolidinecarbodithioic acid) blocked
MMP-2 production and activity, indicating the involvement of NF-κB.
Similarly, inhibition of Big ET-1 maturation by the furin convertase
inhibitor abrogated MMP-2 synthesis.
ET-1 and as its immediate precursor Big ET-1 can be considered as
autocrine factors contributing to the activation of MMPs, thus favouring
ECM degradation. MMPs, particularly MMP-9 and MMP-2, are hyperex-
pressed in chondrosarcoma and osteosarcoma cells. Their production
is stimulated by ET-1, Big ET-1 and IL-1β while it is diminished when
the NF-κB and furine convertase pathways are inhibited. Our study pro-
vides new insights on the catabolic role of ET-1 in ECM degradation.
Thus ET-1 could be involved in diseases where ECM destruction is
caused by an excess of MMP, including bone tumour, degenerative
and inflammatory articular diseases. In an attempt to diminish this
degradation, it would be beneficial to propose a double inhibition of
both ET-1 receptors and MMPs.
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Background Cartilage degradation in osteoarthritis (OA) and rheuma-
toid arthritis constitutes a major structural change in the joint, which may
severely impair its function causing pain and disability. This degradation
is accompanied by the release in the synovial fluid of degraded matrix
constituents that primarily result from an increased matrix catabolism.
Various factors are directly involved in this process. Endothelin-1 (ET-1),
a potent vasoconstrictor and pro-mitogen peptide for many cell types,
including chondrocytes, was recently identified as one such factor.
Objective We previously demonstrated that ET-1 induces matrix metal-
loproteinase (MMP)-1 and MMP-13 synthesis, secretion and activation.
Here, we investigated the mechanism by which ET-1 induces the pro-
duction of these two MMPs.
Methods Human OA chondrocytes were cultured in the presence of
ET-1 with or without inhibitors of protein kinase or LY83583 (an
inhibitor of soluble guanylate cyclase and of cGMP) and then MMP-1,
MMP-13 and nitric oxide (NO) levels were measured by ELISA and
Griess reaction, respectively. Additionally, inducible nitric oxide syn-
thase (iNOS) and activated forms of p38 mitogen-activated protein
kinase, p44/42, SAP/JNK and serine threonine kinase Akt were deter-
mined by western blot, Bad and Bcl2 proteins by immunocytochemistry
and apoptosis by TUNEL.
Results ET-1 greatly increased MMP-1 and MMP-13 production, NO
release and iNOS expression. LY83583 decreased the production of
both MMPs below basal levels, whereas the inhibitor of p38 kinase,
SB202190, suppressed ET-1-stimulated production only. Similarly, the
ET-1-induced NO production was partially suppressed by the p38
kinase inhibitor and completely suppressed by the PKA kinase inhibitor,
KT5720, and LY83583, suggesting the involvement of these enzymes in
ET-1 signaling pathways. ET-1 does not induce apoptosis and could even
have a protective effect through the induction of Akt phosphorylation.
Conclusions In human OA chondrocytes, ET-1 controls the production
of MMP-1 and MMP-13. ET-1 also induces NO release via iNOS induc-
tion. Thus, ET-1 and NO should become important target molecules for
future therapies aimed at stopping cartilage destruction.
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IL-1Ra exists in four isoforms, three of which are created by alternate
transcriptional splice mechanisms and remain in the cytoplasm. The
objective of these studies was to determine whether the major intracel-
lular isoform of IL-1Ra, the 18 kDa type (icIL-1Ra1), bound specifically
to cytoplasmic proteins and exerted antiinflammatory effects inside
cells. A yeast two-hybrid screen with HeLa cell lysates indicated
binding of icIL-1Ra1 to the third component of the COP9 signalosome
complex (CSN3). The CSN complex contains eight subunits, is found
in the cytoplasm and nucleus of all mammalian cells, and appears to
function as an interface between signal transduction pathways and
ubiquitin-dependent proteolysis [1]. The binding of icIL-1Ra1 to CSN3
was confirmed by far western blot analysis and sedimentation in a glyc-
erol gradient; icIL-1Ra1 bound only to CSN3 and not to the other
seven components of the CSN. Glutathione pull-down experiments
showed that only icIL-1Ra1, and not the other isoforms of IL-1Ra,
bound to CSN. Co-immunoprecipitation experiments also indicated
binding only of icIL-1Ra1 to the CSN. In addition to binding specifically
to CSN3, icIL-1Ra1 inhibited phosphorylation of IκB, p53 and c-Jun by
CSN-associated kinases. Furthermore, icIL-1Ra1 blocked p53 phos-
phorylation by recombinant protein kinase 2 and protein kinase D, two
kinases associated with the CSN.
To examine the biological function of icIL-1Ra1, this cDNA was trans-
fected into the intestinal epithelial cell line Caco-2, which expresses no
endogenous IL-1Ra isoforms. The transfected icIL-1Ra1 inhibited IL-1-
induced IL-6 and IL-8 production; this effect was not due to release of
icIL-1Ra1 by the cells and blockade of IL-1 receptors [2]. Furthermore,
the levels of IL-1-induced IL-6 and IL-8 production in various ker-
atinocyte cell lines were inversely related to the baseline levels of icIL-
1Ra1 in the cells. The keratinocyte line A431 contained large amounts
of icIL-1Ra1 and exhibited weak production of IL-6 and IL-8 after
culture with IL-1. In contrast, KB cells contained no icIL-1Ra1 and
exhibited a robust production of IL-6 and IL-8 after stimulation with IL-1.
Transfection of icIL-1Ra1 into KB cells led to inhibition of IL-1-induced
IL-6 and IL-8 production. To explore whether these antiinflammatory
effects of icL-1Ra1 are mediated through interaction with CSN3,
experiments are in progress to examine IL-1-induced cytokine produc-
tion in keratinocyte cell lines after blockade of CSN3 or icIL-1Ra1 pro-
duction using specific siRNAs. Similar experiments on the effects of
icIL-1Ra1/CSN3 interactions on cytokine and matrix metalloproteinase
production in human synovial fibroblasts are also in progress.
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The aim of this study was to examine the in vivo effects of
PD-0200347, an α2δ ligand of voltage-activated Ca2+ channels and a
member of the gabapentin family, on the development of cartilage
structural changes in an experimental osteoarthritis (OA) dog model.
We examined its effects on the major pathways involved in OA carti-
lage degradation including metalloproteases (MMPs), the inducible
form of nitric oxide synthase (iNOS) and IL-1β.
OA was surgically induced in dogs by sectioning the anterior cruciate
ligament. OA dogs were divided into three groups and treated orally
with placebo, with 15 mg/kg/day PD-0200347, or with 90 mg/kg/day
PD-0200347. Dogs were sacrificed 12 weeks after surgery. The sever-
ity of lesions was scored macroscopically and histologically. Cartilage
specimens from femoral condyles and tibial plateaus were processed
for quantitative PCR and immunohistochemistry. Specific probes and
antibodies were used to study IL-1β, iNOS, MMP-1, MMP-3 and MMP-
13 mRNA and protein levels, respectively.
No clinical signs of drug toxicity were noted in the treated animals.
PD-0200347 treatment at both dosages tested (15 or 90 mg/kg/day)
reduced the development of cartilage lesions. There was a reduction in
the score of lesions, and statistical significance (P  < 0.01) was
reached at the highest dosage of the drug. This score reduction was
mainly related to the decrease in the lesion surface size. Quantitative
PCR and immunohistochemical analyses showed that PD-0200347
treatment also significantly reduced key OA mediators, IL-1β, iNOS,
MMP-1, MMP-3 and MMP-13 gene expression and synthesis.
This study demonstrated the efficacy of PD-0200347 at reducing the
progression of cartilage structural changes in an OA dog model. It also
showed that this effect is linked to the inhibition, at the transcriptional
level, of the major pathophysiological mediators. The mechanism of
action could be related to a significant reduction of Ca2+ current ampli-
tude via voltage-gated calcium channels, which in turn downregulates
the downstream signaling pathways.
Assessment of clinical and structural changes
of arthritis
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Purpose Nonsteroidal antiinflammatory drugs (NSAIDs) are used to
alleviate osteoarthritis (OA) symptoms and are not considered disease-
modifying. We studied NSAID use in subjects with hip or knee OA to
investigate the relationship between NSAIDs and OA severity.
Methods Subjects (seen over 2 years at teaching hospitals in London,
Ontario) were referred to orthopedic surgeons or rheumatologists, had
radiographs available, but had no inflammatory arthritis or evidence of
secondary OA. Subjects were divided into mild, moderate (mod) and
severe OA by X-ray (worst joint selected). A questionnaire was mailed
asking about current/ever use of specific NSAIDs (by generic and
trade names) including over the counter and acetylsalicylic acid.
Coxibs were not available over the study period. A toal of 608 subjects
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were studied, having mild (71), mod (129) and severe (408) OA, with a
disease duration of 10 years in each group (62% were women, who
had proportionately more mild disease than men).
Results Those with severe versus mild OA were older (70 versus 61
years), so age was adjusted for. There was an inverse dose–response
with use of > 3 NSAIDs being used by mild versus severe OA (odds
ratio 3.7), mild versus mod OA (odds ratio 2.5) and mod versus severe
OA (odds ratio 1.5) (P < 0.0001), and the same was found with > 2
NSAIDs (P < 0.0002); and 7% of mild, 15% of mod and 12% of
severe OA had received no NSAIDs ever. Only one NSAID (ever used)
was increased in severe OA (sulindac, P  < 0.008) compared with
naproxen, tiaprofenic acid and diclofenac, more frequently used in mild
than mod or severe OA (P < 0.01). Other NSAID use ever was not dif-
ferent between the groups (including indomethacin, thought to be
chondrodestructive), but numbers using indomethacin were small. Limi-
tations may include inability to study accurately the duration of NSAID
use, older age in those with severe OA (which could affect NSAID
treatment choice), recall bias and unknown confounders. We did not
illicit body mass index or pain level in each group.
There may be biases for referring to different specialists as the rheuma-
tologists prescribed NSAIDs more often and surgeons treated more
subjects with severe OA (P < 0.0001). When analyses were stratified
by specialist type, there were no differences between mild, mod and
severe OA for NSAID use in subjects treated by rheumatologists;
however, the trend for increased NSAID use with milder OA was
evident in those seen by orthopedic surgeons. When stratified by knee
and hip OA, the dose–response remained (P < 0.003 and P < 0.03,
respectively). Subjects were followed by general practitioners, so we
assumed past NSAIDs should have been prescribed equally in all
groups, but this was not the case.
Conclusions Those with more severe OA are more rapidly progressive
(having similar disease duration to the other groups) and could be
innate NSAID nonresponders. However, one would assume that they
should be exposed to more NSAIDs (looking for one to be helpful). We
conclude that NSAID use and the number of NSAIDs used was greater
in mild radiographic OA and postulate that lowering prostaglandins in
the joint with NSAIDs may be protective for cartilage. Prospective
studies are needed to confirm observations. Some in vitro models of
NSAIDs in OA support our observations.
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The etiology and significance of nonfull thickness chondral defects is
uncertain. This study had two objectives. Firstly, to describe the differ-
ences in chondral defect prevalence and severity between offspring of
those with severe knee osteoarthritis (OA) and age-matched and sex-
matched controls without this history and, secondly, using this popula-
tion as a convenience sample, to describe the associations between
chondral defects and pain, age, body mass index, joint surface area,
cartilage volume and radiographic features of OA. We interviewed 372
male and female adults aged between 26 and 61 years (58% female,
mean age 45 years). Of these, 50% had a parent who has severe knee
OA requiring knee replacement and 50% were age-matched and sex-
matched randomly selected controls. Chondral defects, cartilage
volume and joint surface area was determined at the patella, medial
and lateral tibial compartments of the right knee by quantitative mag-
netic resonance imaging. Anthropometric factors were measured while
knee injury history, knee pain and occupation involving significant
bending were assessed by questionnaire. Radiographic knee OA was
assessed by semi-flexed AP views. Chondral defects were surprisingly
common and were more prevalent and severe in the offspring (57%
versus 43%, P = 0.007; defect score 5.7 versus 5.1, P = 0.002). This
was independent of other factors with the exception of pain and joint
surface area, suggesting these three factors are all linked. In addition,
chondral defects at the patella and femoral but not tibial sites were
associated with knee pain but not injury history. Defect prevalence and
severity also increased with increasing age and body mass index, espe-
cially in females. Adjustment for radiographic features of OA decreased
the magnitude of these associations, suggesting they are directly rele-
vant to OA. Defect prevalence and severity also increased with osteo-
phytes and increasing joint surface area and were associated with
decreased joint space width and cartilage volume. Finally, knee carti-
lage defect severity was associated with a urinary marker of cartilage
breakdown (r = +0.18, P  < 0.001). In conclusion, knee cartilage
defects are common, have a genetic component that is linked to the
genetic contribution to knee pain and bone size, and may have a role in
the genetic pathogenesis of knee OA. Furthermore, the associations
between defects and OA risk factors, joint surface area and cartilage
breakdown suggest that nonfull thickness defects in younger life may
be a marker of OA risk in later life.
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There is now ever-increasing acceptance that magnetic resonance
imaging (MRI) can provide valuable, possibly unique, measurement
data for an articular joint as a complete organ. Thus a single MRI scan,
duration 10 min, which can be measured with most whole body scan-
ners, visualises not only all the soft tissues within the joint capsule
(articular cartilage, ligaments, menisci) and those surrounding it
(muscles, tendons, blood vessels), but also the bone (both cortical and
trabecular). Importantly, recent software developments enable quantita-
tion of the dimensions of those structural elements. Particular attention
has focused on human knee articular cartilage and a large number of
studies have already reported measurement of total volumes or local
volumes, and of mean cartilage thickness for an entire condyle or more
localised regions.
This poster will provide an overview of studies from the Herchel Smith
Laboratory that demonstrate the practical realities of quantitative mea-
surements relevant to the longitudinal studies that must be made for
human drug trials. The specific questions that we have explored since
1995 include the following:
• Is it best to make ‘focal’ or ‘total’ measurements?
• How to enhance reproducibility of spatial relocation for serial mea-
surements?
• What are the best statistical definitions of measurement repeata-
bility?
• How to decrease interobserver variations of spatial measurements?
• How to enhance measurement ergonomics?
• How to automate the measurement processes?
Acknowledgement Herchel Smith endowment.
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Purpose Previous studies have demonstrated an association between
osteoarthritis (OA) progression and inflammation as measured by sys-
temic C-reactive protein (CRP) levels. We hypothesized that CRP
levels in patients with OA are pathogenically linked to synovial mem-
brane inflammation. This study investigated the relationship between
CRP and local synovial appearance, synovial histology, and synovial
fluid IL-6 levels.
Methods Patients with idiopathic OA undergoing either total hip or
knee arthroplasty or knee arthroscopic debridement were identified.
Synovial membrane inflammation was graded intraoperatively and by
Available online http://arthritis-research.com/supplements/6/S3S24
histologic examination of samples obtained from standardized loca-
tions. Synovial fluid IL-6 levels and plasma CRP levels were measured
using a high-sensitivity ELISA.
Results Twelve patients with early OA and 37 patients with end-stage
OA were identified. These OA patients were dichotomized into two
groups: high CRP (CRP level > 3 µg/ml) and low CRP (CRP
<3µg/ml). The high CRP group demonstrated elevated synovial fluid
IL-6 levels (P < 0.001) as well as increased intraoperative and histo-
logic synovitis scores (P = 0.045 and P = 0.03, respectively) com-
pared with the low CRP group. There was a highly statistically
significant correlation between synovial fluid IL-6 levels and systemic
CRP levels (rho = 0.66, P < 0.001).
Conclusions We have demonstrated an association between a marker
of systemic inflammation and local synovial inflammation in patients
with OA. The more aggressive disease seen in OA patients with ele-
vated CRP levels may be mechanistically linked to a more inflammatory
synovial response in the diseased joint.
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Background C-reactive protein (CRP) is an acute phase reactant. It is
usually increased in rheumatoid arthritis (RA) patients when disease is
most active. These patients would be expected to participate in clinical
trials, high CRP being a frequent requirement for inclusion. At the same
time this group of patients is usually treated with moderate to high
dose steroids. Steroids have the potential to decrease CRP without
modifying disease progression. It has been our clinical observation that
very active patients are probably not influenced very much by steroids,
but patients with moderate disease activity who use low doses of
steroids have their CRP lowered or suppressed.
Hypothesis Patients treated with low doses of corticosteroids would
have a lower CRP than those treated with no steroids, precluding them
from participating in clinical trials.
Methods We studied the correlation between CRP and corticosteroid
doses in RA patients, fulfilling the American Rheumatism Association
1987 criteria, treated with oral steroids, disease-modifying anti-
rheumatic drugs, and cyclooxygenase-2 selective inhibitors. Patients
were on stable doses of their medications. CRP and steroids were
measured during 250 visits performed in 65 patients. Patients were
divided into three groups: those with ≤ 5 mg prednisone per day, those
with > 5 mg prednisone per day and those without steroids. All other
drugs remained stable.
Results Patients on ≤ 5 mg/day prednisone showed a significantly
lower CRP compared with the patients not using steroids (85.71
versus 59.09, P < 0.001). However, patients with > 5 mg prednisone
per day had a significantly higher CRP compared with patients with
≤ 5 mg/day prednisone (91.98 versus 59.09, P < 0.001).
Conclusion Randomized clinical trials are the current method to evalu-
ate new therapies in RA. Patients are selected by strict inclusion and
exclusion criteria including high CRP. Severe RA patients with very
high CRP treated with more than 5 mg prednisone are not influenced
by steroids, but moderately active patients on more than 0 but ≤ 5
mg/day prednisone could be excluded from clinical trials as a conse-
quence of lowered CRP. A prospective, randomized, clinical trial is
underway to prove or disprove this hypothesis.
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Autoimmune diseases (AID) affect 5–8% of occidental populations.
Theses AID are characterized by the destruction of self-tissue following
activation of autoimmune responses mediated by T cells or B cells, or
both. Manipulations of immune responses to protect against autoimmu-
nity as potential immunotherapeutic implications using DNA vaccina-
tion could help to treat and/or prevent AID.
Recently, we have generated an animal model to study the role of the
molecular mimicry in breaking tolerance to a neo-antigen in the liver.
Transgenic (Tg) mice expressing the nucleoprotein (NP) gene from
lymphocytic choriomingitis virus (LCMV) as neo-self antigen in their
hepatocytes develop an autoimmune hepatitis after immunization with
plasmids coding for intracellular or secreted LCMV-NP forms [1]. Four
groups of transgenic mice (Tg-NP) were immunized via the intramuscu-
lar route with both these plasmids (pNP) alone or co-injected with IL-
12-expressing plasmid (pIL-12). NP-specific serum antibody titres were
detected in an ELISA test.
All animals injected with different plasmid-based gene expression
vectors showed different anti-NP antibody profiles. The IgG1 subclass
is an indication of Th2 immune response, whereas IgG2 subclass pro-
duction reflects a Th1 immune response. Mice vaccinated with intracel-
lular form-coding plasmid alone or with pIL-12 developed an antibody
response characterized by more pronounced Th2 profiles (IgG1
isotype). In contrast, those injected with the secreted form injections
alone or with pIL-12 produced exclusively IgG2 isotypes indicative of a
Th1 response. Theses results suggest that immune response profiles
provoked by DNA vaccine seem to be dependent on the protein form
rather than on the cytokine adjuvant or on the administration route of
the DNA vaccine. Even if cytokine (IL-12) driving B cells and T cells to
a Th1 phenotype response was added, specific serum antibody titres
were significantly higher in mice co-injected with the intracellular form
compared with those co-immunized with the secreted form.
The form of autoantigen used in DNA vaccination may induce protec-
tion from autoimmunity by inducing a cytokine shift in the immune
response to the antigens responsible for the disease. Moreover, the
induction of shift strategies could orient the profile of T cells respond-
ing to disease target antigens from Th1 to Th2 or Th2 to Th1 according
to the autoimmune process involved in each AID in order to induce a
selective protective immune response.
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Objective In human rheumatoid arthritis interactions of immune cells with
resident cells, especially synovial fibroblasts, play a crucial role in the per-
petuation of inflammatory and destructive processes in affected joints.
Apart from macrophages, Th cells are predominant in cell infiltrates, and
Th cell responses are specified as Th1 type. As interferon gamma (IFN-γ)-
secreting Th1 cells are suspected to promote autoimmune diseases,
there is the notion that a shift of a Th1 response towards a Th2 response
might ameliorate arthritis. However, in different models and therapy
studies conflicting results are described. Thus, we investigated the role
of IFN-γ in murine antigen-induced arthritis (AIA), a model with homolo-
gies to human rheumatoid arthritis in terms of histopathology, chronicity
and responses to several immunomodulatory drugs.
Methods  AIA was evaluated in IFN-γ–/– mice in comparison with
C57BL/6 wild-type mice by clinical, histological and immunological
parameters. Furthermore, Th cells isolated from immunised mice were
separated according to their IFN-γ on the cell surface into IFN-γ+ and
IFN-γ– Th cells and than transferred into naive mice, which received at
the same time a single injection of antigen (methylated bovine serum
albumin) into the knee joint for arthritis induction. In cocultures with
synovial fibroblasts, the stimulatory capacity of IFN-γ– and IFN-γ+ Th
cells was tested in vitro, analysing the levels of matrix metallopro-
teases, IL-6, and nitric oxide in supernatants.
Results IFN-γ–/– mice developed a more severe arthritis than wild-type
mice with higher knee joint swelling, stronger acute inflammation and
increased chronic joint destruction, even though IgG levels (total and
methylated bovine serum albumin-specific) were reduced. Application
of rIFN-γ ameliorates the severity of AIA in IFN-γ–/– mice. Congruently,
the transfer of IFN-γ– Th cells from immunised wild-type mice into naive
mice led to a more severe arthritis than the transfer of IFN-γ+ Th cells.
Furthermore, IFN-γ– Th cells had a stronger stimulatory capacity for
matrix metalloproteases and IL-6 in synovial fibroblasts in vitro,
whereas IFN-γ+ Th cells were more potent nitric oxide inducers. Induc-
ing processes are mainly driven by direct cell contact.
Conclusion These experiments suggest a protective role of IFN-γ in the
experimental arthritis model. The lack of IFN-γ in Th cells exerted a higher
disease-promoting effect in vivo as well as a higher stimulatory capacitiy
to synovial fibroblasts in vitro. The recent data generated in experimental
models indicate a more complex role of IFN-γ in the pathogenesis of Th1-
mediated autoimmune diseases than originally proposed.
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Enhanced effector cell activation to deposited autoantibodies and
immune complexes (IC) is a significant factor causing inflammatory
responses in immunologic diseases like autoimmune hemolytic anemia,
rheumatoid arthritis, lupus nephritis and Goodpasture`s syndrome.
Recent studies in animal models show that the development of such
diseases is caused by the impairment of balance between
activating/inhibitory Fc receptors (FcγRs). The ratio of the opposing
FcγRs is critical in determining whether an antibody-dependent
response will result. In the present study we aimed to investigate the
role of C5a anaphylatoxin on the FcγR effector system in IC lung injury.
We analysed the reverse passive arthus reaction in the lungs of mice
lacking different FcγRs, or C5aR. The expression of FcγR
mRNA/protein on alveolar macrophages (AM) effector cells was
studied by TaqMan real-time PCR and FACS analysis. The contribution
of AM to the IC alveolitis was investigated using the AM-depletion/AM-
transfer technique. The autocrine synthesis of C5a by AM and the role
of G-protein-dependent signalling was studied using in vitro stimulation
of MH-S AM cells with IgG1 IC.
We have shown that C5a anaphylatoxin is produced in the lung of mice
already 2 hours after IC deposition. Moreover, C5a:C5aR interaction
exacerbates IC inflammation by altering the ratio of activating to
inhibitory FcγR expression on AM, enhancing the former and suppress-
ing the latter. Elimination of AM results in diminished IC alveolitis similar
to that observed in FcγRIII–/– and C5aR–/– mice, as well as in AM-defi-
cient mice with transplanted FcγRIII–/– or C5aR–/– AM. In vitro block-
ade of C5aR on MH-S cells using anti-C5aR antibodies, or pertussis
toxin, confirms IgG IC-dependent generation of C5a by AM.
These data establish the critical link between complement and FcγRs in
the initiation of IC lung injury. Moreover, AM effector cells provide cellu-
lar cross-talk of C5a and FcγR effector systems. In vitro studies
suggest the central role of G-protein-dependent C5aR signalling in the
control of FcγR activation of AM.
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Background Dendritic cells (DC) acquire, during their maturation, the
expression of the chemokine receptor CCR7 and the ability to migrate
to lymph nodes in response to MIP3 beta (CCL19). This migration is
impaired in mice lacking the leukotriene (LT) C4 transporter and is
restored by addition of exogenous LTC4.
Objectives To further define the role of LT in human DC function, we
studied their expression of LT receptors during their differentiation from
monocytes and their maturation.
Results Monocyte-derived immature DC had a lower expression of the
LTD4 receptor (CysLT1) than monocytes, whereas their expression of
the LTC4/LTD4 (CysLT2) and the LTB4 (BLT1) receptors remained
stable. Maturation of DC with lipopolysaccharide, a classical Toll-like
receptor (TLR)4 agonist, reduced CysLT1 expression by a further 50%,
whereas CysLT2 expression was increased and BLT1 expression was
only marginally reduced. Zymosan, a TLR2 agonist, reduced all recep-
tor levels, whereas the TLR3 agonist poly I:C had no effect on CysLT
expression. LTC4, more than LTD4, was able to enhance human DC
migration in response to CCL19 and promote DC activation of T-cell
proliferation, when DC were matured with lipopolysaccharide or
zymosan, but not polyI:C.
Conclusion Our data suggest that human DC may differentially respond
to LT, depending on their maturational stimuli, and thus potentially affect
both innate and adaptive immunity in the context of inflammation.
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The receptor activator of NF-κB/receptor activator of NF-κB ligand
(RANK/RANKL) pathway is critical in osteoclastogenesis and bone
Available online http://arthritis-research.com/supplements/6/S3S26
erosion and has been implicated in the process of focal bone erosion in
rheumatoid arthritis (RA). However, its involvement in the immune
response during chronic inflammation remains to be clarified since defi-
cient mice show major lymph node (LN) abnormalities.
We investigated by immunohistochemistry the RANK and RANKL
expression pattern of dendritic cell (DC) and T cell subsets in paired
RA synovium–LN and also in normal peripheral blood mononuclear
cells (PBMC) stimulated with phorbol miristate acetate/phytohemag-
glutin during 4, 24, and 48 hours. In RA synovium, RANKL+ cells were
detected in the lining layer and the lymphocytic infiltrates, whereas
RANK expression was restricted to perivascular infiltrates. In LN,
RANK+ and RANKL+ cells were diffusely expressed in both the T-cell
zone and germinal centers. Double staining with anti-RANK or anti-
RANKL and anti-CD1a or anti-DC-LAMP antibodies showed that some
immature CD1a+ DC expressed RANK and RANKL, whereas some
mature DC-LAMP+ DC only expressed RANK. Double staining with the
CD3, CD4 T-cell markers and the interferon gamma and IL-17 Th1 cell
markers showed that some CD3+, CD4+, interferon gamma+, and
IL-17+ cells produced RANKL whereas none of them express RANK.
The same pattern was observed on activated PBMC. RANK+ cells were
detected in unstimulated PBMC and identified as CD14+ monocytes.
This study showed the involvement of RANK/RANKL in DC–T cell
interactions as found during the inflammatory process, and makes
RANK and RANKL potential therapeutic targets outside the bone field.
Lipid mediators and arthritis
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Background Recent data indicate that adipose tissue synthesizes and
releases numerous immunocompetent molecules such as tumor necro-
sis factor (TNF) alpha, C3a and C1-inhibitor. As adipose tissue is also
part of rheumatoid joints, we examined whether adiponectin (apM-1),
which has structural homologies to complement proteins and members
of the TNF family, and its receptors are present in rheumatoid arthritis
(RA) and osteoarthritis (OA) synovium. In addition, owing to the ability
of adiponectin to exert several immunmodulatory functions, the effect
and regulation of adiponectin-dependent synthesis of proinflammatory
and antiinflammatory cytokines was examined.
Methods Snap-frozen synovial sections of patients with RA, OA and
articular adipose tissue were evaluated by adiponectin and adiponectin
receptors type 1 and 2-specific primers, by in situ hybridization using
adiponectin riboprobes and antibodies against adiponectin in combina-
tion with double-labeling for fibroblasts. In addition, fresh synovial
fibroblasts derived from RA and OA patients undergoing knee joint
endoprothetic surgery were stimulated with adiponectin in concentra-
tions from 0.2 to 100 µg/ml for 15 hours and compared with unstimu-
lated fibroblasts. Supernatants were examined for production of IL-1β,
IL-4, IL-6, IL-10, matrix metalloproteinase (MMP)-1 and MMP-3 by com-
mercially available ELISA.
Results In all patients, strong expression of adiponectin mRNA could
be detected in synovial lining and to a lesser extent in synovial sublin-
ing. Double-labeling with anti-vimentin (fibroblasts) showed that up to
60% of RA fibroblasts expressed the adiponectin gene and
adiponectin type 1 and 2 receptors. Stimulation of synovial fibroblasts
with adiponectin showed a dose-dependent upregulation of IL-6 and
MMP-1, both in RA and OA synovial fibroblasts. Whereas treatment
without or with a small concentration of adiponectin (0.2 µg/ml)
resulted only in a low production of IL-6, a concentration-dependent
increase could be found with the highest amount produced with
100 µg/ml adiponectin. In contrast, synthesis of IL-1β, IL-4, and IL-10
was not altered by adiponectin stimulation. Of interest, both the TNF
inhibitors adalimumab and etanercept were able to downregulate
adiponectin-dependent IL-6 and MMP-1 synthesis significantly.
Conclusions The results show that adipocytokines such as
adiponectin are not only present in arthritic synovium, but also that
adiponectin has stimulatory effects both on the production of distinct
cytokines (e.g. IL-6) and of matrix-degrading enzymes (e.g. MMP-1) in
synovial fibroblasts. Therefore, the data support the hypothesis that
adiponectin may alter the expression of local synovial cytokines and
thus may not only represent a candidate gene of a complement/TNF-
related pathway operative in RA, but also one of the targets of TNF
inhibitor therapy.
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Background Leptin is an adipocyte-derived hormone with an important
role in regulation of feeding behavior, energy expenditure and, there-
fore, body weight via central nervous system mechanisms. Plasma
leptin levels are reliably increased with increasing body mass index.
Leptin receptors are widely distributed in peripheral tissues as well.
Several different forms of leptin receptor have been identified, although
the long isoform or Ob-Rb is the only isoform with clearly demonstrated
signaling capability. Ob-Rb is related to the type I cytokine receptors
and signals via janus-activated kinase-signal transducer and activator of
transcription pathways; however, other second messenger systems
may also be stimulated. A role for leptin as a modulator of the immune
response and inflammatory processes has been proposed. Our group
has demonstrated that leptin increases production of eicosanoids in rat
macrophages. A role for leptin as an intermediary of obesity-related
osteoarthritis (OA) has been proposed [1]. Leptin levels are elevated in
synovial fluid of OA patients and correlate with the body mass index.
Leptin and its receptor (Ob-Rb) are expressed in OA chondrocytes,
and leptin treatment increases expression of transforming growth factor
beta and insulin-like growth factor 1.
Aim There is a paucity of information regarding the effect of leptin on
human synovial cells, and we aimed to determine whether leptin altered
production of eicosanoids and proinflammatory cytokines.
Methods and results All experiments were performed in primary
human synovial cells of patients with rheumatoid arthritis or OA col-
lected at the time of surgery, and were repeated at least three times
with cells from three different patients. We determined that the leptin
receptor (Ob-Rb) is expressed by human synovial fibroblast-like cells
using RT-PCR. Leptin receptor expression is unaffected by treatment
with IL-1β (1 ng/ml). Treatment of human synovial fibroblasts with leptin
(100 ng/ml) increased production of IL-6, IL-8, and prostaglandin (PG)
E2, although to a modest degree compared with IL-1β (1 ng/ml) used
as a positive control. The mechanism of increased PGE2 production
involves several PG biosynthetic enzymes. We demonstrated that
leptin increased phosphorylation of cPLA2 by 15 min after treatment.
Leptin also increased cyclooxygenase-2 protein levels. Microsomal
prostaglandin E synthase 1 expression was not changed. We next eval-
uated the signaling pathways that may contribute to increased produc-
tion of inflammatory mediators. Leptin (100 ng/ml) increased
phosphorylation of p42/p44 ERK, p38, and JNK by 15–30 min after
treatment, and phospho-MAPK levels were increased for 1–2 hours.
Conclusions Taken together, these data suggest that leptin may affect
production of proinflammatory mediators in synovial tissues and
enhance inflammation in patients with arthritis.
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Membrane-associated prostaglandin (PG) E synthase-1 (mPGES-1)
catalyzes the conversion of PGH2 to PGE2, which plays a critical role in
the pathogenesis of arthritis. Peroxisome proliferator-activated receptor
gamma  (PPARγ) is a ligand-activated transcription factor and was
shown to regulate a number of inflammatory genes in several cell types.
In this study, we examined the effect of PPARγ ligands on IL-1β-
induced mPGES-1 expression in human synovial fibroblasts.
The PPARγ ligand 15-deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) and
the thiazolidinedione troglitazone (TRO), but not the PPARα ligand
Wy14643, dose-dependently suppressed IL-1β-induced PGE2 pro-
duction, as well as mPGES-1 protein and mRNA expression. 15d-PGJ2
and TRO suppressed IL-1β-induced activation of the mPGES-1 pro-
moter. Overexpression of wild-type PPARγ further enhanced, whereas
overexpression of a dominant negative PPARγ alleviated, the suppres-
sive effect of both PPARγ ligands. Furthermore, pretreatment with an
antagonist of PPARγ, GW9662, relieved the suppressive effect of
PPARγ ligands on mPGES-1 protein expression, suggesting that the
inhibition of mPGES-1 expression is mediated by PPARγ.
Previous studies have shown that Egr-1 plays a pivotal role in transacti-
vation of mPGES-1 gene. We demonstrated that PPARγ ligands sup-
pressed Egr-1-mediated induction of the activities of the mPGES-1
promoter and of a synthetic reporter construct containing three tandem
repeats of an Egr-1 binding site. Electrophoretic mobility shift and super-
shift assays for Egr-1 binding sites in the mPGES-1 promoter showed
that both 15d-PGJ2 and TRO suppressed IL-1β-induced DNA binding
activity of Egr-1. This occurs without interfering with Egr-1 expression.
These data define mPGES-1 and Egr-1 as novel targets of PPARγ and
provide further support for the promising application of PPARγ ligands
in the treatment of arthritis.
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Objective 15-Deoxy-∆12,14-prostaglandin J2 (15d-PGJ2) is a natural
ligand for peroxisome proliferator-activated receptor gamma (PPARγ)
and has been reported to inhibit the expression of a number of inflam-
matory genes in several cell types. However, its effects on cyclooxyge-
nase-2 (COX-2) expression remains controversial. In the present study,
we investigated the effects of 15d-PGJ2 on IL-1β-induced COX-2
expression in human synovial fibroblasts.
Methods COX-2 protein and mRNA expression were evaluated using
western blotting and real-time PCR analysis, respectively. The COX-2
promoter activity was analyzed in transient transfection experiments.
Chromatin immunoprecipitation assays were performed to evaluate the
level of histone acetylation and the recruitment of HDAC1, HDAC2,
HDAC3, and p300 to the COX-2 promoter.
Results 15d-PGJ2 inhibited IL-1β-induced COX-2 protein and mRNA
expression, as well as COX-2 gene promoter activation. The suppression
of COX-2 protein expression was abrogated by the PPARγ antagonist,
GW9662, suggesting that this effect is mediated by PPARγ. The induc-
tion of COX-2 by IL-1β is associated with hyperacetylation of histone H3
and H4 at the COX-2 promoter. Interestingly, 15d-PGJ2 selectively
blocked IL-1β-induced histone H3 acetylation. This reduction was
demonstrated to not correlate with the recruitment of histone deacetylase
(HDAC) to the COX-2 promoter. Also, treatment with the specific HDAC
inhibitor, trichostatin A, did not relieve the suppressive effect of 15d-
PGJ2, indicating that HDACs are not involved in the inhibitory effect of
15d-PGJ2 on COX-2 expression. Furthermore, 15d-PGJ2 blocked IL-1β-
induced recruitment of the histone acetylase (HAT) p300 to the COX-2
promoter, which may be the mechanism for decreased histone H3 acety-
lation and COX-2 expression. In line with this, overexpression of p300,
but not of a mutant p300 lacking HAT activity, relieved the inhibitory
effect of 15d-PGJ2 on COX-2 promoter activation.
Conclusion Our data suggest that 15d-PGJ2 can inhibit IL-1β-induced
COX-2 expression in a PPARγ-dependent, HDAC-independent mecha-
nism, probably by interfering with the HAT p300.
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The leukotrienes (LTs) are potent inflammatory mediators whose func-
tions include modulation of vascular permeability, induction of adhesion
molecule expression, potent leukocyte chemoattraction, stimulation of
smooth muscle contraction, induction of synovial fibroblast proliferation
and triggering of cytokine secretion. Knowing that these bioactivities
are active in the context of inflammatory arthritis, we hypothesized that
the LTs may play a critical role in the pathogenesis of murine K/BxN
serum transfer arthritis. We used a genetic approach to demonstrate
the functional requirement for specific LT species in the induction of
K/BxN serum transfer arthritis. We find that mice lacking 5-lipoxyge-
nase, a proximal enzyme in LT biosynthesis, are resistant to the devel-
opment of arthritis. We further demonstrate that LTA4
hydrolase-deficient mice, specifically lacking LTB4, are also profoundly
resistant to arthritis induction. In contrast, mice lacking LTC4 synthase
(and thus lacking all cysteinyl LTs), are fully competent to develop
arthritis. The profound requirement for LTB4 highlights the importance
of this lipid mediator of inflammation in the orchestrated, yet poorly
understood, process of arthritis. Furthermore, these observations
provide an in vivo rationale for pursuit of therapies directed at LTs and
their receptors, an inflammatory pathway not currently utilized in treat-
ment of patients with inflammatory arthritis.
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Aim To ameliorate the understanding of the mechanisms involved in
rheumatoid arthritis (RA) and to identify new therapeutic targets and
develop novel diagnosis tools. The microarray technology allowed us to
identify a set of gene specifically expressed in the synovial tissue of RA
patients in comparison with osteoarthritis (OA). Among them, we
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focused on clusterin since it has multiple functions related to the patho-
physiological processes suspected to be involved in RA.
Results Using real-time quantitative PCR on a larger set of samples
than on the microarray study, we demonstrated the highly significant
(P < 0.0001) underexpression of clusterin in RA versus OA and versus
synovial tissues of healthy individuals. The fold differential expression
between OA and RA was 9.8 and between healthy tissue and RA was
close to 5.2. Northern blot analysis further confirmed this differential
expression and did not demonstrate an alternative splicing form of
mRNA between RA and OA. Immunohistochemistry analyses of syn-
ovial tissues demonstrated that clusterin protein was mainly localised in
synovial cells. The differential expression between OA and RA per-
sisted in third-passage synovial cells. Western blot extended this differ-
ential expression at the protein level and pointed towards specific
impairment of protein isoforms in RA tissues compared with OA
tissues. The differential expression concerned both the intracellular and
nuclear isoforms of the protein as evidenced by real-time quantitative
PCR and western blot analysis.
Conclusions Due to the numerous functions associated with clusterin,
the strong underexpression of clusterin mRNA in RA synovial tissue,
which is associated with the specific impairment of the intracellular
forms of the protein, could have tremendous effects on several patho-
physiological processes taking place in RA.
T-cell regulation
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Objective Human T-lymphocyte homeostasis is a complex process
wherein the number of T lymphocytes is held relatively constant in
normal individuals. How the body senses the numbers of circulating T-
cells and regulates their expansion and survival is unclear. We sought
to better understand this process by profiling serum cytokines in severe
combined immunodeficiency (SCID) before and after T-cell reconstitu-
tion with bone marrow transplantation.
Methods We used a novel protein microarray technology to simultane-
ously measure the levels of 78 different soluble proteins in the serum of
10 normal subjects and 31 SCID subjects before and at various times
after transplantation. We used a linear mixed analysis of variance model
and novel SAS graphics tools to identify factors that were altered in
SCID and changed in response to T-cell engraftment.
Results We identified that IL-15 > MCP-1 > HCC4 > IL-7 were over-
expressed in SCID patients before transplantation at times when there
were few circulating T cells (P < 0.001 compared with controls). Both
IL-7 and IL-15 normalized after successful transplantation with normal
levels of circulating T cells, but not after failed transplants. HCC4 and
MCP-1 levels remained high despite transplantation. Levels of nine
growth factors were decreased and levels of six proinflammatory
cytokines were increased after successful transplantation for SCID.
Conclusion Our studies in a human model of aberrant T-lymphocyte
homeostasis wherein IL-15 and, to a lesser extent, IL-7 levels inversely
correlate with circulating T-lymphocyte levels provide evidence that IL-
15 and IL-7 may regulate human T-lymphocyte homeostasis. In addi-
tion, the downmodulation of numerous growth factors and upregulation
of proinflammatory cytokines after successful T-cell reconstitution iden-
tify factors other than IL-15 and IL-7 that may be involved in the sensing
and regulation of T-lymphocyte homeostasis in man.
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An imbalance in cytokine homeostasis is thought to play an important
part in the pathogenesis of chronic inflammatory diseases such as
rheumatoid arthritis and multiple sclerosis. We demonstrated that T
cells might exert a pathological effect through direct cellular contact
with monocyte-macrophages, inducing a massive upregulation of IL-1
and tumor necrosis factor (TNF). More recently, we showed that this
mechanism, likely to be of relevance to chronic inflammation, is specifi-
cally inhibited by high-density lipoproteins (HDL). Like many other stimuli
besides proinflammatory cytokines, the contact-mediated activation of
monocytes induces the production of cytokine inhibitors such as IL-1
receptor antagonist (IL-1Ra). We observed that HDL inhibited the pro-
duction of IL-1β and TNF but not that of IL-1Ra induced in monocytes
after activation by membranes isolated from stimulated T cells to mimic
cellular contact. This was also observed in peripheral blood mononu-
clear cells stimulated by either phytohemagglutinin or tetanus toxoid, in
which the presence of isolated HDL inhibited the production of IL-1β
and TNF while that of IL-1Ra remained unchanged. This effect was con-
firmed by activating isolated monocytes with CHAPS-solubilized mem-
branes from stimulated T cells, suggesting that HDL interacted with a
specific factor expressed at the surface of T cells and not unspecifically
with isolated membranes. Similarly, IL-1Ra mRNA expression was not
inhibited, contrary to IL-1β and TNF mRNA. This demonstrates that dif-
ferent molecules at the surface of stimulated HUT-78 cells are involved
in the induction of IL-1β, TNF and IL-1Ra in monocytes, IL-1β and TNF
being activated by one or more HDL-specific ligands. Separation of
CHAPS-solubilized membrane molecules by liquid isoelectric focusing
revealed two activity peaks: one activating IL-1β, TNF and IL-1Ra pro-
duction; the other inducing the production of IL-1Ra in the absence of
IL-1β and TNF. Thus different factors are expressed at the surface of
stimulated T cells that are differently affected by HDL and differentially
trigger the production of proinflammatory and antiinflammatory factors.
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Chronic inflammation in rheumatoid arthritis (RA) is mediated by
repeatedly activated proinflammatory Th1 cells. In contrast, Th2 cells
that might downmodulate the chronic autoimmune response are rarely
found in RA. It has been previously documented that RA T cells are
severely impaired in their ability to differentiate into Th2 effectors while
exerting enhanced Th1 differentiation. The mechanisms underlying this
functional abnormality, however, have not been delineated. As IL-4 is a
most critical determinant in regulating immune responses by promoting
Th2 cell development and inhibiting Th1 cell differentiation, we ana-
lyzed the role of single nucleotide polymorphisms (SNP) in the IL-4
receptor α-chain, which is critical for binding of IL-4 and for IL-4 signal
transduction, in the differentiation of human T cells. Naive and memory
CD4 T cells were isolated from the peripheral blood of 348 healthy
individuals and genotyped by allele-specific PCR for the two IL-4R
α-chain SNPs that are located in functionally important regions of the
IL-4R α-chain — the I50V SNP50 and the Q551R SNP551 in the IL-4-
binding and STAT6-binding domains, respectively. To analyze the func-
tional role of IL-4R α-chain SNPs for T-cell differentiation, CD4-positive
T cells were purified from the peripheral blood from the individuals who
were homozygous for either allele at SNP50 and SNP551, and primed
for 5 days with mAbs to CD28 and/or CD3 in the presence or absence
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of exogenous IL-4. The phenotype of the resulting differentiated effec-
tor cells was then analyzed by flow cytometric analysis of cytoplasmic
cytokines. The SNP551 alleles did not significantly affect T-cell differ-
entiation. In marked contrast, the inhibitory effect of IL-4 on Th1 cell dif-
ferentiation was significantly diminished in CD4 T cells that were
homozygous for the mutated allele at SNP50 (50V) as compared with
those with the wild-type allele (I50). Likewise, the augmenting effect of
IL-4 on Th2 cell differentiation was markedly enhanced on T cells that
were homozygous for the wild-type allele as compared with T cells
expressing the mutant allele. The data indicate that the mutated allele
of the IL-4R α-chain SNP50 is associated with a decreased T-cell
response to IL-4. Thus, SNP50 of the IL-4R α-chain might regulate T-
cell differentiation by altering T-cell responses to IL-4 and contribute to
the development of unbalanced Th subset activation, as characteristic
for autoimmune diseases, such as RA.
72 (P5.4)
GATA-3 in human T helper cell type 2 development
A Skapenko1, J Leipe1, U Niesner2, K Devriendt3, R Beetz4, 
A Radbruch2, JR Kalden1, PE Lipsky5, H Schulze-Koops1
1University of Erlangen, Erlangen, Germany; 2Deutsches
Rheumaforschungszentrum, Berlin, Germany; 3University of Leuven,
Leuven, Belgium; 4University of Mainz, Mainz, Germany; 5NIAMS,
Bethesda, Maryland, USA
Arthritis Res Ther 2004, 6(Suppl 3):72 (DOI 10.1186/ar1428)
Autoimmune inflammation, such as in rheumatoid arthritis, is character-
ized by activated Th1 cells without sufficient Th2 differentiation that
might downmodulate the chronic immune response. Delineation of the
mechanisms that control T-cell differentiation is therefore of major
importance for the understanding of the pathogenesis of autoimmune
diseases. The transcription factor GATA-3 has been implicated in regu-
lating Th2 cell differentiation in murine T cells in vitro, but its role in vivo
and, in particular, in human T-cell differentiation is currently unknown.
To dissect the role of GATA-3 in human T-cell differentiation and T-cell-
mediated effector functions, we used the unique opportunity to analyze
T-cell functions in human individuals lacking one functional GATA-3
allele. The patients had no history of severe or opportunistic infections,
normal peripheral T-cell counts and normal frequencies and absolute
numbers of CD4 helper and CD8 cytotoxic T cells. CD4 T cells from
GATA-3+/– individuals expressed significantly reduced levels of
GATA-3, associated with markedly decreased Th2 frequencies in vivo,
as determined by analyzing cytokine secretion profiles of freshly iso-
lated CD4 T cells, and in vitro, as determined by employing an in vitro
cell culture system that allows the differentiation of T-cell effectors after
short-term priming. Moreover, Th2 cell-mediated effector functions, as
assessed by serum levels of Th2-dependent immunoglobulins (IgG4,
IgE), were dramatically decreased, whereas the Th1-dependent IgG1
was elevated compared with GATA-3+/+ controls. Concordant with
these data, silencing of GATA-3 in GATA-3+/+ CD4 T cells with small
interfering RNA significantly reduced Th2 cell differentiation. Moreover,
GATA-3 mRNA levels increased under Th2-inducing conditions and
decreased under Th1-inducing conditions in vitro. Taken together, the
data strongly suggest that GATA-3 is an important transcription factor
in regulating human Th2 cell differentiation in vivo. GATA-3 might
therefore constitute a promising target for immunomodulatory treat-
ment strategies in diseases that are characterized by biased activation
of Th cell subsets, such as autoimmune diseases or allergies.
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factor by CD40 ligand or cellular contact with
stimulated T cells depends on the degree of
maturity of human monocytes
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Cellular contact with stimulated T cells potently induces cytokine pro-
duction in monocytes, a mechanism likely to be of relevance to chronic
inflammation. Although the identity of the surface molecules involved in
this process remains elusive, CD40 and its ligand CD40L are thought
to be implicated, considering that they are expressed at the inflamma-
tory site. To assess the involvement of CD40L we compared the activa-
tion of three different types of human monocytic cells: freshly isolated
monocytes, monocytes primed with interferon gamma (IFNγ-
macrophages), and THP-1 cells. These cells were activated by either
membranes isolated from stimulated T cells (HUT-78 or T lymphocytes)
to mimic cellular contact, by soluble extracts from isolated membranes,
or by CD40L trimer (CD40LT). The production of tumor necrosis factor
(TNF) and IL-1β was induced by membranes of stimulated T cells in the
three types of target cells, whereas CD40LT induced TNF production
in IFNγ-macrophages only. Similar results were obtained with soluble
extracts of T-cell membranes, demonstrating that the difference
between membranes and CD40LT was not due to the particulate form
of membranes. CD40LT induced neither transcript nor protein of
cytokines in monocytes, whereas in IFNγ-macrophages IL-1β and TNF
mRNA were observed, only TNF being detected in cell supernatants.
Finally, anti-CD40L antibodies failed to inhibit TNF and IL-1β produc-
tion induced in IFNγ-macrophages by solubilized membranes, while
TNF production induced by CD40LT was inhibited. These results
demonstrate that CD40L is not required in monocyte activation by
direct cellular contact with stimulated T cells, although soluble
CD40LT induces the production of TNF in IFNγ-macrophages.
Other arthritic diseases
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Arthritis Research Center, Institute of Medical Science, St Marianna
University, Kawasaki, Kanagawa, Japan
Arthritis Res Ther 2004, 6(Suppl 3):74 (DOI 10.1186/ar1410)
Introduction The number of fibromyalgia patients has recently been
increasing in Japan. We currently studied numerous patients with early
to severe neuropathic pain on not only ‘specific sites’ according to
American College of Rheumatology ACR-90 criteria, but also wide-
spread severe pain such as hyperpathia or allodynia.
Symptoms in these patients are sometimes accompanied with extra-
muscular symptoms such as irritable colon, interstitial cystitis, severe
dry eye and mouth, and various psychogenic symptoms. Twenty-seven
patients with severe and systemic complications were misdiagnosed
with other psychogenic disorders. We classified patients with
fibromyalgia in five categories according to disease progression.
Patients and method A total 153 patients with fibromyalgia who
visited our rheumatology or psychiatry clinics in the past 2 years were
assessed; 132 (86.5%) female patients and 21 (13.5%) male patients.
The mean age was 52.3 ± 15.0 years for females, 50.4 ± 18.6 years
for males. These patients were classified into five stages according to
clinical symptoms (Table 1).
Results and discussion As shown in Table 1, 64 patients fulfilled the
ACR-90 criteria. Patients classified in stages II–IV had painful symp-
toms that spread through the whole body and were extremely severe.
Eight of 153 patients had extramuscular systemic symptoms. The
results of the SPECT study revealed that 80% of the 40 patients
clearly identified a low level in regional blood flow. Twenty-seven cases
of the patients were misdiagnosed with psychogenic or neurological
Available online http://arthritis-research.com/supplements/6/S3S30
disorders for a long time. Based on such clinical diversity, it is essential
to classify fibromyalgia according to disease progression.
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Raynaud’s phenomenon secondary to rheumatoid
arthritis may be predictive of more erosive disease
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Purpose  Raynaud’s phenomenon (RP) occurs less frequently in
rheumatoid arthritis (RA) than with other connective tissue diseases,
such as scleroderma and systemic lupus erythematosus. We studied
the relationship between RP and other disease characteristics
common to RA to determine whether RP can be predictive of more
severe disease. Secondary analyses were preformed to assess correla-
tions between other antibodies/manifestations that occur in RA, and
the onset of RP versus RA disease duration.
Methods Using a standardized assessment, data were collected on a
cross-sectional cohort of RA subjects (n = 329; mean age 60.3 ± 0.7
years; 77% female; 76% erosions, 75% positive rheumatoid factor
[RF]) who met the American College of Rheumatology criteria for RA
and had been seen at a London, Ontario rheumatology clinical practice
during the 6-month study period. Study participants were prevalent
(follow-up) cases and new referrals. A subsequent chart review was
performed to verify clinic data and also to collect data on all variables
that were not available at the time of the clinic visit. RP was defined as
pallor of the fingers along with rubor, cyanosis, or both.
Results The mean disease duration was 12 ± 0.6 years. Seventy
patients (22%) had RP. RP status was not related to gender, age, or
disease duration. The mean age at onset of RP was 50.7 ± 2 years and
the mean RP duration was 9.2 ± 1.5 years. Patients presented with RP
a mean of 3.8 ± 1.4 years after the diagnosis of RA (95% confidence
interval, 0.9–6.6 years; minimum, maximum = 31 years before RA diag-
nosis, 32 years after). RP status was not associated with the presence
of nodules and erosions. Patients with sclerodactyly [all was distal to
proximal interphalangeal joints] were more likely than those without to
have RP (34% versus 17%, P < 0.001). Subjects with sclerodactyly
(26%) were also more likely than those without to have erosions (86%
versus 72%, P  < 0.02). Patients who developed RP after their RA
diagnosis were more likely to have erosions than those who developed
RP before RA (P < 0.005). As expected, positive RF was associated
with longer disease duration (P < 0.04). Higher RF values were associ-
ated with longer disease duration (P < 0.005) and increased RP dura-
tion (P < 0.01).
Conclusion RP was present in 22% of the RA patients seen in a
rheumatology clinical practice in London, Ontario during the 6-month
study period. RP appears to develop relatively soon (approximately 1–7
years) after RA diagnosis in the majority of cases. Idiopathic RP may be
different from RP secondary to RA, the latter of which may be associ-
ated with more erosive RA. Sclerodactyly is associated with erosive
arthritis and RP in RA. Higher RF values were indicative of increased
RA and RP duration.
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The role of TLR4 and neutrophil expression in
infection-triggered arthritis
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Background The initial response to Chlamydia-induced arthritis proba-
bly involves innate immunity but the nature of this interaction has not
been defined. In the present study, we examined the role of neutrophils
in experimental arthritis in mice with targeted elimination of the small
GTPAases Rac1 and Rac2, and the role of toll-like receptors in this
model.
Methods Arthritis was induced in either wild-type or Rac-deficient mice
by intra-articular inoculation of synoviocyte-packaged Chlamydia
trachomatis. The scoring of arthritis was assessed by joint swelling and
quantitative histopathological scoring. Immunohistochemistry was used
to determine the infiltration of neutrophils into the joint. The persistence
of  Chlamydia in joints of mice after injection was determined by
immunoassay. The expression of TLR2 and TLR4 in neutrophils was
detected by semiquantitative PCR. Mice genetically deficient in TLR4
were also assessed.
Results  In the acute phase, wild-type mice developed more severe
arthritis than Rac-deficient mice. At this stage there was abundant infil-
tration of neutrophils into the joint. In the chronic phase, the Rac-defi-
cient mice developed more severe arthritis and these mice
demonstrated defective clearance of the pathogen from the joint. In
vitro stimulation of neutrophils with Chlamydia upregulated expression
of TLR4 but not TLR3 in wild-type mice. However, neutrophils from
Rac-deficient mice did not show this upregulation of TLR4. Sustained
TLR4 expression in neutrophils was found to be dependent on expres-
sion of Rac. We examined mice genetically deficient in TLR4 expres-
sion and demonstrated that such mice developed more severe arthritis
than controls. Thus Rac expression plays a profound role in infection-
triggered arthritis and demonstrates a bimodal influence on the disease
process, exacerabating acute joint inflammation but controlling chronic
arthritis. Rac-deficiency was associated with diminished TLR4 expres-
sion, impaired host clearance of the pathogen and more severe chronic
arthritis.
Conclusions In infection-triggered arthritis, innate immunity plays a crit-
ical role. Effective host clearance of an arthritogenic pathogen depends
on intact Rac expression by neutrophils and by appropriation of TLR4
by these cells. A defect in this pathway of host defence profoundly
influences the outcome of the infection. This study also highlights the
changing microenvironment of the joint over time with implications for
therapeutic approaches to arthritis.
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Table 1
Classification of fibromyalgia according to disease progression frequency in 153 cases
Stage I Existence of pressure pain on specific sites according to ACR-90 criteria 64 (41.8%)
Stage II Expanding of pain from trunks to extremities and also changing nature of pain from pressure pain to spontaneous pain 46 (30.0%)
Stage III Persistent pain is generalized and induction of burning pain by mild change of temperature, stimulation on nail and hair, and so on 16 (10.5%)
Stage IV Sleep disturbance, restless, interfere keeping same postulation by hyperpathia, severe decreasing quality of life, allodynia 16 (10.5%)
Stage V Severe pain is generalized and complicated tremendous extramusculoskeletal symptoms such as irritable colon, bladder, dry eye,  11 (7.2%)
dry mouth and mucocutaneous symptomsS31
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mechanism for the protective effects of heparin in
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The antiphospholipid syndrome (APS), defined by thrombosis and
recurrent pregnancy loss in the presence of antiphospholipid (aPL)
antibodies, is generally treated with anticoagulation. Because comple-
ment activation is essential and causative in aPL antibody-induced fetal
injury, we hypothesized that heparin protects mice from fetal loss in
APS by preventing complement activation on trophoblasts and that
anticoagulation,  per se, is not sufficient to prevent miscarriage. We
used a murine model of APS in which pregnant mice are injected with
human IgG-containing aPL antibodies (aPL-IgG) or IgG from healthy
individuals (NH-IgG). Passive transfer of aPL-IgG caused a
43.3 ± 3.5% frequency of fetal resorption (P < 0.001 versus NH-IgG)
and treatment with either unfractionated heparin (UFH) (10 U or 20 U
subcutaneously twice daily) or low molecular weight heparin (LMWH)
(enoxaparin) reduced the frequency of fetal resorption to that of mice
treated with NH-IgG: UFH10 + aPL, 9.6 ± 3.2; UFH20 + aPL
10.4 ± 2.1; LMWH + aPL, 11.8 ± 2.8; NH-IgG, 10.5 ± 2.5% (P < 0.01
versus aPL). Even in the absence of detectable anticoagulation, as in
mice treated with 10 U UFH, heparins prevented aPL-induced preg-
nancy loss and inhibited systemic complement activation evidenced by
generation of C3adesArg (aPL, 1212 ± 101* ng/ml; UFH10U + aPL,
178 ± 25; LMWH + aPL, 180 ± 15; NH-IgG, 215 ± 381, * P < 0.05
versus NH-IgG). Heparin limited C3 deposition in deciduas of mice
treated with aPL. Neither fondaparinux nor hirudin inhibited the genera-
tion of complement split products or prevented pregnancy loss, despite
anticoagulation levels comparable with heparin, indicating that antico-
agulation is insufficient therapy for APS-associated miscarriage.
We assessed the effects of anticoagulants on complement activation
in vitro using BeWo cells, trophoblast-like cells with externalized phos-
phatidylserine recognized by aPL. APL-opsonized BeWo cells cultured
with mouse serum activated complement, evidenced by increased
surface-bound C3 fragments (detected as C3 staining by FACS) and
generation of soluble C3adesArg in supernatants. In the presence of
UFH or LMWH, however, complement activation was completely inhib-
ited (C3adesArg [ng/ml]: aPL, 680 ± 30; UFH + aPL, 120 ± 20*;
LMWH + aPL, 105 ± 18*; % C3-positive BeWo cells by FACS: aPL,
31 ± 11; aPL + UFH, 9 ± 5*; LMWH + aPL, 5 ± 3; * P < 0.01 versus
aPL). In contrast, neither fondaparinux nor hirudin inhibited complement
activation in vitro.
In conclusion, heparins inhibit complement activation in vitro and in vivo.
Heparins may prevent obstetrical complications in APS by blocking acti-
vation of complement induced by aPL targeted to deciduas — not by
preventing placental thrombosis. These findings explain how subantico-
agulant doses of heparin can limit antibody-mediated tissue injury.
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Advanced glycation endproducts in the
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Background Osteoarthritis (OA) is one of the most prevalent and dis-
abling chronic conditions affecting the elderly. The most prominent
feature of OA is the progressive destruction of articular cartilage result-
ing in impaired joint motion, severe pain and, ultimately, disability. Age
is identified as the main risk factor for the development of OA, but the
mechanism by which aging is involved still remains largely unclear.
Age-related changes in the articular cartilage could play an important
role in the susceptibility of cartilage to OA. One of the major age-
related changes in articular cartilage is the accumulation of advanced
glycation endproducts (AGEs), resulting from the spontaneous reac-
tion of reducing sugars with proteins. The present studies were
designed to investigate whether AGE accumulation in cartilage may
predispose to the development of OA.
Methods The role of AGEs in the development of OA was studied by a
combination of in vitro, ex vivo and in vivo experiments. The type and
quantity of AGEs in human articular cartilage were determined using
HPLC and GC-MS methods. Effects of AGE accumulation on cartilage
extracellular matrix turnover were assessed in human articular cartilage
and bovine alginate cultures using radiolabel incorporation, colorimet-
ric, enzyme activity and HPLC analyses. The in vivo role of AGEs in OA
predisposition was studied in the canine ACLT model for OA.
Results High levels of all well-characterized AGEs (pentosidine, car-
boxymethyllysine and carboxyethyllysine) accumulate with age in carti-
lage collagen. Furthermore, an age-related increase of general
measures of AGEs (fluorescence at 370/440 nm, browning, and amino
acid modification) was also observed [1]. Accumulation of AGEs was
correlated with increased stiffness and brittleness of the cartilage, ren-
dering it more prone to mechanical damage. In addition to affecting the
mechanical properties of tissues, articular cartilage chondrocytes show
decreased proteoglycan and collagen synthesis at increased AGE
levels. Degradation of AGE-modified collagen by matrix metallopro-
teinases is impaired compared with unmodified collagen. In a canine
study of experimentally induced OA by anterior cruciate ligament tran-
section, animals with elevated AGE levels suffered from more severe
OA than those with normal AGE levels [2]. Moreover, in a cross-sec-
tional study using human articular cartilage samples obtained at
autopsy, the presence of cartilage degeneration was associated with
higher AGE levels in the joint cartilage.
Conclusion AGE accumulation in cartilage leads to decreased
mechanical properties (increased stiffness and brittleness) and
impaired extracellular matrix turnover (decreased synthesis and degra-
dation). Together these data support the hypothesis presented in Fig. 1
that the age-related accumulation of AGEs changes the properties of
articular cartilage and thereby renders the tissue more prone to the
development of OA.
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Figure 1
Hypothesis of how advanced glycation endproduct (AGE)-related
accumulation of AGEs could predispose to the development of
osteoarthritis (OA).
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Background The key features of osteoarthritis (OA) are the focal
destruction of the articular cartilage and the abnormal growth of the
subchondral bone producing outgrowths. Since in humans OA devel-
ops and changes very slowly, it is difficult to follow that disease over
any length of time. Besides that, the heterogeneity of the disease
results in controversy as regards its aetiology and progression. Thus,
study of early events of the degenerative process cannot be made in
humans and recourse must be made to animal models. We have
recently inactivated the transcription factor Pitx1, which is highly
expressed in articular and growth plate chondrocytes during mouse
development. Pitx1-null mice displayed poorly developed joints, which
are markedly apoptotic. Interestingly, Pitx1+/– mice that are phenotypi-
cally normal at birth exhibit with aging clinical features of OA such as
progressive joint stiffness associated with an abnormal fibrillation and
calcification of their articular cartilage. Histological analysis of mineralized
adult femurs and tibias revealed also an increased thickening of subchon-
dral, trabecular and cortical bone. At the molecular level, expression
analysis of Pitx1-null and Pitx1+/– mice allowed one to identify and char-
acterize a novel molecular cascade involved in OA pathogenesis.
Objective To assess whether a loss-of-function of Pitx1 transcription
factor in human articular chondrocytes and the subsequent activation
of Reg growth factors trigger OA pathogenesis.
Methods RNA isolated from articular cartilage of Pitx1-null mice and
from patients with OA and age-matched and gender-matched subjects
were prepared to perform a molecular expression analysis. In parallel,
cartilage explants were analyzed by immunohistochemistry method to
detect the presence of Reg I proteins, and transient transfection assays
were performed to assess the contribution of Reg growth factors in the
activation of NF-κB induced by proinflammatory cytokines in OA.
Results Expression analysis showed the expression of Pitx1 only in
matched controls. Moreover, the lack of Pitx1 in OA articular chondro-
cytes leads to a marked up regulation of Reg I growth factor and its
receptor, which has been confirmed at the protein level by immunohis-
tochemistry assays with human Reg I antibodies on OA articular carti-
lage. We have also demonstrated in vitro that the gain-of-function of
Reg receptor enhances by several fold the activation of NF-κB induced
by tumor necrosis factor alpha or IL-1β, suggesting that Reg signaling
activity is a key mediator of proinflammatory cytokine action in OA
pathogenesis. This was further supported by the fact that gain-of-func-
tion of Pitx1 abrogates Reg I, Reg II and Reg receptor expression com-
pletely, which may explain why proinflammatory cytokines cannot
activate NF-κB in cells devoid of Reg receptor.
Conclusion Taken together these results revealed the role of new
emerging transcription and growth factors involved in OA pathogene-
sis, which could lead to a more rational approach for the development
of better therapeutic compounds to prevent and cure OA.
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Objective To compare gene expression and regulation of the bone
morphogenic protein (BMP) antagonists follistatin, gremlin, chordin and
noggin in human normal and osteoarthritis (OA) chondrocytes and syn-
ovial fibroblasts.
Methods Follistatin protein production was measured using a specific
ELISA, and localization of follistatin and gremlin in cartilage was deter-
mined by immunohistochemistry. Basal and induced gene expression
was determined using real-time PCR. Gene expression was monitored
following treatment with inflammatory, antiinflammatory, growth and
developmental factors.
Results All BMP antagonists, except noggin, were expressed in chon-
drocytes and synovial fibroblasts. Follistatin and gremlin were signifi-
cantly upregulated in OA chondrocytes, but not in OA synovial
fibroblasts. Chordin was weakly expressed in normal and OA cells. Pro-
duction of follistatin protein paralleled the gene expression pattern. Fol-
listatin was expressed preferentially by the chondrocytes at the
superficial zone of cartilage. Gremlin was not detected in normal carti-
lage; in OA it was found at the superficial zone, not at the very superfi-
cial layers of cartilage but rather at the upper intermediary layers.
Tumor necrosis factor alpha and interferon gamma stimulated follistatin
expression, but downregulated gremlin. IL-1β had no effect on follis-
tatin, but reduced gremlin. Conversely, BMP-2 and BMP-4 significantly
stimulated gremlin, but downregulated follistatin. IL-13, dexametha-
sone, transforming growth factor beta1, basic fibroblast growth factor,
platelet-derived growth factor BB and epidermal growth factor down-
regulated the expression of both antagonists.
Conclusion We show, for the first time, the involvement of the BMP
antagonists follistatin and gremlin in OA pathophysiology. Data suggest
that follistatin and gremlin expression is timed with specific stages in
the progression of OA. The balance of BMP antagonist levels during
the OA process may play a critical role in influencing the progression of
OA, making these antagonists interesting new targets for the treatment
of this disease.
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Objective Cartilage breakdown in arthritis is thought to result from dis-
equilibrium of catabolic and anabolic mechanisms. Tumor necrosis
factor (TNF) alpha is a potent stimulator of catabolic pathways,
whereas its influence on anabolic pathways is currently unknown.
Herein, we studied the effect of systemic overexpression of TNF on
bone morphogenic protein (BMP) expression in articular cartilage and
cartilage matrix synthesis.
Methods Analyses were performed in human tumor necrosis factor trans-
genic (hTNFtg) mice, which suffer from chronic destructive arthritis, and
wild-type mice. Expression of cartilage-derived morphogenetic protein
(CDMP)-1, CDMP-2, and BMP-6 and BMP-7 in articular cartilage was
assessed by immunohistochemistry. Cartilage samples from the knee
joints were assessed for DNA content and [35S]sulfate incorporation
assays to assess chondrocyte number and matrix synthesis, respectively.
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Results Expression of all four BMP family members was significantly
decreased in articular cartilage of hTNFtg mice. The numbers of
stained cells were reduced by about 60% for CDMP-1, CDMP-2 and
BMP-6 (P < 0.004) and by 44% for BMP-7 (P < 0.02). There was no
difference in DNA content in the investigated cartilage samples,
whereas isotope incorporation into newly synthesized matrix macromol-
ecules was significantly decreased by an average of 61% in cartilage
derived from hTNFtg mice compared with wild-type controls (P < 0.001).
Conclusion Chronic overexpression of TNF leads to decreased
expression of BMPs and reduced matrix macromolecule synthesis in
the articular cartilage. These data suggest that TNF, aside from func-
tioning as a catabolic mediator, potently inhibits anabolic mechanisms,
which aim to restore the integrity of articular cartilage.
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Background and objective In previous studies, the effects of attach-
ment of synovial fibroblasts (SF) to different matrix compounds such as
type I collagen or fibronectin on IL-16 expression were investigated.
The focus of this study is the analysis of gene expression in SF upon
stimulation with transforming growth factor beta (TGF-β) after attach-
ment to LN1-laminin (EHS laminin).
Methods Expression of IL-1α, IL-1β, IL-6, IL-8, IL-16, IL-18 as well as
matrix metalloproteinase (MMP)-1 and MMP-3 were investigated in SF
from rheumatoid arthritis patients (n = 6) or osteoarthritis patients
(n = 5) in primary or early passage cultures. Cells were derived from
biopsies and expanded in DMEM + 10% FCS medium. Fibroblasts
were seeded onto LN1-laminin-coated vessels (BD BioCoat®) for
24–72 hours, and cells attached to cell culture vessels served as con-
trols in all experiments. After these incubations, transcript amounts of
individual genes were enumerated by quantitative RT-PCR. A recombi-
nant cytokine standard and GAPDH RT-PCR served as controls in
each sample. Expression of the α1, β1 and γ1 chains of LN-1 laminin
by SF was investigated by RT-PCR and immunocytochemistry.
Results Growth of SF on LN1-laminin coated surfaces without addi-
tional stimuli induced a significant IL-8 response (3.1-fold, ± 1.24;
P ≤ 0.001) and lower responses for IL-1β, IL-16, IL-1α, IL-18 and IL-6.
MMP-1 was upregulated 2.3-fold (± 0.79, P ≤ 0.001), MMP-3 only 1.5-
fold. Upon incubation of SF on LN10-laminin, the cytokine and MMP
expression were not changed. Addition of TGF-β (10 ng/ml, 24 hours)
to SF attached to tissue culture vessels showed a different induction
profile. Here IL-6 showed the most prominent induction (4.1-fold,
± 3.6; P ≤ 0.21), IL-1β, IL-α, IL-8, IL-16 and MMP-1 were induced to a
lesser degree, and IL-18 mRNA was lower whereas MMP-3 was
induced (3.15-fold, ± 0.7; P ≤ 0.04), when compared with controls.
Next, the combination of activation by TGF-β and laminin signaling
were investigated. For cytokine expressions, no additive effects of com-
bining these signals were seen and MMP-1 expression was induced
only to some extent (3-fold, ± 1.76). In contrast, MMP-3 was induced
more than 10-fold. In SF mRNA encoding α1, β1 and γ1 laminin, which
encode the proteins for LN1-laminin, were detected by RT-PCR —
whereas  α5 laminin mRNA, encoding the α-chain of LN10-laminin,
remained undetectable by RT-PCR. Using an anti-EHS serum, LN1-
laminin was detected on SF by immunocytochemistry. However, using
monoclonal antibodies to laminin α1 or γ1 proteins, staining signals
were very weak.
Conclusions Attachment to LN1-laminin in the presence of TGF-β may
induce elevated MMP-3 expression in SF. An autocrine stimulation of
MMP-3 expression by SF via TGF-β and LN1-laminin seems rather
unlikely, as LN1-laminin is not expressed in high amounts in the adult
synovial membrane. Still, activation of SF by LN1-laminin may serve as
a model for activation of fibroblasts by extracellular matrix compounds
in the presence of growth factors or cytokines, and both pathways con-
tribute to the aggressive invasive growth of SF in the course of rheuma-
toid arthritis.
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Objective Elevated production of prostaglandin (PG) E2 plays an
important role in the pathogenesis of arthritis. Recently, an inducible
microsomal prostaglandin E synthase-1 (mPGES-1) was identified.
This enzyme is functionally coupled with cyclooxygenase-2 and con-
verts the cyclooxygenase product PGH2 to PGE2. In the present study
we analyzed the expression of mPGES-1 in human normal and
osteoarthritic (OA) cartilage and determined the effect of different
inflammatory agonists on the expression of mPGES-1 in OA chondro-
cytes.
Methods Expression of mPGES-1 mRNA and protein in cartilage was
determined by quantitative real-time RT-PCR and immunohistochem-
istry, respectively. OA chondrocytes were treated with different inflam-
matory agents and mPGES-1 protein expression was evaluated by
western blot. Activation of the mPGES-1 promoter was assessed in
transient transfection experiments.
Results Levels of mPGES-1 mRNA and protein were markedly ele-
vated in OA versus normal cartilage. Treatment of chondrocytes with
IL-1β induced the expression of mPGES-1 protein in a dose-dependent
and time-dependent manner. This appears to occur at the transcrip-
tional level as IL-1β induced the expression of mPGES-1 mRNA and
the activity of this gene promoter. Tumor necrosis factor alpha and
IL-17 also upregulated the expression of mPGES-1 protein and dis-
played a synergistic effect with IL-1β. 15-Deoxy-∆12,14-prostaglandin J2
inhibited IL-1β-induced mPGES-1 protein expression, an effect that
was reversed by exogenous PGE2.
Conclusion This study shows for the first time that mPGES-1 expres-
sion is upregulated in OA versus normal cartilage and that proinflam-
matory cytokines increased mPGES-1 expression in chondrocytes.
These data suggest that mPGES-1 may prove to be an interesting ther-
apeutic target for controlling PGE2 synthesis.
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Imaging studies have shown that bone marrow changes occur in
patients with rheumatoid arthritis (RA). To address whether bone
marrow is affected in the course of arthritis, human tumor necrosis
factor transgenic (hTNFtg) mice, constituting an established animal
model of human RA, were examined for bone marrow changes. The
hind paws (tarsal area) of 22 untreated hTNFtg mice, of five hTNFtg
mice treated with anti-tumor necrosis factor (infliximab) and of five wild-
type mice were examined histologically, immunohistochemically and by
means of mRNA in situ hybridization. All untreated hTNFtg mice with
moderate (n = 10) and severe (n = 7) disease developed inflammatory
bone marrow lesions during the course of disease, whereas no such
lesions appeared in hTNFtg mice with mild disease (n = 5) and in wild-
type mice. Bone marrow infiltrates were almost exclusively composed
of lymphocytes and the overwhelming proportion (> 80%) were B
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cells. The presence and extent of bone marrow infiltrates were closely
linked to severity of arthritis. In addition, blockade of tumor necrosis
factor effectively reduced bone marrow inflammation. Interestingly,
osteoblast numbers were increased at the endosteal surface in the
vicinity of these lesions. Moreover, osteoid deposition, expression of
bone matrix proteins, such as osteocalcin and osteopontin, and miner-
alization were enhanced, suggesting that inflammatory bone marrow
infiltrates induce bone formation. Indeed, B lymphocytes of these
lesions expressed bone morphogenetic protein (BMP)-6 and BMP-7,
which are important stimulators of new bone formation. Thus, we con-
clude that bone marrow actively participates in destructive arthritis by
generating B-lymphocyte-rich bone marrow lesions and inducing
endosteal bone formation.
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Introduction Recent data indicate that bone marrow plays an impor-
tant role not only as a primary lymphoid organ responsible for
haemopoiesis, but also as a secondary lymphoid organ with capability
of antigen presentation exceeding that of lymph nodes. Although in
chronic inflammatory/immune disease, like rheumatoid arthritis (RA),
bone marrow participates in the initiation and/or perpetuation of the
disease, there is little information about the real number of lymphocyte
subpopulations in bone marrow of these patients and how they can be
modulated by T-cell growth factors. IL-15 acting through IL-15 recep-
tors (including the high-affinity IL-15R alpha chain) is a key cytokine
influencing the development of natural killer cells in bone marrow, and
proliferation and maintenance of the memory T-cell pool. However,
there is no information about the levels of IL-15 in bone marrow.
Objective In the present study we measured the real numbers of lym-
phocyte subsets in bone marrow isolated from RA and osteoarthritis
(OA) patients in correlation with the levels of soluble IL-15 and surface-
expressed IL-15R alpha.
Methods Bone marrow samples, obtained from nine RA and nine OA
patients (mean age 53.1 ± 10.6 years and 54.3 ± 13.6 years, respec-
tively) undergoing joint replacement surgery, were diluted four times in
heparinized PBS. Bone marrow plasma samples were obtained by cen-
trifugation and levels of IL-15 were measured using specific ELISA. The
real number of lymphocytes stained for CD3+, CD4+, CD8+ and
CD19+ were counted in the presence of TruCount beads using flow
cytometry. Surface-expressed IL-15R was done on cells separated by
gradient centrifugation, acid wash of surface-bound IL-15 and flow
cytometric analysis.
Results The real number of CD3+, CD4+, CD8+ T cells and CD19+ B
cells, and statistical significance of these data are presented in Table 1.
There were twice as many T (CD3+) cells in RA in comparison with OA
bone marrow. In contrast, only 42% of B (CD19+) cells present in OA
were observed in RA. Interestingly, lymphocytes isolated from RA
patients expressed a significantly higher level of surface IL-15R alpha
chain, indicating their activation status. In addition, there is a tendency
(although not statistically significant, P = 0.08) for elevated levels of IL-
15 in bone marrow plasma from RA in comparison with OA patients
(2390 ± 1687 pg/ml and 1292 ± 457 pg/ml, respectively).
Conclusion  A highly significant increase of CD3+ (both CD4+ and
CD8+) T-cell numbers in RA in comparison with OA suggest that T
cells in RA are actively trafficking to bone marrow or vigorously prolifer-
ate in situ, or both. Since lymphocytes from RA, in contrast to OA,
express IL-15 receptors, and since there is a tendency to higher levels
of IL-15 in RA, it is likely that T cells actively proliferate in bone marrow
in response to locally produced IL-15. Significantly lower B-cell
numbers in RA than in OA suggest that these cells actively emigrate
from RA bone marrow to peripheral blood and affected joints.
Table 1
Real number of lymphocytes isolated from bone marrow of rheumatoid
arthritis (RA) and osteoarthritis (OA) patients
Patients CD3+ CD4+ CD8+ CD19+
RA 6.1 ± 2.8 3.0 ± 1.2 3.0 ± 1.7 0.85 ± 0.3
OA 3.2 ± 1.6 1.6 ± 0.8 1.6 ± 0.9 2.0 ± 0.9
RA versus OA P < 0.008 P < 0.004 P < 0.03 P < 0.02
Data presented as cell number × 106/ml bone marrow.
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Introduction Mesenchymal stem cells (MSC) may differentiate into
adipocytes, osteoblasts or chondrocytes, the latter leading to hyper-
trophic chondrocytes responsible for endochondral ossification. The
presence of the transcription factor cbfa1 is a prerequisite for
osteoblast development, but is also of major importance in chondro-
cyte transition to the hypertrophic state. For cartilage tissue engineer-
ing, we need to prevent hypertrophic phenotype of MSC differentiated
to chondrocytes. For this, we transfected mesenchymal stem cells tran-
siently with anti-cbfa1 siRNA and investigated its effect on bone mor-
phogenic protein (BMP)-2-induced osteogenesis in monolayer culture,
or chondrogenesis in cultured micropellets.
Methods We used the murine MSC C3H10T1/2 to obtain chondro-
genic differentiation in micropellets. In order to assess impact of cbfa1
inhibition, we used a plasmid encoding the osteocalcin promoter
coupled to the luciferase gene. Cells were transfected using
1–30 pmoles siRNA designed to inhibit cbfa1 per 10,000 cells and
oligofectamine according to standard protocols, and thereafter incu-
bated for up to 28 days.
Results It appeared that both the cbfa1 expression (RT-PCR) and
nuclear protein levels (immunohistochemistry) were diminished up to
75% at day 5. Furthermore, cells transfected with a plasmid containing
the osteocalcin promoter coupled to the luciferase gene displayed an
approximate 65% reduction in luciferase activity subsequent to tran-
sient exposure to anti-cbfa1 siRNA. cbfa1 suppression also markedly
reduced the expression of several osteoblast-related genes (i.e. osterix;
collagen-I; alkaline phosphatase; osteocalcin; secreted protein acidic,
cysteine-rich or osteonectin; and osteopontin).
Functional parameters such as enzymatic activity of alkaline phos-
phatase and mineralization surface profiles over a period of 28 days
were both delayed by a mean of 8 days. In contrast, cells differentiated
to chondrocytes in micropellets and transfected with the siRNA duplex
did not display altered expression of aggrecan or collagen II, as com-
pared with nontransfected cells.
Conclusion In summary, these experiments indicate that a transient
and substantial suppression of cbfa1 in C3H10T1/2 cells, grown in the
presence of BMP-2, is sufficient to delay mineralization, while not
reducing their ability to differentiate towards functional chondrocytes.
Vectors to express anti-cbfa1 siRNA and to stably transfect stem cells
are in progress.
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Background Osteoarthritis (OA) is characterized by cartilage loss, syn-
ovial inflammation, osteophytes, and abnormal subchondral bone
remodeling including sclerosis. Bone sclerosis in OA is due to an abun-
dant osteoid collagen matrix. Collagen type 1 synthesis is increased in
in vivo OA bone tissue and there is an abnormal ratio of collagen type
1α1 chains (Coll1α1) to Coll1α2 chains in this tissue. The mecha-
nisms responsible for this abnormal osteoid matrix remain unknown.
Objective In this study using in vitro subchondral osteoblasts (Ob)
from normal and OA individuals, we investigated the mechanisms
responsible for abnormal collagen production.
Methods We used primary human subchondral Ob from normal and
OA individuals. Cells were stimulated or not with 100 ng/ml parathy-
roid hormone (PTH), 500 nM prostaglandin E2 (PGE2) or 50 nM
1,25(OH)2D3. RNA was extracted with TRIzol and used to perform RT-
PCR and real-time PCR of Coll1A1 and Coll1A2. Coll1 synthesis was
assessed as the release of the carboxy terminal peptide fragment
(CICP), which reflects de novo collagen synthesis. Proteins were sepa-
rated by SDS-PAGE and detected using selective antibodies against
Coll1α1, Coll1α2, or membrane-type 1 or membrane-type 2 matrix
metalloprotease (MT1-MMP and MT2-MMP). MMP-2 and MMP-9 activ-
ities were assessed by zymography. Mineralization was evaluated by
the von Kossa staining of cells after 30 days of culture in the presence
or not of 10 ng/ml bone morphogenic protein-2 (BMP-2).
Results Data showed that basal Coll1A1 mRNA levels were signifi-
cantly increased in OA Ob compared with normal using real-time PCR,
whereas Coll1A2 levels in OA Ob were similar to normal. This trans-
lated into an α1 to α2 collagen type I ratio of 2.5 in normal Ob whereas
it increased to 7.2 in OA Ob. PTH and PGE2 both reduced Coll1A1
and Coll1A2 mRNA levels in normal Ob yet this was reduced for OA
Ob. Indeed, PGE2 reduced Coll1A1 and Coll1A1 mRNA levels about
half as in normal, and the effect of PTH was virtually absent in OA Ob.
Basal collagen type I synthesis, determined by the release of the C-ter-
minal propeptide and by western blot analysis, was also higher in OA
Ob than normal. MMP-2 and MMP-9 were increased in OA Ob com-
pared with normal as determined by zymography. Western blot analysis
showed an increase in MT2-MMP but not in MT1-MMP in OA Ob.
Finally, the mineralization of OA Ob was significantly reduced com-
pared with normal as determined by Von Kossa staining under both
basal conditions and following BMP-2 stimulation.
Conclusion These results suggest that a cellular defect of OA Ob and
an abnormal response to PTH and PGE2 challenge could explain
abnormal production and ratio of α1 to α2 chains of mature collagen
type 1 in these cells. Coupled to the increase in MMP activities, this
could explain the abnormal collagen remodeling observed in OA bone
tissue in vivo.
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Increased osteoclast activity is a key factor for bone loss in rheumatoid
arthritis (RA). This suggests that osteoclast-targeted therapies could
effectively prevent skeletal damage in RA. Zoledronic acid (ZA) is one
of the most potent agents to block osteoclast function. We therefore
investigated whether ZA can inhibit inflammatory bone loss.
Human tumor necrosis factor transgenic (hTNFtg) mice, which develop
severe destructive arthritis as well as osteoporosis, were treated with
PBS, single or repeated doses of ZA, calcitonin or anti-tumor necrosis
factor at the onset of arthritis.
Synovial inflammation was not affected by ZA. In contrast, bone erosion
was retarded by single administration (–60%) and almost completely
blocked by repeated administration (–95%) of ZA. Cartilage damage
was partly inhibited (–40%), and synovial osteoclast counts were signifi-
cantly reduced upon ZA treatment. Systemic bone mass dramatically
increased in hTNFtg mice upon ZA administration, which was due to an
increase of trabecular number and connectivity. In addition, bone
resorption parameters were significantly lowered after ZA. Calcitonin
had no effect on synovial inflammation, bone erosions, cartilage damage
or systemic bone mass. Anti-tumor necrosis factor entirely blocked syn-
ovial inflammation, bone erosion, synovial osteoclast formation and carti-
lage damage, but had only minor effects on systemic bone mass.
ZA appears as an effective tool to protect bone from arthritic damage.
In addition to antiinflammatory drug therapy, modern bisphosphonates
are promising candidates to maintain joint integrity and to reverse sys-
temic bone loss in arthritis.
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Objective To study the influence of gender, menopausal status,
smoking, previous nonvertebral fractures, hormone replacement use,
disease duration and glucorticoid use for low bone mineral density
(BMD) in rheumatoid arthritis patients.
Method A cross-sectional study in 177 patients (164 females and 13
males). BMD was assessed in the spine and femoral neck in a DXA
Norland XR26. Low BMD was defined as Z score < –1 compared with
our normal population. Student’s t test, logistic regression, stepwise
logistic regression and multiple logistic regression were calculated.
Results See Tables 1 and 2 overleaf.
Conclusions When risk factors for low BMD were analyzed in an age-
adjusted and sex-adjusted model, disease duration and glucorticoid
use appeared as significant risk factors for low BMD. In a multivariate
analysis, disease duration longer than 5 years appears as indepen-
dently significant for low femoral neck BMD. Related to glucorticoid
use, only more than 10 g cummulative dose was independently signifi-
cant for low BMD both in the spine and femoral neck.
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SLE and Sjögren syndrome
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Studies of human B-cell tolerance have been hampered by the low fre-
quency of antigen-specific autoreactive B cells in healthy subjects as
well as by lack of access to secondary lymphoid tissue in autoimmune
patients. We have resolved the first problem by studying the fate of a
population of human B cells endowed with intrinsic autoreactivity
owing to the expression of antibodies encoded by the VH4.34 gene
segment (VH4.34 B-cells and VH4.34 antibodies, respectively) [1].
These pathogenic autoantibodies are very abundant in systemic lupus
erythematosus (SLE), where they represent 10–40% of serum IgG,
correlate with disease activity, renal and central nervous system
involvement, and contribute substantially to the anti-dsDNA and anti-
lymphocyte antibody repertoire [2–5]. Of note, increased production of
VH4.34 antibodies is highly specific for SLE and has not been
observed in other autoimmune diseases. Taking advantage of the abun-
dance of VH4.34 B cells in healthy individuals and of the ability of the
anti-idiotypic monoclonal antibody 9G4 to specifically recognize
VH4.34 B cells, we previously proposed that healthy VH4.34 B cells
are negatively selected during the germinal center (GC) reaction [1].
Herein, we have expanded our initial studies to further dissect this
observation using tonsil biopsies obtained from patients with SLE
(n = 8) and rheumatoid arthritis (n = 3) as a source of secondary lym-
phoid tissue. Using both flow cytometry, intracellular calcium analysis
and immunocytochemistry, our studies demonstrate that in normal sub-
jects 9G4+ autoreactive VH4.34 B cells display an anergic phenotype
and undergo strong counter selection in the early phase of the GC
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Table 2
Multivariable analysis of risk factors for low bone mineral density (BMD) 
Spine, odds ratio  Femoral neck, odds ratio 
Variable Comparison (95% confidence interval) P (95% confidence interval) P
Menopause Premenopause 0.85 (0.42–1.74) 0.66 1.08 (0.52–2.52) 0.83
Ever HRT Never HRT 0.69 (0.22–2.16) 0.53 0.55 (0.17–1.76) 0.31
Disease duration
1–5 years < 1 year 0.95 (0.30–3.07) 0.94 2.31 (0.63–8.52) 0.21
5 years < 1 year 1.22 (0.41– 3.62) 0.72 4.83 (1.44–16.21) 0.01
Corticosteroids
Never Ever 0.87 (0.38–2.03) 0.75 0.69 (0.21–2.23) 0.54
< 5 g cummulative Never 1.35 (0.37–4.89) 0.65 1.62 (0.45–5.89) 0.46
>10 g cummulative Never 5.39 (1.95–14.86) 0.0001 3.73 (1.23–11.26) 0.02
Low BMD, Z score < –1 compared with our normal population. HRT, hormone replacement therapy.
Table 1
Risk factors for low bone mineral density (BMD) in the age-adjusted and sex-adjusted model
Spine, odds ratio  Femoral neck, odds ratio 
Variable Comparison (95% confidence interval) P (95% confidence interval) P
Female Male 1.43 (0.44–4.68) 0.55 1.35 (0.41–4.47) 0.63
Menopause Premenopause 0.96 (0.51–1.81) 0.92 1.34 (0.72–2.52) 0.49
Ever smoking Never smoked 0.88 (0.42–1.89) 0.76 1.19 (0.57–2.51) 0.64
Nonvertebral
Fracture No fracture 0.98 (0.28–3.39) 0.98 1.38 (0.42–4.53) 0.59
Ever HRT Never HRT 0.41 (0.15–1.15) 0.09 0.30 (0.14–1.10) 0.08 
Disease duration
1–5 years < 1 year 1.51 (0.55–4.06) 0.42 3.07 (0.91–10.34) 0.07
5 years < 1 year 2.54 (1.06–6.05) 0.04 7.46 (2.47–22.48) 0.0001
Corticosteroids
Ever Never 3.19 (1.56–6.54) 0.001 2.07 (1.06–4.02) 0.03
< 7.5 mg daily Never 2.75 (1.28–5.88) 0.009 1.83 (0.89–3.74) 0.09
7.5 mg daily Never 4.29 (1.81–10.20) 0.001 2.61 (1.15–5.91) 0.02
< 5 g cummulative  Never 1.51 (0.56–3.99) 0.42 1.04 (0.41–2.67) 0.93
5–10 g cummulative  Never 2.61 (0.99–6.88) 0.05 0.95 (0.34–2.63) 0.92
> 10 g cummulative Never 5.11 (2.3–11.29 0.0001 4.05 (1.9–8.61) 0.0001
Low BMD, Z score < –1 compared with our normal population. HRT, hormone replacement therapy.S37
reaction, as indicated by their decline in the transition from the GC
founder stage to the centroblast stage and by their absence from prolif-
erative GCs. In contrast, SLE 9G4+ B cells participate in approximately
20% of all productive GC reactions, as substantiated by flow cytometry
and histological analyses and as reflected by a 10-fold to 20-fold
expansion into the post-GC IgG memory and plasma cell compart-
ments. Remarkably, in patients with RA, 9G4+ B cells behave like
healthy 9G4+ B cells and are also strongly counter-selected in the GC.
Overall, our results strongly indicate that a critical checkpoint in the
maintenance of B-cell tolerance depends on effective negative selec-
tion of autoreactive B cells in the GCs and that this checkpoint is
specifically defective in SLE. Detailed comparisons of the cellular, bio-
chemical and genetic profiles of the cells targeted at this checkpoint
(GC founders) between healthy control and SLE patients should shed
considerable light into the mechanisms responsible for disease devel-
opment, thereby suggesting new therapeutic approaches.
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Background Both interferon (IFN) alpha and IFN-γ have been impli-
cated in the pathogenesis of systemic lupus erythematosus (SLE).
Recently, microarray screens have demonstrated increased IFN-
inducible gene (IFIG) expression in peripheral blood mononuclear cells
of patients with active SLE. We investigated the relative roles of IFN-α
and IFN-γ in gene expression and disease in SLE patients.
Methods Quantitative real-time PCR was employed to identify IFIGs
that are regulated by either IFN-α or IFN-γ. Peripheral blood mononu-
clear cells from 77 SLE patients were compared with those of 22
disease controls and 28 healthy donors (HD) for expression of three
genes preferentially induced by IFN-α (PRKR, IFIT1, IFI44) and three
genes preferentially induced by IFN-γ (IRF1, SERPING1, and GBP1)
inducible genes. IFN-α and IFN-γ scores were then calculated for all
individuals, based on the number of IFIGs overexpressed and the level
of increased expression above the mean value for that gene in the HD
group. IFNs in plasma were measured by ELISA and assayed for IFIG-
inducing activity. Disease activity was assessed using the SLE disease
activity index-2000 (SLEDAI-2K) and severity with the number of Amer-
ican College of Rheumatology (ACR) criteria fulfilled and the Systemic
Lupus International Cooperating Clinics (SLICC) damage index. Sera
were tested for autoantibodies to dsDNA, Sm, ribonucleoprotein, Ro,
La, and antiphospholipid antibody (APLA).
Results Two IFN-α-inducible genes (PRKR and IFI44), but no IFN-γ-
inducible gene, showed higher expression in SLE than in disease con-
trols (P  = 0.005 and P  = 0.01, respectively) or healthy donors
(P = 0.01 and P = 0.03). Moreover, IFN-α scores were higher in SLE
patients than in both control groups (P  < 0.01), with 50% of SLE
patients demonstrating a high IFN-α score (defined as ≥ 2). Plasma
from all SLE patients contained high levels of IFN-α and some con-
tained IFN-α-gene inducing capacity that was inhibited by anti-IFN-α
antibody. Expression of IFN-α-regulated genes correlated with erythro-
cyte sedimentation rate (r = 0.33, P = 0.003), serum C3 (r = –0.3, P =
0.008), C-reactive protein (r = –0.3, P = 0.03), SLEDAI-2K (r = 0.22,
P = 0.05), and SLICC damage index (r = 0.33, P = 0.003). It was also
associated with a greater number of ACR criteria, Caucasian race, and
renal disease. Interestingly, SLE patients had increased prevalence of
autoantibodies to Ro (P = 0.0008) and to any RNA binding protein
(one or more of Sm, ribonucleoprotein, Ro, La; P = 0.0002). In con-
trast, the prevalence of anti-dsDNA or APLA was not associated with
IFN gene expression.
Conclusions These data demonstrate that activation of the IFN-α
pathway is a characteristic of SLE and that IFN-α is the predominant
stimulus for IFIG expression in those patients. IFN-α-inducible genes
are candidate biomarkers identifying patients with increased disease
activity and define a subgroup of SLE patients with serum autoreactiv-
ity against RNA-binding proteins.
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B cells play a central role in the pathogenesis of systemic lupus erythe-
matosus (SLE) [1]. The availability of a highly effective and relatively
safe B-cell-depleting drug, rituximab (Rituxan®; Genentech, South San
Francisco, CA, USA, and Biogen Idec, San Diego, CA, USA), has per-
mitted us to begin to test the hypothesis that removal of B cells would
provide a therapeutic benefit for SLE patients [2]. An initial phase I
safety trial was undertaken to ensure that rituximab did not have any
unexpected toxicities in this new population. Patients with moderately
active SLE (SLE Disease Activity Index > 1) who had failed at least one
cytotoxic agent and had current involvement of a major organ system
were eligible to enroll in the study. The treatment regimen was the
same approved for B-cell lymphoma: a single course of four weekly
doses of rituximab intravenously at 375 mg/m2. Patients received
100 mg methylprednisolone intravenously before each infusion. During
the treatment period, they could not be on immunosuppressives, and
prednisone doses were kept constant. Patients were followed for
1 year after treatment with repeated laboratory screens, measures of
clinical disease activity, and analyses of the subsets of peripheral blood
lymphocytes.
To date, 20 patients have been enrolled in the study. The first two
patients received lower doses of rituximab, and were found to develop
positive human anti-chimeric antibody tests. One patient developed a
serious adverse event (hyptotension and bradycardia), which may have
been related to the medication. All subsequent patients were sched-
uled to receive the full therapeutic dose. The results discussed here
pertain to the nine patients on whom data were available at the time of
abstract submission. All patients tested so far depleted their peripheral
blood B cells by at least 95%. Six of eight patients who received the
full dose showed an improvement in SLE Disease Activity Index,
although four of these ‘responders’ required the addition of azathio-
prine or mycophenolate mofetil after 1–6 months. B cells returned to
Available online http://arthritis-research.com/supplements/6/S3S38
the peripheral blood as early as 3 months after treatment, although
some patients remained depleted after 1 year. Low titer, transient
human anti-chimeric antibody positivity was observed in two patients.
Rituximab was well tolerated, without infusion-related serious adverse
effects. One death occurred in a patient due to severely active SLE.
Serum immunoglobulins, anti-DNA and antinuclear antibody titers did
not fall, nor did complement levels change. Patients had antibody titers
against pneumococcal polysaccharides and tetanus tested before and
after treatment, and then received booster immunizations (Pneumovax
and tetanus toxoid) approximately 6 months after treatment. For the
four patients in whom results are available, three failed to respond to
this antigenic challenge.
This experience suggests that rituximab is potentially effective and rea-
sonably safe for patients with SLE. It remains to be determined how
best it should be used (timing and amount of doses, concomitant med-
ications) and whether it will add significantly to the toxicity of immuno-
suppressive therapies. Randomized, double-blind, placebo-controlled
trials are necessary at this point to approach these questions.
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Background Disturbances in peripheral B-cell homeostasis have been
found to be characteristic of primary Sjögren’s syndrome (pSS). Abnor-
mal chemokine receptor expression has been proposed to be involved
in the pathogenesis of autoimmune diseases.
Objective This study aimed to further delineate disturbances in periph-
eral CD27– naive and CD27+ memory B cells and their expression of
chemokine receptors in pSS.
Methods Isotype-specific immunoglobulin heavy chain (IgH) tran-
scripts as well as chemokine receptor (CXCR4 and CXCR5) specific
mRNA transcripts were analyzed in single-sorted CD19+D27– naïve
and CD19+CD27+ memory B cells from pSS patients and normal
healthy subjects (NHS).
Results A significantly higher frequency of B cells coexpressing µ, α,
and/or γ chain transcripts were found in pSS patients compared with
controls (58.0% versus 14.3%, P < 0.0001). Contrasting the findings
in NHS, peripheral memory B cells in pSS patients were characterized
by heavily mutated IgVH transcripts (mutational frequency, 8.6% versus
4.4%; P < 0.0001). Notably, this included significantly enhanced muta-
tional frequencies of Cµ-transcripts (9.6% in pSS versus 2.5% in NHS,
P < 0.0001). A CD27– memory-type B-cell subpopulation expressing
mutated Cµ-transcripts was exclusively found in pSS patients. More-
over, a significantly enhanced frequency of CXCR4-mRNA-positive
CD27– naive B cells was found in pSS patients when compared with
NHS (36.0% versus 18.1%, P < 0.0001).
Conclusions Altogether, B-cell hyperactivity and abnormalities in
peripheral B-cell memory are characteristic of patients with pSS. Differ-
ential expression of chemokine receptors appear to be involved in dis-
turbances of peripheral B-cell homoestasis in pSS.
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Background The inflammatory cellular infiltrate typical of several
chronic diseases, including Sjogren syndrome (SS), is often organized
in lymphoid-like structures. CXCL13 and CCL21 are lymphoid
chemokines critical for physiologic development of secondary lymphoid
organs. They have also been implicated in the formation of ectopic lym-
phoid neogenesis in various experimental and pathological conditions.
To define the relationship between the in situ production of CXCL13
and CCL21 and lymphoid organization in SS we examined the expres-
sion of these chemokines in relation to the degree of B-cell and T-cell
segregation, the presence of follicular dendritic cell (FDC) (CD21+)
networks and germinal centre (GC) reactions as well as the develop-
ment of high endothelial venule (HEV) (PNAd+)-like vessels.
Aims The aim of this study was to characterize the organization of
neolymphoid tissue in the salivary glands of SS patients and to corre-
late its development and maturation with the ectopic expression of lym-
phoid chemokines CXCL13 and CCL21
Methods Periductal foci in 26 SS salivary gland biopsies and nine
disease controls with nonspecific sialoadenitis were analysed on the
base of a grading score (G1, ≤ 50 cells; G2 > 50 cells; and G3 = G2
+ presence of GCs). This was related to follicular organization and
maturation assessed in respect to T-cell and B-cell segregation,
CD45RO and CD45RA expression (CD3+, CD20+ and UCH10,
S130), FDC networks (CD21+) and PNAd (MECA-79+) HEV forma-
tion and CXCL13 and CCL21 expression.
Results In SS samples, G1 aggregates showed preponderance of
CD3+/CD45RO+ infiltrating lymphocytes without B/T area segregation,
G2 revealed an increasing number of CD20+/CD54RA+ and a variable
degree of organization (54.55% not segregated, 21.21% atypically
segregated, 24.24% segregated), while G3 exhibited CD20+/
CD54RA+ majority with the typical segregation of secondary lymphoid
follicles. Within G2 and G3 aggregates we identified CD21+ cells clus-
terized or in a reticular pattern within the GCs. MECA79+ vessels were
detected on the edge of the aggregates. CXCL13 expression was
seen in 4.07% of G1, 46.16% of G2 and 100% of G3 lymphocytic
aggregates. CXCL13 was localized within G2 aggregates, in G3 inside
CD21+ GCs and in some infiltrated ducts. CCL21 expression was
detected in 2.5% of G1, 17.85% of G2 and 47.62% of G3 aggre-
gates. CCL21 was related with the endothelium of HEV morphology
structures and some cells surrounding these structures. In nonspecific
sialoadenitis samples we detect no follicle formation or features of sec-
ondary lymphoid organ formation.
Conclusions In the salivary gland of patients with SS a true phenome-
non of lymphoneogenesis appears to take place, characterized by the
formation of mature follicles with GCs, B/T segregation, FDC networks
and PNAd expression on HEVs.
CXCL13 and CCL21 expression clearly correlates with the higher
grades of organization of the infiltrates. The presence of lymphoid
structures within the target organs for the disease and the association
of these structure with chemokines acting as regulators of lymphoneo-
genesis in secondary lymphoid organs, combined with the possible
expression of CXCL13 even in the absence of professional FDCs, sug-
gests a key role for these molecules in the pathogenesis, maintenance
and evolution of the disease process.
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Angiogenesis, or new blood vessel formation, is key in vasculoprolifera-
tive disorders including rheumatoid arthritis. Here we report that the
mediation of angiogenesis by P-selectin, an important member of the
selectin adhesion molecule family, is unexpectedly sex dependent. In
vivo angiogenesis measured in a Matrigel plug, in a sponge granuloma,
and in a corneal micropocket was consistently impaired in P-selectin
gene deficient mice compared with wild-type mice, but only if the P-
selectin-deficient mice were female. Estrogen appeared to be one sig-
nificant mediator of P-selectin sensitivity. In vitro the chemotactic
activity of soluble P-selectin for human dermal microvascular endothe-
lial cells was augmented by 17β-estradiol (E2). Conversely, an antibody
blockade of P-selectin reduced E2-induced sprout formation in female
mouse corneal endothelial cell morphogenesis assays, inhibited E2-
induced endothelial cell signaling via the Src and mitogen-activated
protein kinase pathways, and decreased E2-induced secretion of angio-
genic basic fibroblast growth factor. In addition to its classical roles in
leucocyte extravasation, P-selectin may also contribute to a variety of
inflammatory diseases as a sex-restricted angiogenic intermediary.
96 (P10.2)
Synovial cadherin-11
D Lee, H Kiener, S Agarwal, J Higgins, M Brenner
Brigham and Women’s Hospital, Division of Rheumatology,
Immunology and Allergy, Harvard Medical School, Boston,
Massachusetts, USA
Arthritis Res Ther 2004, 6(Suppl 3):96 (DOI 10.1186/ar1431)
Cadherin-11 is a homophilic adhesion molecule that is expressed on
fibroblast-like synoviocytes. To investigate a role for cadherin-11 in
modulating synovial function, we have examined the synovial architec-
ture and inflammatory responses in cadherin-11 mutant mice. We find
these mice display a hypoplastic synovial lining with decreased cellular
condensation and reduced extracellular matrix deposition. When chal-
lenged with arthritogenic serum in the KRN anti-GPI antibody-induced
arthritis model in mice, cadherin-11-deficient animals display resistance
to arthritis development. In animals that do develop detectable swelling
and inflammation, there is a noted absence of cartilage damage, com-
pared with wild-type animals with arthritis. Moreover, the architecture of
the synovial response to inflammation is disorganized. In contrast to
wild-type arthritic mice in which the synovial lining undergoes marked
hyperplasia, the cadherin-11-deficient synovial reaction lacks a clearly
detectable lining layer and shows a disorganized random inflammatory
reaction. These results support the concept that fibroblast-like synovio-
cytes are direct participants in the highly orchestrated synovial reaction
that occurs in inflammatory arthritis. Furthermore, these results reveal a
role for synovial cadherin-11 in regulating synovial fibroblast function
both in the healthy state and in the pathologic context of inflammatory
arthritis.
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Background  The synovial microenvironment in rheumatoid arthritis
(RA) is often hypoxic with evidence of anaerobic metabolism. This
results from an imbalance between high metabolic demands and
impaired tissue perfusion due to microvascular damage. Cellular
responses to hypoxia are mediated by the transcription factor HIF-1α,
which is exquisitely and rapidly controlled by cellular oxygen tension.
HIF-1α has been shown to play a key role in promoting tumor angio-
genesis, and was recently shown to be critically important in inflamma-
tory responses.
Methods  To better define the effects of hypoxia in the synovial
microenvironment, we studied the response of fibroblast-like synovio-
cytes (FLS) to hypoxic stimulation using the gene expression microar-
ray, quantitative RT-PCR, and matrix-assisted laser desorption-time of
flight mass spectrometry. The expression of HIF-1α in fresh RA synovial
tissue explants was evaluated under both normoxic and hypoxic condi-
tions. In addition, FLS were infected by an adenoviral vector carrying a
modified HIF-1α gene with the oxygen degradation domain removed.
This vector has been shown to induce normoxic expression of genes
with hypoxia responsive elements.
Results Under normoxic conditions, HIF-1α expression in fresh samples
of RA synovium was patchy and generally confined to the nuclei of cells
in hyperplastic lining layers. Under conditions of 1% O2 or CoCl2, HIF-
1α expression was markedly increased in FLS and in the lining cells of
synovial tissue explants. Interestingly, while hypoxia induced the stabi-
lization of HIF-1α protein by preventing its degradation, it also resulted
in a significant downregulation of HIF-1α gene expression. Of the
approximately 80 genes known to be directly regulated by HIF-1α, 75%
were found to be upregulated by hypoxia in FLS. This included angio-
genic mediators such as vascular endothelial growth factor, angiopoi-
etins, and leptin, apoptosis mediators such as BNIP3, glycolysis-related
enzymes such as G6PI, and the chemokine CXCL12 and its receptors
CXCR4. Regulation of CXCL12 by HIF-1α was confirmed by its nor-
moxic induction in adenoviral infected FLS lines. In addition, a spectrum
of novel genes and proteins not known to be regulated by HIF-1α were
shown to be induced in FLS by hypoxic stimulation.
Conclusions Hypoxic conditions in RA synovium promote persistence
by inducing angiogenesis, enhancing FLS survival, and enhancing lym-
phocyte recruitment. Hypoxic induction of G6PI may promote the
development of anti-G6PI autoantibodies.
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Objective There is accumulating evidence that rheumatoid arthritis syn-
ovial fibroblasts (RA-SF) are resistant to FasL-induced apoptosis
despite the abundant expression of Fas. Tumor necrosis factor alpha
(TNF-α) has been suggested to contribute to this process mainly
through the transient activation of transcription factors such as NF-κB.
However, in addition to short-term induction of transcriptional regula-
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tors, long-term activation of RA-SF has gained increasing interest. In
this context the small ubiquitin-like modifier SUMO-1 appears to be of
importance, and some data indicate that increased levels of SUMO-1
are linked to the resistance of RA-SF against programmed cell death.
However, little is known about the regulation of SUMO-1 in fibroblast-
like cells. Here, we investigated the effects of long-term stimulation of
RA-SF with TNF-α on the activation of NF-κB, the expression of
SUMO-1, and on spontaneous as well as FasL-induced cell death.
Methods Synovial tissues were obtained from patients with rheumatoid
arthritis at joint replacement surgery, and synovial fibroblasts were iso-
lated by enzymatic digestion. Long-term effects of TNF-α were ana-
lyzed by stimulation of RA-SF with 10 or 100 ng/ml TNF-α for
24 hours. Nuclear binding of NF-κB was assessed by electrophoretic
mobility shift assay. The expression of SUMO-1 in TNF-α-stimulated
and unstimulated RA-SF was determined by quantitative real-time PCR
and western blot. To induce apoptosis, TNF-α pretreated and
untreated RA-SF were stimulated with recombinant human FasL
(100 ng/ml) for 16 hours. Apoptosis was measured by a histone frag-
mentation assay (Cell Death ELISA; Roche Diagnostics, Mannheim,
Germany) and confirmed by FACS analysis with intercellular TUNEL
staining (Apo-BRDU™ Kit; BD Biosciences, Heidelberg, Germany).
Results Treatment of RA-SF with TNF-α over 24 hours did not induce
cell death but slightly reduced the rate of spontaneous apoptosis. More
significantly, long-term exposure of RA-SF to TNF-α clearly prevented
the induction of apoptosis by recombinant human FasL in a dose-
dependent manner. This was accompanied not only by a sustained
activation of NF-κB, but also by a significant increase in the expression
of SUMO-1. The induction of SUMO-1 by TNF-α was dose dependent
and seen both at the mRNA and the protein level.
Conclusions The data suggest that long-term exposure of RA-SF to
TNF-α inhibits FasL-induced apoptosis not only through sustained acti-
vation of NF-κB, but also through upregulation of the small ubiquitin-
like modifier SUMO-1. Although SUMO-1 has been demonstrated to
be elevated in RA-SF in the absence of continuous stimulation with
inflammatory cytokines and to be part of the stable activation of RA-SF,
TNF-α in the inflamed synovium may enhance further the expression of
SUMO-1 and, thus, contribute to the resistance of RA-SF against
apoptosis.
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Purpose Vascular endothelial growth factor C (VEGF-C) is a member of
the platelet-derived growth factor/vascular endothelial growth factor
family of growth factors. Functionally, VEGF-C has been characterized
as both a lymphangiogenic and angiogenic factor and can induce
chemotaxis of macrophages. The exact mechanism by which the angio-
genic, lymphangiogenic and cell recruitment processes are induced and
maintained in the rheumatoid synovium of patients with rheumatoid
arthritis (RA) is currently not known. We hypothesized that VEGF-C may
be involved in RA and in this study proceeded to characterize its regula-
tion in synoviocytes and tissue from RA and osteoarthritis (OA) patients.
Methods Protein lysates were prepared from synovial tissue isolated
from seven RA and six OA patients undergoing arthroplasty. Fibroblast-
like synoviocytes (FLS) were grown out of synovial tissue samples and
used at passages 2–5. Western blotting was employed to examine the
VEGF-C isoforms. RT-PCR was used to examine VEGF-C receptors.
Results Western blots revealed an increase in the processed forms of
VEGF-C in protein lysates prepared from synovial tissue of RA com-
pared with OA patients. FLS produced substantial amounts of VEGF-
C, the majority of which was secreted as the partially processed
29-kDa and 31-kDa forms that have been reported to bind to the lym-
phangiogenesis-associated VEGFR-3. These secreted forms were
increased about 1.6-fold (P = 0.02) in RA FLS compared with OA FLS.
The addition of 10 µg/ml tumor necrosis factor alpha (TNF-α) to the
culture media increased the secreted VEGF-C forms an average of 1.4-
fold in RA lines and 1.9-fold (P  = 0.002) in OA lines. Additionally,
mRNA levels for neuropilin-2, a receptor for VEGF-C and class 3 sema-
phorins that has been shown to be necessary for the formation of small
lymphatic capillaries, were increased approximately 20-fold in both OA
and RA lines 24 hours after TNF-α addition.
Conclusions This is the first study to demonstrate that TNF-α-driven
FLS may modulate synovial inflammation and joint destruction by
paracrine and/or autocrine mechanisms involved in lymphangiogenesis.
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Patellofemoral joint pain is one of the most common pathologies
observed in orthopedic clinics. It is widely held that abnormal joint
mechanics play a causative role in the development of anterior knee
pain and that chronic patellofemoral joint pain may lead to cartilage
degeneration, arthritis and permanent disability [1]. However, the rela-
tionship between joint kinematics and clinical symptoms remains
unclear. We applied a new magnetic resonance imaging (MRI)-based
method to assess three-dimensional patellar tracking during loaded
knee flexion to determine whether anterior knee pain is associated with
abnormal joint kinematics.
The symptomatic and matched knees of 60 subjects (20 cases with
anterior knee pain and clinical evidence of patellar malalignment; 20
cases with anterior knee pain and no clinical evidence of patellar
malalignment, and 20 controls matched for age, gender and physical
activity level) were imaged through a range of loaded knee flexion using
a validated MRI-based method [2]. Using this novel evaluation tool, the
motion of the patella relative to the femur was determined as a function
of knee flexion angle. Group values through a common range of knee
flexion were compared using analysis of variance.
In the control group, the normal pattern of patellar motion is increasing
medial rotation, tilt and shift as the patella approaches the trochlear
groove during loaded knee flexion (from 19° to 28°). In the group with
pain and clinical signs of malalignment, the patella is translated 2.6 mm
more laterally and rotated 1.3° more medially (P < 0.001). Statistically,
differences in patellar kinematics are observed between the control
group and the group with pain and no clinical evidence of malalign-
ment; however, the magnitude of the differences are all within the
range of the accuracy and repeatability of the technique with the
exception of the decreased distance between the patella and femur
(P < 0.001).
This MRI-based method detects a normal pattern of patellar kinematics
that is consistent with previous reports [3] and detects abnormal kine-
matics in subgroups of individuals with anterior knee pain. In the cases
with pain and clinical evidence of patellar malalignment, the increased
lateral shift and medial rotation is consistent with weakness of the
vastus medialis oblique muscle, which has been linked with
patellofemoral joint pain previously. Our results do not support the
notion that increased lateral tilt is associated with patellofemoral joint
pain. In the cases with pain and no clinical evidence of patellar
malalignment, the closer positioning of the patella relative to the femur
may reflect a decrease in cartilage thickness. Of note is that in most
cases the pattern of patellar motion was similar to that for the controls.
Longitudinal studies using this novel MRI-based method will aid in
determining the link between knee pain and joint mechanics.
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Purpose Although reduced labour force participation is often a conse-
quence of physical disability, little is known about the role of workplace
accommodation. This study uses a conceptual model based on the
World Health Organization International Classification of Functioning,
Disability, and Health and hypothesizes perceived need for workplace
accommodation as a mediating variable between activity limitation and
not in labour force.
Methods Data from the Canadian Health and Activity Limitation Survey
were used. Working-age participants (25–64 years) with arthritis dis-
ability were included. Employment status was dichotomized into 0 = in
labour force (employed and unemployed), 1 = not in labour force. Two
latent constructs (lower body and upper body disability) were used to
represent 12 categorical physical disability indicators (e.g. difficulty in
walking) and one latent construct was derived for eight workplace
accommodation indicators (e.g. lack of accessible workstation, elevator
or flexible hours if needed). Personal variables (age, sex, education, and
occupation) were also incorporated into the model. MPLUS was used
to perform the categorical factor analysis and standard error of the
mean analyses.
Results Physical activity limitations affected labour force participation
both directly and indirectly through perceived need for workplace
accommodation. As people’s activity limitations became severe they
were more likely to perceive the need for workplace accommodation,
and in turn, this lead to reduced labour force participation. Lower body
activity limitations had more impact on labour force than upper body
activity limitation. Older age, female gender, and low education were
also associated with reduced labour force participation.
Conclusion Most of the effect of arthritis-associated physical activity
limitations and all on labour force participation is mediated by per-
ceived workplace accommodation, which underscores the importance
of workplace accommodation provision.
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Aims Research projects completed and ongoing by members of our
research team include: (i) validation of quantitative cartilage measure-
ments using a 1 T extremity magnetic resonance imaging (MRI)
scanner; (ii) radiographic evaluation of soft-tissue structures — a com-
parison between 1 T and 1.5 T MRI scanners; (iii) short-term and long-
term reproducibility of computer-determined medial minimum joint
space width (mJSW) of the knee using a fixed-flexion X-ray protocol;
(iv) determination of ‘normal’ values of minimum medial joint space
width of the knee, bone density using dual X-ray absorptiometry around
the knee joint and cartilage volume and thickness in men and women
per decade between the ages of 20 and 69 years; (v) determination of
values of medial mJSW of the knee, bone density around the knee joint
and cartilage volume and thickness in men and women with varying
degrees of knee osteoarthritis (OA); (vi) development of a longitudinal
database of patients with OA of the knee, documenting pain, physical
function, quality of life, history, medication use, family history, physical
examination, blood tests, plain film radiographs and MRI of the knee
using a 1 T extremity MRI scanner; (vii) development of a more fully
automated technique for cartilage segmentation of three-dimensional
(3D) MRI data; and (viii) quantification of 3D trabecular bone structure
using high-resolution MRI.
Methods Healthy volunteers and patients with knee OA referred for
assessment to a rheumatologist are invited to participate in the various
studies. All patients are asked to complete preset questionnaires. Radi-
ographs of the knee are performed postero-anteriorly in a standardized
fixed-flexion position by trained technicians. Radiographs are subse-
quently digitized and analyzed for mJSW using an automated computer
algorithm. A 1 T extremity MRI scanner is used for imaging each individu-
al’s knee. Sequences include a saggital T1-weighted, 3D spoiled gradient
echo with fat saturation, a saggital T1-weighted fast spin echo (FSE), a
coronal T2-weighted FSE and an axial FSE inversion recovery sequence.
Results Quantitative cartilage measurements of normal and OA sub-
jects’ knees were obtained using a validated segmentation technique
on both 1 T and 1.5 T MRI images. The 1 T extremity MRI scanner has
been found to be reliable and of comparable precision in comparison
with a 1.5 T whole-body scanner.
The use of a fixed-flexion position and a computer algorithm to deter-
mine medial mJSW of the knee in patients having normal or
osteoarthritic knees has been found to be reliable in both short-term
and long-term studies. Forty-seven pairs of knee radiographs were
assessed in the short-term study while 14 pairs in a long-term study
were assessed. Reliability for both studies was measured by means of
intraclass correlation coefficient and found to be 0.95–0.99 for both
healthy subjects and those with OA.
A cross-sectional study of 45 patients referred for assessment of knee
pain is being completed. Data analyses will include comparison of pain
scales, history and physical examination with MRI findings in the knee.
Conclusions Quantitative cartilage measurements using a 1 T office-
based extremity MRI scanner have been found to be reliable and of
comparable precision with those obtained using a 1.5 T whole-body
MRI scanner. The use of a fixed-flexion radiographic technique for
assessing mJSW has been found to be reliable in a long-term repro-
ducibility study at our center. Early diagnosis and prompt assessments
of patients with OA can be accessible using an office-based extremity
MRI scanner and could prove to be a valuable clinical tool with the
development of disease-modifying agents for the treatment of OA.
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